carmustine has been researched along with Brain Neoplasms in 920 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 9.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 9.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 9.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "Carmustine wafer implantation during surgical resection followed by the standard chemoradiation protocol for newly diagnosed glioblastoma in adults resulted in a significant progression-free survival benefit." | 9.20 | Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. ( Audureau, E; Barat, JL; Bauchet, L; Caire, F; Corns, R; Desse, N; Devaux, B; Dezamis, E; Duntze, J; Emery, E; Faillot, T; Guyotat, J; Hieu, PD; Langlois, O; Le Reste, PJ; Lechapt-Zalcman, E; Lefranc, M; Litre, CF; Menei, P; Metellus, P; Nader, E; Noel, G; Pallud, J; Parraga, E; Pavlov, V; Peltier, J; Petit, A; Vignes, JR; Voirin, J; Zanello, M, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 9.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 9.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 9.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 9.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme." | 9.12 | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. ( Briceño, E; López-González, MA; Sotelo, J, 2006) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 9.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 9.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma." | 9.11 | Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. ( Buckner, JC; Dinapoli, RP; Fitch, TR; Krishnan, S; Maurer, MJ; Nordstrom, K; O'Fallon, JR; Rao, RD; Scheithauer, B; Schomberg, PJ, 2005) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 9.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 9.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas." | 9.09 | Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. ( Buckner, JC; Cascino, TL; Ingle, JN; Pitot, HC; Rajkumar, SV; Schomberg, PJ, 1999) |
| "The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma." | 9.09 | A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001) |
| "To quantify the quality of life of malignant glioma patients treated on a randomized Phase I/II trial of twice-daily radiation therapy (RT) and carmustine, using a modified quality adjusted survival (QAS) model, and to compare the QAS among assigned treatment arms." | 9.08 | Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. ( Curran, WJ; Farnan, N; Fischbach, AJ; Murray, KJ; Nelson, DF; Porter, A; Scott, C, 1995) |
| "Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy." | 9.08 | Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. ( Chang, CN; Chen, LH; Cheng, WC; Ho, YS; Kiu, MC; Leung, WM; Lin, TK; Ng, KT; Tang, SG; Wong, CW, 1995) |
| "To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation." | 9.08 | Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. ( Heiskanen, O; Kalimo, H; Kivipelto, L; Kuurne, T; Timonen, U; Toivanen, P; Unsgaard, G; Valtonen, S, 1997) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma." | 9.08 | Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ( Ames, MM; Bagniewski, PJ; Buckner, JC; Cascino, TL; Marks, RS; Rajkumar, SV; Reid, JM; Schomberg, PJ, 1998) |
| "We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and PCNU with those of RT and carmustine (BCNU) in patients with malignant glioma." | 9.07 | Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. ( Arusell, RM; Brown, LD; Buckner, JC; Dinapoli, RP; Earle, JD; Krook, JE; Maier, JA; O'Fallon, JR; Scheithauer, BW; Tschetter, LK, 1993) |
| "We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy." | 9.07 | Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. ( Bigner, DD; Burger, PC; Cairncross, JG; Dropcho, EJ; Halperin, EC; Herndon, JE; Macdonald, DR; Morawetz, R; Schold, SC; Vick, NA, 1993) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 9.06 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. ( Carabell, S; Chang, CH; Diener-West, M; Goodman, R; Nelson, DF; Nelson, JS; Sause, WT; Schoenfeld, D; Weinstein, AS, 1986) |
| "Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial to determine its efficacy in patients with anaplastic gliomas compared to the more standard 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment following whole-brain irradiation." | 9.06 | Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Erexson, GL; Kligerman, AD; Schold, SC; Wilmer, JL, 1987) |
| "Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy." | 9.05 | Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model. ( Aronin, P; Dudka, L; Mahaley, MS; Steinbok, P; Zinn, D, 1981) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 9.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "A randomized prospective study was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 9.05 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. ( Carabell, S; Goodman, RL; Nelson, DF; Nelson, JS; Schoenfeld, D; Wasserman, T; Weinstein, AS, 1983) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 8.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU) wafers are approved for recurrent glioblastoma and newly diagnosed malignant glioma (MG)." | 8.84 | Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. ( Giese, A; Sabel, M, 2008) |
| "Widespread use of carmustine wafers (CWs) to treat high-grade gliomas (HGG) has been limited by uncertainties about their efficacy." | 8.31 | Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Widespread use of carmustine wafers (CW) to treat high-grade gliomas (HGG) has been limited by uncertainties about its efficacy." | 8.31 | Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect." | 8.12 | Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas. ( Ammar, H; Baroud, M; Benevello, C; Benzakoun, J; Chretien, F; Dezamis, E; Dhermain, F; Moiraghi, A; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Varlet, P; Zah-Bi, G; Zanello, M, 2022) |
| "Patients with a low micro-RNA-181d (miRNA-181d) level in glioblastoma tissue benefit most of carmustine wafer use." | 8.12 | MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use. ( Ketter, R; Oertel, J; Quiring, A; Schulz-Schaeffer, W; Sippl, C; Teping, F; Urbschat, S, 2022) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 8.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "MiRNA-26a expression turned out to be a promising predictor of therapy response and clinical outcome in glioblastoma patients treated with carmustine wafer implantation." | 7.91 | miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. ( Braun, L; Ketter, R; Kim, YJ; List, M; Nakhoda, A; Oertel, J; Schoeneberger, L; Sippl, C; Teping, F; Urbschat, S; Wemmert, S, 2019) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 7.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "Carmustine wafers are approved for localized treatment of malignant glioma." | 7.83 | Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. ( Inoue, A; Kikuchi, K; Kohno, S; Kumon, Y; Ohnishi, T; Ohue, S; Seno, T; Suehiro, S; Yamashita, D, 2016) |
| "Carmustine (BCNU) wafer (Gliadel(®) Wafer) implantation after tumor resection is an approved treatment for high-grade glioma (HGG)." | 7.83 | Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma. ( Akutsu, H; Ishikawa, E; Kohzuki, H; Masuda, Y; Masumoto, T; Matsuda, M; Matsumura, A; Nakai, K; Okamoto, E; Takano, S; Yamamoto, T, 2016) |
| "The development of perifocal edema and tumor bed cyst has been reported after implantation of biodegradable carmustine wafers for the treatment of malignant gliomas." | 7.83 | The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T; Yokoi, S, 2016) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 7.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| " In this study, we have assessed the role of MDT in implementing the TA121 appraisal of the use of carmustine wafers in high grade gliomas." | 7.78 | NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. ( Ashkan, K; Cruickshank, G; Grundy, P; Price, SJ; Whittle, IR, 2012) |
| "Innovated catanionic solid lipid nanoparticles (CASLNs) carrying carmustine (BCNU) (BCNU-CASLNs) were grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/BCNU-CASLNs) and applied to inhibiting the propagation of human brain malignant glioblastomas cells." | 7.77 | Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. ( Kuo, YC; Liang, CT, 2011) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our institution with a carmustine (BCNU)--methotrexate (MTX) combination." | 7.76 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. ( About, M; Gerlotto-Borne, MC; Jacot, W; Pouderoux, S; Poujol, S; Romieu, G; Thezenas, S, 2010) |
| "Transferrin (Tf), an iron-transporting serum glycoprotein, which binds to receptors expressed at the surface of most proliferating cells with particularly high expression on erythroblasts and cancer cells, was chosen as the ligand to develop BCNU-loaded biodegradable poly(D,L-lactic acid) nanoparticles (NPs) containing a ligand, which specifically binds to glioma cells, and their anti-tumor ability was evaluated using a C6 glioma model." | 7.75 | Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. ( Albadany, A; Chang, J; Guo, Y; Kang, C; Li, Y; Pu, P; Sheng, J; Yu, S; Yuan, X; Zhang, Z; Zhong, Y, 2009) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 7.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 7.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 7.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma." | 7.73 | Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. ( Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 7.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "The human glioblastoma multiforme (GBM) cell line U87 and the rodent C6 glioma were treated with genistein at 4 microM, combined with BCNU (0-50 microM)." | 7.71 | Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. ( Khoshyomn, S; Manske, GC; Nathan, D; Osler, TM; Penar, PL, 2002) |
| " We investigated whether quinacrine could improve carmustine therapy in C6 cell cultures and in C6 malignant gliomas implanted subcutaneously into Wistar rats." | 7.71 | Quinacrine enhances carmustine therapy of experimental rat glioma. ( Herrera, LA; Ostrosky, P; Reyes, S; Sotelo, J, 2001) |
| "Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose was used to study 10 patients with recurrent glioblastoma before and 24 hours after a first dose of carmustine (120 mg/m2)." | 7.69 | Acute effect of carmustine on glucose metabolism in brain and glioblastoma. ( De Witte, O; Goldman, S; Hildebrand, J; Luxen, A, 1994) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 7.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Sequential positron emission tomographic scans with [18F]-2-fluorodeoxyglucose (PET-FDG) were performed on 6 patients with glioblastoma multiforme who were treated with adjuvant BCNU." | 7.68 | Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. ( Cohen, JD; Hanson, JM; Levine, RL; Mehta, MP; Nickles, RJ; Rozental, JM, 1993) |
| "Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy." | 7.68 | Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. ( Feun, LG; Janus, TJ; Maor, M; Yung, WK, 1992) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 7.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 7.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 7.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 6.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| "The outcome after treatment for glioblastoma remains poor." | 6.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors." | 6.68 | High-dose carmustine for high-grade gliomas in childhood. ( Biron, P; Bouffet, E; Brunat-Mentigny, M; Khelfaoui, F; Philip, I; Philip, T, 1997) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| " This mathematical model has wide applications about drug release in multiple dosage forms, such as long sustained release microspheres, oral extended release hydrophilic matrix tablets, hydrogel, and sustained release topical rings." | 5.72 | A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma. ( Chen, H; Hu, G; Ouyang, D, 2022) |
| "Gliomas are the most common brain tumors in humans." | 5.51 | A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. ( Jie, C; Yang, F; Yi, S; Zhang, G, 2019) |
| "Carmustine wafers (CW) were approved in Japan for newly diagnosed and recurrent malignant gliomas during 2013." | 5.46 | Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. ( Beppu, T; Kanamori, M; Kawataki, T; Kinouchi, H; Kumabe, T; Matsuda, KI; Nomura, S; Oda, M; Ogasawara, K; Sadahiro, H; Saito, R; Sakurada, K; Sasajima, T; Sato, Y; Shibahara, I; Shimizu, H; Sonoda, Y; Suzuki, M; Tominaga, T, 2017) |
| "Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance." | 5.46 | MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. ( Hu, J; Liu, JH; Wang, GB; Xue, K, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 5.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 5.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Carmustine wafer was not an independent predictor (P=." | 5.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| "High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively." | 5.35 | Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. ( Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Rogers, G; Somerville, M; Stein, K, 2008) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 5.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 5.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 5.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| "Retinamide treatment resulted in increased ratios of deamidated verses transamidated levels of Bcl-xL in U87 cells." | 5.33 | Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. ( Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) |
| " Dose-response studies with SH-6 administered to glioma cell lines were performed using a luminescent cell-viability assay (0." | 5.33 | Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. ( Broaddus, WC; Cash, D; Fillmore, H; Van Meter, TE, 2006) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 5.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| "Fotemustine is a chloroethylnitrosourea with antitumor activity in disseminated melanoma and adult primary brain tumors." | 5.30 | Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. ( Boland, I; Gouyette, A; Lacroix, C; Lellouch-Tubiana, A; Margison, GP; Morizet, J; Parker, F; Pierre-Kahn, A; Poullain, MG; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM; Watson, AJ, 1998) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 5.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "To determine the efficacy of methylguanine methyltransferase (MGMT) depletion + BCNU [1,3-bis(2-chloroethyl)-1- nitrosourea: carmustine] therapy and the impact of methylation status in adults with glioblastoma multiforme (GBM) and gliosarcoma." | 5.20 | A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( Blumenthal, DT; Moore, DF; Padula, GD; Rankin, C; Rushing, EJ; Schulman, SB; Sloan, AE; Spence, AM; Stelzer, KJ; Wade, ML, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 5.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "Carmustine wafer implantation during surgical resection followed by the standard chemoradiation protocol for newly diagnosed glioblastoma in adults resulted in a significant progression-free survival benefit." | 5.20 | Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. ( Audureau, E; Barat, JL; Bauchet, L; Caire, F; Corns, R; Desse, N; Devaux, B; Dezamis, E; Duntze, J; Emery, E; Faillot, T; Guyotat, J; Hieu, PD; Langlois, O; Le Reste, PJ; Lechapt-Zalcman, E; Lefranc, M; Litre, CF; Menei, P; Metellus, P; Nader, E; Noel, G; Pallud, J; Parraga, E; Pavlov, V; Peltier, J; Petit, A; Vignes, JR; Voirin, J; Zanello, M, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 5.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 5.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 5.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 5.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "Anticonvulsant therapy is usually recommended before surgery in all patients affected by high grade glioma who are planned to be treated with Carmustine 1,3-bis [2 chloroetyl]-1-nitrosurea, or BCNU) wafers." | 5.15 | Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Lombardi, G; Manara, R; Rossetto, M; Rotilio, A; Scienza, R, 2011) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "Carmustine (1,3-bis[2-chloroetyl]-1-nitrosurea (BCNU)) wafers are approved for the local treatment of newly diagnosed and recurrent malignant glioma." | 5.14 | The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Manara, R; Paola Gardiman, M; Rossetto, M; Rotilio, A; Scienza, R, 2010) |
| "451 patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine (BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART." | 5.12 | Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. ( Ballman, KV; Buckner, JC; Burton, GV; Cascino, TL; Jaeckle, KA; Marshall, NE; Michalak, JC; Sandler, HM; Schomberg, PJ, 2006) |
| "To examine the effect of adding chloroquine to conventional therapy for glioblastoma multiforme." | 5.12 | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. ( Briceño, E; López-González, MA; Sotelo, J, 2006) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 5.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 5.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma." | 5.11 | Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. ( Buckner, JC; Dinapoli, RP; Fitch, TR; Krishnan, S; Maurer, MJ; Nordstrom, K; O'Fallon, JR; Rao, RD; Scheithauer, B; Schomberg, PJ, 2005) |
| "The study involved a randomized comparison of surgery, external beam radiotherapy, and carmustine (BCNU) versus surgery, external beam therapy, interstitial radiotherapy boost, and BCNU in newly diagnosed malignant gliomas." | 5.10 | The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. ( Albright, R; Arena, VC; Barnett, GH; Blackwood, MS; Bloomfield, S; Burger, P; Gilder, JC; Green, S; Hiesiger, E; Hochberg, FH; Malkin, MG; Mealey, JJ; Neal, JH; Olson, J; Robertson, JT; Selker, RG; Shapiro, WR, 2002) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 5.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 5.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas." | 5.09 | Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. ( Buckner, JC; Cascino, TL; Ingle, JN; Pitot, HC; Rajkumar, SV; Schomberg, PJ, 1999) |
| "The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma." | 5.09 | A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001) |
| "Intra-arterial chemotherapy with carmustine (BCNU) and interstitial radiation therapy with the use of stereotactically placed 125I sources are aggressive local therapies for malignant glioma." | 5.08 | Evaluating glioma therapies: modeling treatments and predicting outcomes. ( Brothers, M; Cairncross, G; Florell, R; Irish, W; Kirby, S; Macdonald, D; Schold, C, 1995) |
| " We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas." | 5.08 | Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. ( Black, K; Brem, H; Brem, S; Burger, PC; Mohr, G; Piantadosi, S; Selker, R; Sisti, M; Vick, NA; Walker, M, 1995) |
| "To quantify the quality of life of malignant glioma patients treated on a randomized Phase I/II trial of twice-daily radiation therapy (RT) and carmustine, using a modified quality adjusted survival (QAS) model, and to compare the QAS among assigned treatment arms." | 5.08 | Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. ( Curran, WJ; Farnan, N; Fischbach, AJ; Murray, KJ; Nelson, DF; Porter, A; Scott, C, 1995) |
| "Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy." | 5.08 | Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. ( Chang, CN; Chen, LH; Cheng, WC; Ho, YS; Kiu, MC; Leung, WM; Lin, TK; Ng, KT; Tang, SG; Wong, CW, 1995) |
| " Conventional phase II clinical trials conducted in patients with recurrent or progressive brainstem gliomas using single chemotherapy agents such as cyclophosphamide, carboplatin, cisplatin, etoposide and thiotepa or combinations of chemotherapy agents have produced low response rates in the range of 15-20%." | 5.08 | Contemporary chemotherapy issues for children with brainstem gliomas. ( Allen, JC; Siffert, J, 1996) |
| "To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation." | 5.08 | Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. ( Heiskanen, O; Kalimo, H; Kivipelto, L; Kuurne, T; Timonen, U; Toivanen, P; Unsgaard, G; Valtonen, S, 1997) |
| "A Phase I study to determine the safety, toxicity, and maximum tolerated dose (MTD) of carmustine (BCNU) and interferon alpha-2a (IFN-a) when combined with radiation as initial therapy in high-grade glioma." | 5.08 | Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. ( Buckner, JC; Burch, PA; Cascino, TL; Dinapoli, RP; Rajkumar, SV; Schomberg, PJ, 1998) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma." | 5.08 | Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ( Ames, MM; Bagniewski, PJ; Buckner, JC; Cascino, TL; Marks, RS; Rajkumar, SV; Reid, JM; Schomberg, PJ, 1998) |
| "We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and PCNU with those of RT and carmustine (BCNU) in patients with malignant glioma." | 5.07 | Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. ( Arusell, RM; Brown, LD; Buckner, JC; Dinapoli, RP; Earle, JD; Krook, JE; Maier, JA; O'Fallon, JR; Scheithauer, BW; Tschetter, LK, 1993) |
| "We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy." | 5.07 | Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. ( Bigner, DD; Burger, PC; Cairncross, JG; Dropcho, EJ; Halperin, EC; Herndon, JE; Macdonald, DR; Morawetz, R; Schold, SC; Vick, NA, 1993) |
| "Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks." | 5.07 | Combined intra-arterial chemotherapy and irradiation of malignant gliomas. ( Hager, B; Hirschberg, H; Nome, O; Watne, K, 1991) |
| "Between April 1986 and March 1989, ten patients under 21 years of age with histologically confirmed malignant astrocytoma, received marrow-ablative chemotherapy with either thiotepa and Etoposide (five patients) or thiotepa, Etoposide and BCNU (five patients), followed by bone marrow 'rescue'." | 5.06 | High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. ( August, C; Bayever, E; Finlay, JL; Freid, A; Kamani, N; Kramer, E; Packer, R; Rorke, L; Sutton, L; Zimmerman, R, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial in patients with malignant gliomas to evaluate 4 treatment arms: 1) 60 Gy to the whole brain; 2) 60 Gy plus 10-Gy boost; 3) 60 Gy plus carmustine (BCNU); and 4) 60 Gy plus semustine plus dacarbazine." | 5.06 | Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. ( Chang, CH; Diener-West, M; Horton, J; Nelson, DF; Nelson, JS; Schoenfeld, D, 1988) |
| "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 5.06 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. ( Carabell, S; Chang, CH; Diener-West, M; Goodman, R; Nelson, DF; Nelson, JS; Sause, WT; Schoenfeld, D; Weinstein, AS, 1986) |
| "Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial to determine its efficacy in patients with anaplastic gliomas compared to the more standard 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment following whole-brain irradiation." | 5.06 | Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Erexson, GL; Kligerman, AD; Schold, SC; Wilmer, JL, 1987) |
| "Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy." | 5.05 | Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model. ( Aronin, P; Dudka, L; Mahaley, MS; Steinbok, P; Zinn, D, 1981) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 5.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "A randomized prospective study was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 5.05 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. ( Carabell, S; Goodman, RL; Nelson, DF; Nelson, JS; Schoenfeld, D; Wasserman, T; Weinstein, AS, 1983) |
| "Within three weeks of definitive surgical intervention, 467 patients with histologically proved malignant glioma were randomized to receive one of four treatment regimens: semustine (MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus radiotherapy." | 5.05 | Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; MacCarty, CS; Mahaley, MS; Mealey, J; Owens, G; Ransohoff, J; Robertson, JT; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1980) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| " Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment)." | 4.93 | Advanced interstitial chemotherapy for treating malignant glioma. ( Kau, YC; Liu, SJ; Tseng, YY, 2016) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 4.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy." | 4.90 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014) |
| "The 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; carmustine) polymer wafer (Gliadel) was developed for use in malignant glioma to deliver higher doses of chemotherapy directly to tumor tissue while bypassing systemic side effects." | 4.88 | The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. ( Nagpal, S, 2012) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "Loco-regional chemotherapy with carmustine wafers (Gliadel) positioned at surgery and followed by radiotherapy has been shown to prolong survival in first-diagnosis glioblastoma, as well as concomitant radiochemotherapy with temozolomide." | 4.87 | Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. ( Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A, 2011) |
| "Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU) wafers are approved for recurrent glioblastoma and newly diagnosed malignant glioma (MG)." | 4.84 | Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. ( Giese, A; Sabel, M, 2008) |
| "Carmustine wafers (Gliadel) and temozolomide (Temodal) were recently approved for initial management of glioblastoma." | 4.84 | [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. ( Ducray, F; Honnorat, J, 2007) |
| "Temozolomide (TMZ) is a new, orally administered, second-generation imidazotetrazine prodrug with essentially 100% oral bioavailability that has demonstrated meaningful efficacy and an acceptable safety profile in the treatment of patients with recurrent glioblastoma multiforme." | 4.80 | Future directions in the treatment of malignant gliomas with temozolomide. ( Prados, MD, 2000) |
| "Widespread use of carmustine wafers (CWs) to treat high-grade gliomas (HGG) has been limited by uncertainties about their efficacy." | 4.31 | Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Widespread use of carmustine wafers (CW) to treat high-grade gliomas (HGG) has been limited by uncertainties about its efficacy." | 4.31 | Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Carmustine wafers can be implanted in the surgical bed of high-grade gliomas, which can induce surgical bed cyst formation, leading to clinically relevant mass effect." | 4.12 | Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas. ( Ammar, H; Baroud, M; Benevello, C; Benzakoun, J; Chretien, F; Dezamis, E; Dhermain, F; Moiraghi, A; Oppenheim, C; Pallud, J; Parraga, E; Peeters, S; Roux, A; Varlet, P; Zah-Bi, G; Zanello, M, 2022) |
| "Patients with a low micro-RNA-181d (miRNA-181d) level in glioblastoma tissue benefit most of carmustine wafer use." | 4.12 | MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use. ( Ketter, R; Oertel, J; Quiring, A; Schulz-Schaeffer, W; Sippl, C; Teping, F; Urbschat, S, 2022) |
| "The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy." | 4.12 | [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities]. ( Imai, R; Sasaki, H, 2022) |
| "Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown." | 4.12 | Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures. ( Fujii, Y; Goto, T; Hanaoka, Y; Hardian, RF; Hongo, K; Horiuchi, T; Kato, H; Ogiwara, T, 2022) |
| "Clinical trial data of Carmustine implant (Gliadel Wafer) in Japanese patients with malignant glioma are limited; thus, we conducted a postmarketing surveillance study to evaluate the safety of Gliadel in real-world clinical practice in Japan." | 4.02 | Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan. ( Iwata, H; Matsuoka, T; Muramoto, K; Nishikawa, R; Sakata, Y, 2021) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 4.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "Carmustine wafers (CW) are approved to treat newly or recurrent high-grade gliomas (HGG)." | 3.96 | Implantation of carmustine wafers (Gliadel ( Champeaux, C; Weller, J, 2020) |
| "MiRNA-26a expression turned out to be a promising predictor of therapy response and clinical outcome in glioblastoma patients treated with carmustine wafer implantation." | 3.91 | miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. ( Braun, L; Ketter, R; Kim, YJ; List, M; Nakhoda, A; Oertel, J; Schoeneberger, L; Sippl, C; Teping, F; Urbschat, S; Wemmert, S, 2019) |
| "In situ carmustine wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are commonly used for the treatment of recurrent glioblastoma to overcome the brain-blood barrier." | 3.88 | Incomplete copolymer degradation of in situ chemotherapy. ( Apra, C; Boissenot, T; Bourdillon, P; Carpentier, A; Goldwirt, L; Nicolas, J, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "Although carmustine (Gliadel) wafers improve local tumor control and extend the overall survival in patients with malignant glioma, adverse effects have been documented." | 3.85 | Eosinophilic meningitis triggered by implanted Gliadel wafers: case report. ( Ivanova, A; Saito, K; Sato, Y; Takeishi, G; Takeshima, H; Yamasaki, K; Yokogami, K, 2017) |
| "The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM)." | 3.85 | Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up. ( Berti, F; Cecchin, D; Della Puppa, A; Gardiman, MP; Lombardi, G; Persano, L; Rolma, G; Rossetto, M; Rustemi, O; Scienza, R; Zagonel, V, 2017) |
| "Carmustine wafers are approved for localized treatment of malignant glioma." | 3.83 | Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. ( Inoue, A; Kikuchi, K; Kohno, S; Kumon, Y; Ohnishi, T; Ohue, S; Seno, T; Suehiro, S; Yamashita, D, 2016) |
| "Carmustine (BCNU) wafer (Gliadel(®) Wafer) implantation after tumor resection is an approved treatment for high-grade glioma (HGG)." | 3.83 | Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma. ( Akutsu, H; Ishikawa, E; Kohzuki, H; Masuda, Y; Masumoto, T; Matsuda, M; Matsumura, A; Nakai, K; Okamoto, E; Takano, S; Yamamoto, T, 2016) |
| "Carmustine (BCNU) wafer implantation has been used in Japanese patients after resection of high-grade glioma (HGG) since 2013." | 3.83 | [Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons]. ( Ishikawa, E; Yamamoto, T, 2016) |
| "The development of perifocal edema and tumor bed cyst has been reported after implantation of biodegradable carmustine wafers for the treatment of malignant gliomas." | 3.83 | The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T; Yokoi, S, 2016) |
| " The proposed approach fares considerably better than previous approaches in simulations; data on the effectiveness of biodegradable carmustine polymers on recurrent brain malignant gliomas is investigated." | 3.80 | Accelerated hazards model based on parametric families generalized with Bernstein polynomials. ( Chen, Y; Hanson, T; Zhang, J, 2014) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 3.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity." | 3.78 | Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. ( Dörner, L; Kesari, S; Mehdorn, HM; Nabavi, A; Schultka, S; Spalek, K; Ulmer, S, 2012) |
| " In this study, we have assessed the role of MDT in implementing the TA121 appraisal of the use of carmustine wafers in high grade gliomas." | 3.78 | NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. ( Ashkan, K; Cruickshank, G; Grundy, P; Price, SJ; Whittle, IR, 2012) |
| " The purpose of this study was to investigate the efficacy of concurrent therapy with 1,3 bis[2-chloroethyl]-1-nitrosourea (BCNU; carmustine) and Gamma Knife radiosurgery (GKRS; Gamma Knife® Model C, Elekta AB, Stockholm, Sweden) in the C6 rat glioma model." | 3.78 | Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model. ( Cho, KT; Chung, HT; Jung, HW; Kim, DG; Paek, SH; Park, HW, 2012) |
| " Here we examine the extent of β-GUS release in small C6 glioma tumors after a single treatment of doxorubicin (DOX), carmustine (BCNU) and tumor necrosis factor α (TNF-α) with positron emission tomography (PET) and the tracer 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-d-glucopyronuronate, [(18)F]FEAnGA, which has been proven to be selective for extracellular β-GUS." | 3.78 | Induction of β-glucuronidase release by cytostatic agents in small tumors. ( Antunes, IF; de Vries, EF; Di Gialleonardo, V; Dierckx, RA; Elsinga, PH; Haisma, HJ; van Waarde, A; Willemsen, AT, 2012) |
| "Innovated catanionic solid lipid nanoparticles (CASLNs) carrying carmustine (BCNU) (BCNU-CASLNs) were grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/BCNU-CASLNs) and applied to inhibiting the propagation of human brain malignant glioblastomas cells." | 3.77 | Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. ( Kuo, YC; Liang, CT, 2011) |
| "Carmustine (BCNU: N,N'-bis[2-chloroethyl]-N-nitrosourea) wafers are a local chemotherapeutic agent for the treatment of malignant glioma." | 3.76 | Incorporating BCNU wafers into malignant glioma treatment: European case studies. ( Balossier, A; Dörner, L; Emery, E; Heese, O; Mehdorn, HM; Menei, P; Singh, J, 2010) |
| "Epigenetic silencing of the MGMT gene by promoter methylation is associated with loss of MGMT expression, diminished DNA-repair activity and longer overall survival in patients with glioblastoma who, in addition to radiotherapy, received alkylating chemotherapy with carmustine or temozolomide." | 3.76 | Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. ( Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "A retrospective multicenter study was conducted in 26 French Departments of Neurosurgery to analyze practices of French neurosurgeons using Gliadel, compare the adverse effects and survival with those of previous phase III trials, and assess survival in patients with newly diagnosed malignant gliomas (MG) receiving Gliadel plus radiochemotherapy with temozolomide (TMZ)." | 3.76 | Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. ( Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E, 2010) |
| "Since 1999, patients presenting with brain metastases (BM) from breast cancer (BC) are treated in our institution with a carmustine (BCNU)--methotrexate (MTX) combination." | 3.76 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. ( About, M; Gerlotto-Borne, MC; Jacot, W; Pouderoux, S; Poujol, S; Romieu, G; Thezenas, S, 2010) |
| " We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy." | 3.76 | First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. ( Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M, 2010) |
| "This study investigated the effect of TNP-470 in combination with carmustine (BCNU) on the growth of subcutaneously implanted human glioblastoma xenografts in nude mice." | 3.76 | Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts. ( Chen, J; Jiang, X; Yao, D; Zhang, F; Zhao, H; Zhu, X, 2010) |
| " We report the case of a 57-year-old man who had parietal glioblastoma resection with local carmustine chemotherapy and who presented a clostridial brain abscess three weeks later." | 3.75 | [Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature]. ( Bajolet, O; Duntze, J; Eap, C; Litré, CF; Peruzzi, P; Rousseaux, P; Theret, E, 2009) |
| "Transferrin (Tf), an iron-transporting serum glycoprotein, which binds to receptors expressed at the surface of most proliferating cells with particularly high expression on erythroblasts and cancer cells, was chosen as the ligand to develop BCNU-loaded biodegradable poly(D,L-lactic acid) nanoparticles (NPs) containing a ligand, which specifically binds to glioma cells, and their anti-tumor ability was evaluated using a C6 glioma model." | 3.75 | Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. ( Albadany, A; Chang, J; Guo, Y; Kang, C; Li, Y; Pu, P; Sheng, J; Yu, S; Yuan, X; Zhang, Z; Zhong, Y, 2009) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 3.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)." | 3.74 | Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect." | 3.73 | Cerebral edema associated with Gliadel wafers: two case studies. ( Goebel, EA; Weber, EL, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 3.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 3.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma." | 3.73 | Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. ( Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) |
| " The best dose (product of 4x10(6) cells) of TF was also combined with carmustine for experimental therapy in rats with C6 malignant glioma." | 3.73 | Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. ( Arrieta, O; Estrada-Parra, S; Pedraza-Medina, B; Pérez, R; Pineda, B; Rodriguez-Ropon, A, 2005) |
| " The typically local recurrence of glioblastoma in about 80% of the cases has prompted intracavitary treatments of which presently only a biodegradable wafer containing carmustine has shown statistically significant benefit regarding survival in three phase III trials." | 3.72 | Intracavitary chemotherapy for glioblastoma: present status and future directions. ( Hilt, D; Lamszus, K; Westphal, M, 2003) |
| "To investigate the ability of systemically delivered BCNU to enhance the activity of either systemically delivered irinotecan (CPT-11) or locally delivered camptothecin from a biodegradable polymer for treatment of an intracranial 9L gliosarcoma." | 3.72 | Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. ( Brem, H; Moriarity, JL; Renard, VM; Storm, PB; Tyler, B; Weingart, JD; Wilentz, RE, 2004) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 3.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "The human glioblastoma multiforme (GBM) cell line U87 and the rodent C6 glioma were treated with genistein at 4 microM, combined with BCNU (0-50 microM)." | 3.71 | Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. ( Khoshyomn, S; Manske, GC; Nathan, D; Osler, TM; Penar, PL, 2002) |
| " We investigated whether quinacrine could improve carmustine therapy in C6 cell cultures and in C6 malignant gliomas implanted subcutaneously into Wistar rats." | 3.71 | Quinacrine enhances carmustine therapy of experimental rat glioma. ( Herrera, LA; Ostrosky, P; Reyes, S; Sotelo, J, 2001) |
| "Chemosensitivity of previously untreated glioblastomas to mitoxantrone, methotrexate, ACNU and BCNU was tested on cultured tissue." | 3.70 | Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein. ( Damian, MS; Leweke, F; Schachenmayr, W; Schindler, C, 1998) |
| ") carmustine is highly effective for the treatment of intracranial 9L gliosarcoma in tumors." | 3.70 | Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. ( Kleinschmidt-DeMasters, BK; Kong, Q; Lillehei, KO, 1998) |
| " In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy." | 3.70 | A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998) |
| " Survival data from an actual randomized placebo-controlled trial, which evaluates the effectiveness of biodegradable polymers with carmustine to treat malignant gliomas, is used for illustration." | 3.70 | Estimating a treatment effect with the accelerated hazards models. ( Chen, YQ; Wang, M, 2000) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Carmustine and lomustine are nitrosourea antitumor chemotherapeutic agents which were used to determine whether or not they could affect arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adducts in rat glial tumor cell line (C6 glioma)." | 3.70 | Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. ( Hung, CF, 2000) |
| " The present studies examined the ability of injectable polymeric microspheres, formulated to release carboplatin or BCNU for 2-3 weeks, to enhance survival in a rodent model of surgically-resected glioma." | 3.70 | Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors. ( Bartus, RT; Emerich, DF; Hasler, BP; Hu, Y; LaFreniere, D; Marsh, J; Snodgrass, P; Wiens, T; Winn, SR, 2000) |
| " The present studies examined the ability of injectable microspheres, formulated to release carboplatin or BCNU for 2-3 weeks, to enhance survival in a rodent model of deep, inoperable glioma." | 3.70 | Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. ( Agostino, M; Bartus, RT; Emerich, DF; LaFreniere, D; Snodgrass, P; Wiens, T; Winn, SR; Xiong, H, 2000) |
| " The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU)." | 3.70 | Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. ( Andion, E; Baylin, SB; Esteller, M; Garcia-Foncillas, J; Goodman, SN; Herman, JG; Hidalgo, OF; Vanaclocha, V, 2000) |
| "Diffusion MRI could detect water diffusion changes in orthotopic 9L gliomas after doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) that resulted in as little as 0." | 3.70 | Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. ( Chenevert, TL; Greenberg, HS; Rehemtulla, A; Robertson, PL; Ross, BD; Stegman, LD; Taylor, JM, 2000) |
| "To evaluate the potential differential effect of pretreatment with pharmacologic doses of the trace element zinc on the chemosensitivity of glioma cells and bone marrow cells for carmustine (BCNU), we performed in vitro and in vivo studies of zinc toxicity as well as of the combined treatment with zinc and the anticancer drug." | 3.69 | Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine. ( Dougherty, DV; Doz, F; Roosen, N; Rosenblum, ML; Yeomans, KL, 1994) |
| "Previously, we have reported in 1990 that 35% of carmustine treated patients (6 of 17) who survived childhood brain tumors died of pulmonary fibrosis between 2 and 13 years after treatment." | 3.69 | Late carmustine lung fibrosis. Age at treatment may influence severity and survival. ( Gattamaneni, HR; Kalra, S; O'Driscoll, BR; Woodcock, AA, 1995) |
| "This study was designed to explore the question of whether minocycline, a semisynthetic tetracycline shown to inhibit tumor-induced angiogenesis, could control the growth of the rat intracranial 9L gliosarcoma." | 3.69 | The role of minocycline in the treatment of intracranial 9L glioma. ( Brem, H; Sipos, EP; Weingart, JD, 1995) |
| "Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose was used to study 10 patients with recurrent glioblastoma before and 24 hours after a first dose of carmustine (120 mg/m2)." | 3.69 | Acute effect of carmustine on glucose metabolism in brain and glioblastoma. ( De Witte, O; Goldman, S; Hildebrand, J; Luxen, A, 1994) |
| " It has been shown previously that implantation of controlled-release polymers impregnated with the nitrosourea carmustine (BCNU) extended the period of survival in rats bearing the 9L glioma compared with similar rats treated with systemically administered BCNU." | 3.69 | Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. ( Brem, H; Epstein, JI; Olivi, A; Pinn, M; Tamargo, RJ; Weingart, JD; Wharam, M, 1994) |
| " This was done using antibromodeoxyuridine immunohistochemical stain and multiple tracer quantitative autoradiography in a C6 rat brain with an implanted glioma." | 3.69 | The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. ( Diksic, M; Takeda, N; Yamamoto, YL, 1996) |
| " The chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), carboplatin, and camptothecin were incorporated into controlled-release polymers and tested individually against intracranial challenges with one of four tumors (lung carcinoma, renal cell carcinoma, colon carcinoma, and melanoma)." | 3.69 | Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. ( Anderson, RC; Babel, KM; Brat, DJ; Brem, H; Ewend, MG; Pinn, ML; Tabassi, K; Tyler, BM; Williams, JA, 1996) |
| "Fifteen human glioma cell lines were examined for their sensitivity to 1,3-bis(chloroethyl)-nitrosourea (BCNU, carmustine) and cis-dichlorodiamminoplatinum (cisplatin), the induction of DNA interstrand cross-linking (DNA-ISC) induced by the two agents and cellular O6-alkylguanine alkyltransferase (ATase) activity." | 3.69 | DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase. ( Beith, J; Darling, J; Hartley, J; Souhami, R, 1997) |
| "A total of 379 patients with histologic intracranial low-grade glioma received post-operative radiotherapy (n = 361) and intraarterial carmustine (BCNU) chemotherapy (n = 153)." | 3.69 | Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. ( Berg-Johnsen, J; Egeland, T; Hager, B; Hirschberg, H; Lote, K; Skullerud, K; Stenwig, B; Storm-Mathisen, I, 1997) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 3.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Sequential positron emission tomographic scans with [18F]-2-fluorodeoxyglucose (PET-FDG) were performed on 6 patients with glioblastoma multiforme who were treated with adjuvant BCNU." | 3.68 | Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. ( Cohen, JD; Hanson, JM; Levine, RL; Mehta, MP; Nickles, RJ; Rozental, JM, 1993) |
| "Eight patients with malignant gliomas were monitored with clinical examinations to study the effects of the combination of intravenous administration of carmustine and infraophthalmic intra-arterial administration of cisplatin on retinal and optic nerve function." | 3.68 | Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. ( Hiesiger, E; Holopigian, K; Kupersmith, MJ; Noble, K; Seiple, WH; Warren, F, 1992) |
| "Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy." | 3.68 | Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. ( Feun, LG; Janus, TJ; Maor, M; Yung, WK, 1992) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 3.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| " The water-soluble ACNU (nimustine) is an alternative to other nitrosoureas in the treatment of gliomas." | 3.68 | Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma. ( Dahl, O; Schem, BC, 1991) |
| "We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours." | 3.68 | Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. ( Gattamaneini, HR; Hasleton, PS; Kalra, SJ; Lynch, P; O'Driscoll, BR; Poulter, LW; Webster, A; Woodcock, AA, 1991) |
| "Carmustine (BCNU) is an anticancer drug known to produce pulmonary fibrosis as a side effect within three years of treatment." | 3.68 | Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. ( Gattameneni, HR; Hasleton, PS; O'Driscoll, BR; Poulter, LW; Taylor, PM; Woodcock, AA, 1990) |
| "Twenty-six patients with intracerebral tumors (predominantly gliomas) were treated with intraarterial BCNU, VM-26, and cisplatin combined with the systemic administration of VM-26, methotrexate, vincristine, bleomycin, and procarbazine." | 3.67 | Combined intraarterial and systemic chemotherapy for intracerebral tumors. ( Benoit, B; Grahovac, Z; Hugenholtz, H; Richard, M; Russell, N; Stewart, DJ, 1987) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "Intensive monochemotherapy with carmustine (BCNU) (either 1,050, 1,200, or 1,350 mg/m2) and cryopreserved autologous marrow transplantation was administered to 36 patients with malignant glioma: 27 with progressive disease and nine without progression (adjuvant therapy group)." | 3.67 | Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. ( Fay, JW; Herzig, GP; Herzig, RH; Lazarus, HM; Phillips, GL; Schold, C; Wolff, SN, 1986) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| " We treated 25 consecutive patients (13 pilot patients and 12 protocol patients) with histologically confirmed unresectable grade 3 or 4 malignant gliomas with high-dose BCNU (carmustine) followed by autologous bone marrow transplantation and whole brain irradiation." | 3.67 | Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. ( Corwin, JA; Daly, MB; de los Reyes, RA; Johnson, DB; Lamaster, D; Mosley, KR; Petty, AM; Pierson, WP; Smith, MT; Thompson, JM, 1987) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 3.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "Thirteen patients with advanced (Stage III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation." | 3.66 | Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. ( Dantas, ME; Glode, LM; Koeppler, H; Morton, N; Robinson, WA; Sutherland, J; Thomas, MR, 1982) |
| "A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice were used to determine the effect of combined modality therapy with gamma-radiation, and three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.66 | Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. ( Feola, J; Houchens, DP; Ovejera, AA; Slagel, DE, 1982) |
| "A patient who had a pneumonectomy for lung carcinoma was treated with carmustine when brain metastases developed." | 3.66 | Pulmonary toxicity from carmustine (BCNU): a case report. ( Shah, S; Shane, SR; Weiss, RB, 1979) |
| "Five children with recurrent medulloblastomas were treated with Vincristine, BCNU, Methotrexate and Dexamethasone." | 3.66 | Combination chemotherapy in recurrent medulloblastoma. ( Cohen, ME; Duffner, PK; Freeman, AI; Sinks, LF; Thomas, PR, 1979) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "High grade gliomas are associated with poor prognosis and high mortality." | 2.94 | A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. ( Black, KL; Chu, RM; Hu, JL; Mazer, MJ; Nuno, M; Phuphanich, S; Rudnick, JD; Sarmiento, JM; Uy, B; Wang, H; Wheeler, CJ; Yu, JS, 2020) |
| "Glioblastoma is the commonest primary brain cancer in adults whose outcomes are amongst the worst of any cancer." | 2.82 | Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature. ( Akkari, L; Borst, GR; Coope, DJ; McBain, C; O'Connor, J; Quinones-Hinojosa, A; Trifiletti, DM; Waqar, M, 2022) |
| " Subgaleal effusion was the most common adverse event, presenting in 7 patients (46." | 2.79 | Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. ( Chen, YS; Chen, ZH; Chen, ZP; Gao, WC; Guo, CC; Ke, C; Li, X; Lin, FH; Lv, YC; Mou, YG; Sai, K; Wang, J; Yang, QY; Zeng, J; Zhang, XH; Zhong, MG, 2014) |
| "Patients with brain metastases had improvements in their cognitive trajectory, especially memory and executive function, after treatment with resection plus CW." | 2.78 | Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. ( Booth-Jones, M; Brem, S; Ewend, MG; Jain, S; Meyers, CA; Palmer, G, 2013) |
| " In the other five patients the regional superselective chemoinfusion was fulfilled successfully to the arteries feeding the metastatic foci in the brain with Carmustin in dosage 100 mg in combination with radiation therapy that was fulfilled in all six patients before the planned total focal dose." | 2.76 | [Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results]. ( Korytova, LI; Meshechkin, AV; Suvorova, IuV; Zhabina, RM, 2011) |
| "Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas." | 2.75 | Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. ( Ames, MM; Arusell, R; Ballman, KV; Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Hammack, JE; Jaeckle, KA; McGovern, RM; Morton, RF; Nikcevich, DA; Reid, JM; Safgren, SL; Schomberg, PJ; Uhm, JH; Wender, DB, 2010) |
| " Two patients had severe adverse events thought to be related to wafer placement, one with seizures alone, and one with seizures and subsequent respiratory compromise." | 2.73 | Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. ( Brem, S; Carey, LA; Cush, S; Ewend, MG; Gilbert, M; Goodkin, R; Penar, PL; Varia, M, 2007) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "To investigate the therapeutic effect of photodynamic therapy (PDT) combined with interstitial chemo- therapy on gliomas after microsurgery." | 2.71 | [Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas]. ( Chen, LF; Ke, YQ; Wang, SQ; Xu, RX; Yang, ZL, 2005) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 2.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| "The outcome after treatment for glioblastoma remains poor." | 2.69 | Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Twenty patients with recurrent brain tumors aged 0." | 2.69 | Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. ( Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, S; Garvin, JH; Goldman, S; Gollamudi, S; Guruangan, S; Merchant, TE; Rosenblum, M, 1998) |
| "Paclitaxel was given alone (one patient), with cyclophosphamide and cisplatin (two patients), and with cyclophosphamide and cisplatin plus 1,3-bis(2-chloroethyl)-1-nitrosourea (three patients)." | 2.69 | Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. ( Barón, A; Bearman, SI; Cagnoni, PJ; DeBoom, T; Jones, RB; Matthes, S; Nieto, Y; Shpall, EJ, 1999) |
| "Histology included anaplastic astrocytoma (AA) in 15 patients and glioblastoma multiforme (GBM) in 49 patients." | 2.68 | Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. ( Antunovic, V; Djuric, L; Grujicic, D; Jeremic, B; Shibamoto, Y, 1995) |
| " Interstitial chemotherapy with BCNU-polymer with subsequent radiation therapy appears to be safe as an initial therapy." | 2.68 | The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. ( Brem, H; Burger, PC; Ewend, MG; Greenhoot, J; Piantadosi, S; Sisti, M, 1995) |
| "Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors." | 2.68 | High-dose carmustine for high-grade gliomas in childhood. ( Biron, P; Bouffet, E; Brunat-Mentigny, M; Khelfaoui, F; Philip, I; Philip, T, 1997) |
| "Sixteen patients with intracerebral tumors received intraarterial cisplatin, teniposide, and BCNU combined with intravenous cisplatin, teniposide, and cytosine arabinoside." | 2.67 | Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. ( Belanger, G; Benoit, B; DaSilva, V; Grahovac, Z; Hugenholtz, H; Richard, MT; Russell, N; Stewart, DJ, 1993) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Malignant gliomas have been difficult to treat with chemotherapy." | 2.67 | Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. ( Black, KL; Brem, H; Burger, PC; Ciric, IS; Cozzens, JW; Eller, TW; Friedman, AH; Mahaley, MS; Schold, SC; Vick, NA, 1991) |
| "Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges." | 2.66 | Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention. ( Butti, G; Gaetani, P; Knerich, R; Rossi, A; Silvani, V; Spanu, G, 1987) |
| "Patients with anaplastic astrocytoma had a median survival of 27 months as compared to 8 months for patients with glioblastoma." | 2.65 | Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. ( Chang, CH; Horton, J; Kramer, S; Nelson, JS; Perez-Tamayo, R; Salazer, O; Schoenfeld, D; Tsukada, Y; Weinstein, A, 1983) |
| "Thirteen of 19 (68%) evaluable primary brain tumors and 9 of 16 (56%) evaluable brain metastases responded." | 2.65 | Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary ( Addison, D; Benoit, B; Dennery, J; Grahovac, Z; Hugenholtz, H; Maroun, JA; Peterson, E; Richard, MT; Russell, N; Stewart, DJ, 1984) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "The incidence of brain metastases was neither lowered nor delayed by the presence of BCNU in regimens A and C." | 2.64 | Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. ( Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U, 1976) |
| "Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU." | 2.64 | Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). ( Berris, R; Hill, GJ; Parkin, P; Philpott, GW; Ruess, R, 1974) |
| "Temozolomide (TMZ) is a DNA-methylating agent." | 2.53 | Current and Future Drug Treatments for Glioblastomas. ( Hirose, Y; Ohba, S, 2016) |
| "Glioblastoma is the most common adult malignant primary brain tumor." | 2.52 | Current medical treatment of glioblastoma. ( Ahluwalia, MS; Peereboom, DM; Venur, VA, 2015) |
| "Malignant glioma is one of the most challenging central nervous system (CNS) diseases, which is typically associated with high rates of recurrence and mortality." | 2.50 | Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. ( Fan, CH; Liu, HL; Ting, CY; Yeh, CK, 2014) |
| "Radiation necrosis impacts the quality of life in cancer survivors, and it is essential to detect and effectively treat this entity as early as possible." | 2.49 | Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. ( Marko, NF; Rahmathulla, G; Weil, RJ, 2013) |
| "Malignant gliomas are the most frequently occurring, devastating primary brain tumors, and are coupled with a poor survival rate." | 2.49 | Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. ( Juratli, TA; Krex, D; Schackert, G, 2013) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Temozolomide (TMZ) has emerged as an active agent against malignant gliomas." | 2.44 | Management of glioblastoma. ( Aoki, T; Hashimoto, N; Matsutani, M, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Malignant gliomas are among the most devastating human cancers." | 2.43 | Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. ( Brem, H; Brem, S; Gallia, GL, 2005) |
| "Radiation therapy for five primary brain tumors is discussed based on the results of prospective trials." | 2.42 | [Evidence-based radiation therapy for primary brain tumors]. ( Kono, T; Nankoh, S; Shibamoto, Y; Taniguchi, H; Tomita, N; Tsuji, H, 2003) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "New approaches to malignant glioma are being actively investigated." | 2.42 | Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. ( Brem, H; Guerin, C; Lawson, HC; Olivi, A; Weingart, JD, 2004) |
| "We found that those tumors with high MGMT activity and abundance of MGMT protein were resistant to alkylating agents killing effect, while those with low MGMT activity and little MGMT protein were sensitive to alkylating anti-tumor drugs." | 2.42 | [Study on MGMT assay and tumor individual predictable chemotherapy]. ( Zhang, YP, 2004) |
| "Use of interstitial BCNU wafers in the treatment of malignant glioma is currently a controversial topic among neurosurgeons." | 2.41 | The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. ( Engelhard, HH, 2000) |
| "High-grade malignant gliomas are inevitably fatal, despite every effort to improve this prognosis, including various radiotherapeutic modalities, radio- and chemotherapeutic associations, and combinations of several drugs." | 2.41 | High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. ( Basso, U; Brandes, AA; Monfardini, S; Palmisano, V; Pasetto, LM, 2001) |
| "Carmustine (BCNU) has been shown to have limited activity at conventional dosage but is still the standard chemotherapy." | 2.41 | [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma]. ( Alcaraz, L; Benboubker, L; Bergemer-Fouquet, AM; Calais, G; Colombat, P; Destrieux, C; Jan, M; Linassier, C, 2001) |
| "Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed." | 2.41 | Drug delivery to tumors of the central nervous system. ( Brem, H; Langer, R; Lesniak, MS, 2001) |
| " Given the localised nature of the drug in the brain tissue, no direct pharmacokinetic measurements have been made in humans after implantation of a carmustine wafer." | 2.41 | Pharmacokinetics of the carmustine implant. ( Fleming, AB; Saltzman, WM, 2002) |
| "The therapy is more effective for anaplastic astrocytoma than glioblastoma." | 2.40 | [Chemoradiation for malignant brain tumors]. ( Matsutani, M, 1997) |
| "14 other patients with astrocytic glioma, two of whom are children, are reported in the literature to have diffuse bone marrow metastasis." | 2.40 | Bone marrow metastasis in astrocytic gliomata. ( Grimard, L; Hsu, E; Jimenez, C; Keene, D; Matzinger, MA; Ventureyra, E; Wang, HS, 1998) |
| "Esthesioneuroblastoma (olfactory neuroblastoma) is a rare neuroendocrine tumor that arises in the upper nasal cavity from the olfactory epithelium." | 2.40 | Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. ( Buckner, JC; Lewis, JE; McElroy, EA, 1998) |
| "Therapy of brain tumors has been limited by lack of effective methods of drug delivery." | 2.39 | New delivery systems for brain tumor therapy. ( Brem, H; Sipos, EP, 1995) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| " Serious consequences can be avoided by expecting changes in phenytoin dosage requirements after the administration of chemotherapy, monitoring serum levels frequently, and making appropriate adjustments in phenytoin dosages." | 2.38 | Decreased phenytoin levels in patients receiving chemotherapy. ( Gilbert, MR; Grossman, SA; Sheidler, VR, 1989) |
| " Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations." | 2.37 | Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984) |
| " This mathematical model has wide applications about drug release in multiple dosage forms, such as long sustained release microspheres, oral extended release hydrophilic matrix tablets, hydrogel, and sustained release topical rings." | 1.72 | A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma. ( Chen, H; Hu, G; Ouyang, D, 2022) |
| "Gliomas are the most common brain tumors in humans." | 1.51 | A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. ( Jie, C; Yang, F; Yi, S; Zhang, G, 2019) |
| "Here, we report a case of external hydrocephalus caused by Gliadel-induced eosinophilic meningitis that has been previously reported in only 1 case and can be diagnosed by time-spatial labeling inversion pulse magnetic resonance imaging (time-SLIP MRI)." | 1.48 | Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus. ( Abe, M; Adachi, K; Hirose, Y; Kumai, T; Murayama, K; Nakae, S, 2018) |
| "BCNU wafer implantation after resection of recurrent GBM is a reasonably safe treatment in patients aged >65 years." | 1.46 | Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma. ( Daubner, D; Juratli, TA; Klein, J; Krex, D; Radev, Y; Schackert, G; Soucek, S, 2017) |
| "Carmustine wafers (CW) were approved in Japan for newly diagnosed and recurrent malignant gliomas during 2013." | 1.46 | Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. ( Beppu, T; Kanamori, M; Kawataki, T; Kinouchi, H; Kumabe, T; Matsuda, KI; Nomura, S; Oda, M; Ogasawara, K; Sadahiro, H; Saito, R; Sakurada, K; Sasajima, T; Sato, Y; Shibahara, I; Shimizu, H; Sonoda, Y; Suzuki, M; Tominaga, T, 2017) |
| "Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance." | 1.46 | MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. ( Hu, J; Liu, JH; Wang, GB; Xue, K, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 1.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| " Several adverse events(AEs)associated with implantation of BCNU wafers, including cerebral edema or cyst formation, are recognized." | 1.42 | [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas]. ( Asaoka, K; Endo, S; Houkin, K; Ishi, Y; Kamoshima, Y; Kobayashi, H; Motegi, H; Terasaka, S; Yamaguchi, S; Yoshida, M, 2015) |
| "Glioblastoma multiforme is the most common malignant central nervous system tumor, and also among the most difficult to treat due to a lack of response to chemotherapeutics." | 1.39 | Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. ( Payne, CA; Safdar, S; Taite, LJ; Tu, NH, 2013) |
| " This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs." | 1.39 | Effective elimination of cancer stem cells by a novel drug combination strategy. ( Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| " The rate of adverse events, especially hematological toxicity, is relatively high, and in 3 patients treatment had to be terminated due to adverse events (one pulmonary embolism, one pulmonary fibrosis, and one severe bone marrow suppression)." | 1.36 | BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. ( Graf, E; Nikkhah, G; Pinsker, MO; Piroth, T; Reithmeier, T; Trippel, M, 2010) |
| "Malignant glioma is a common and severe primary brain tumor with a high recurrence rate and an extremely high mortality rate within 2 years of diagnosis, even when surgical, radiological, and chemotherapeutic interventions are applied." | 1.36 | Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. ( Chen, JP; Chen, PY; Chen, SM; Chu, PC; Chuang, JI; Feng, LY; Hsueh, C; Hua, MY; Huang, CY; Liu, HL; Lu, YJ; Lyu, LA; Ma, YH; Shin, JW; Tsai, HC; Tseng, IC; Wang, JJ; Wei, KC; Wu, T; Yang, HW; Yen, TC, 2010) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 1.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "12 months." | 1.35 | [Clinical features and combined treatment of the central nervous system in Hodgkin's disease]. ( Filatova, LV; Gershanovich, ML, 2008) |
| "Carmustine wafer was not an independent predictor (P=." | 1.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| "High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively." | 1.35 | Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. ( Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Rogers, G; Somerville, M; Stein, K, 2008) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 1.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 1.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 1.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| "Glioblastoma is the most common primary brain tumour with poor overall survival." | 1.34 | Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence. ( Ng, WH; Too, HP; Wan, GQ, 2007) |
| "Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM)." | 1.34 | Imaging response in malignant glioma, RTOG 90-06. ( Berkey, B; Curran, WJ; Fishbach, J; Jones, CU; Lustig, RA; Movsas, B; Scarantino, C; Seiferheld, W; Simpson, JR; Yung, AW, 2007) |
| "Retinamide treatment resulted in increased ratios of deamidated verses transamidated levels of Bcl-xL in U87 cells." | 1.33 | Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. ( Higashikubo, R; Jiang, Z; Lytle, RA; Rich, KM; Zheng, X, 2005) |
| "While cells from untreated gliomas often have over-representation of chromosome 7, chromosome 22 is typically under-represented." | 1.33 | Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Hank, NC; Scheck, AC; Shapiro, JR, 2006) |
| "Histologic analysis of treated tumors confirmed spatial changes in cellularity as observed by fDM." | 1.33 | The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. ( Chenevert, TL; Hall, DE; Hoff, BA; Johnson, TD; McKeever, PE; Meyer, CR; Moffat, BA; Rehemtulla, A; Ross, BD, 2006) |
| "A substantial percentage of brain tumors overexpressed biomarkers associated with drug resistance, including MGMT (67%), GSTP1 (49%), and mutant p53 (41%)." | 1.33 | In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. ( Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A, 2006) |
| "Cell lines derived from primary and recurrent brain tumors from the same patient and cells selected for resistance to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) were used to identify antiproliferative effects of this extract when used alone and in conjunction with BCNU." | 1.33 | Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells. ( Clark, WD; Hank, NC; Perry, K; Scheck, AC, 2006) |
| " Dose-response studies with SH-6 administered to glioma cell lines were performed using a luminescent cell-viability assay (0." | 1.33 | Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. ( Broaddus, WC; Cash, D; Fillmore, H; Van Meter, TE, 2006) |
| "In all cell lines tested, treatment of glioblastoma multiforme cells with BCNU followed by AMD3100 results in synergistic antitumor efficacy in vitro." | 1.33 | CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. ( Chan, JA; Kung, AL; Redjal, N; Segal, RA, 2006) |
| "With respect to the cerebral edema that can be associated with the carmustine implants, there can appear images in follow-up that are suggestive of relapse." | 1.33 | Patient with resected anaplastic astrocytoma and an image suggestive of relapse. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Rodríguez Lescure, A; Sáez Castán, J; Segura Ibáñez, JM, 2006) |
| "Out of 26 patients with anaplastic astrocytomas 11 were originally low-grade where no postoperative radiotherapy was applied." | 1.31 | BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "The hypodense, roughly spherical cysts clearly demonstrated clinically significant mass effect, and required reoperation despite treatment with high-dose corticosteroids." | 1.31 | Tumor bed cyst formation after BCNU wafer implantation: report of two cases. ( Engelhard, HH, 2000) |
| " The LD50 values for MX2, M2 and BCNU were 10." | 1.31 | An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro. ( Hill, JS; Kaye, AH; Park, SJ, 2000) |
| "Treatment of malignant brain tumors with chloroethylnitrosoureas (CENUs) in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 1.31 | Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. ( Chen, ZP; Huang, Q; Pan, J; Sun, ZF; Wang, AD; Zhou, LY, 2001) |
| " A dose-response relationship for BCNU was observed (hazard ratio 0." | 1.30 | Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. ( Brem, H; Burger, PC; Piantadosi, S; Sipos, EP; Tyler, B, 1997) |
| "Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology." | 1.30 | Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997) |
| "Fotemustine is a chloroethylnitrosourea with antitumor activity in disseminated melanoma and adult primary brain tumors." | 1.30 | Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. ( Boland, I; Gouyette, A; Lacroix, C; Lellouch-Tubiana, A; Margison, GP; Morizet, J; Parker, F; Pierre-Kahn, A; Poullain, MG; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM; Watson, AJ, 1998) |
| "A 35-year-old man presented with partial seizures 10 years after resection of a left-sided glioblastoma multiforme." | 1.30 | Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. ( Cecil, KM; Hackney, DB; Lenkinski, RE; Pruitt, AA; Quan, D, 1999) |
| "Animals with brain tumors treated with 4HC had a median survival span of 77 days compared to the median survival of 21 days in BCNU-treated animals and median survival of 14 days in untreated animals." | 1.29 | Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. ( Brem, H; Buahin, KG; Colvin, OM; Domb, A; Epstein, JI; Judy, KD; Olivi, A, 1995) |
| "Temozolomide was also highly effective against intracerebral implants of the U251 and SF-295 glioblastomas." | 1.29 | Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Grever, MR; Koutsoukos, AD; Moore, TD; Plowman, J; Rubinstein, LV; Waud, WR, 1994) |
| "The SF-767 brain tumors were extremely responsive to BE-4-4-4-4 alone (3 of 8 complete regressions after 2 cycles); however, the growth of the U-87 MG brain tumor was only slightly inhibited by BE-4-4-4-4 treatment." | 1.29 | Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. ( Basu, HS; Casero, RA; Dolan, ME; Feuerstein, BG; Fleig, MJ; Luk, GD; Marton, LJ, 1994) |
| "We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor." | 1.29 | Severe diffuse interstitial pneumonitis induced by carmustine (BCNU). ( Delaval, P; Desrues, B; Le Coz, A; Lena, H; Quinquenel, ML, 1994) |
| "Carmustine is a chemotherapeutic agent frequently employed in the treatment of malignant brain tumors." | 1.29 | Carmustine toxicity presenting as a lobar infiltrate. ( Byron, WA; Lee, TH; Patterson, DL; Wiemann, MC, 1993) |
| "Seven of ten anaplastic astrocytomas were composed primarily of 2n+/- cells and were BCNU resistant." | 1.29 | Chromosome number and carmustine sensitivity in human gliomas. ( Ebrahim, SA; Galicich, JH; Mohamed, AN; Pu, PY; Shapiro, JR; Shapiro, WR, 1993) |
| "Recurrent gliomas are most often treated by chemotherapy." | 1.29 | Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. ( Liang, BC, 1996) |
| "Forty-three patients with brain tumors were entered into the study." | 1.29 | Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. ( Kowada, M; Mineura, K; Watanabe, K; Yanagisawa, T; Yasui, N, 1996) |
| "During chemotherapy and regrowth of brain tumors, tumor-cell heterogeneity, and possibly tumor progression, may change as a result of both the selective forces and mutagenic effects of treatment." | 1.28 | Production of stable phenotypes from 9L rat brain tumor multicellular spheroids treated with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Barcellos-Hoff, MH; Deen, DF; Linfoot, PA; Marton, LJ, 1992) |
| " A method to individualize IA drug dosage is needed to provide each patient with the safest, most effective dose." | 1.28 | Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation. ( Bobo, H; Kapp, JP; Vance, R, 1992) |
| "Berberine was evaluated for antitumor activity against malignant brain tumors." | 1.28 | Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. ( Dougherty, DV; Rosenblum, ML; Zhang, RX, 1990) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| "Bromodeoxyuridine labeling was manipulated to differentially label metaphases from cycling and noncycling cells for sister chromatid exchange." | 1.28 | Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells. ( Barcellos-Hoff, MH; Deen, DF; Marton, LJ, 1990) |
| " Occurrence of such leukoencephalopathy is not always predictable based on BCNU dosage and cannot always be reliably distinguished from tumor regrowth or tumor necrosis by radiological and clinical evaluation." | 1.28 | Pathology of high-dose intraarterial BCNU. ( Geier, JM; Kleinschmidt-DeMasters, BK, 1989) |
| " The kinetics and dose-response relationship of this interaction were determined by measuring residual GSH and residual BCNU-cytotoxicity in aGSH/BCNU mixture over a 45-min period and at varying BCNU concentrations." | 1.28 | Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. ( Ali-Osman, F; Caughlan, J; Gray, GS, 1989) |
| " The single dosage was 100 mg/m2 and repeated every 4-6 weeks." | 1.28 | [Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma]. ( Wu, ZL, 1989) |
| "Human gliomas were grown as permanent tissue cultures and xenografts in nude mice." | 1.28 | Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice. ( Fischer, H; Hutter, KJ; Kunze, S; Schwechheimer, K; Sturm, V; Wowra, B; Zeller, WJ, 1989) |
| " Sorted populations of cells from 5 tumors had dose-response curves that were similar, although differences in cell kill of up to a half-log were commonly found between cells from different DNA peaks treated with the same BCNU dose." | 1.27 | Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content. ( Dougherty, DV; Hoshino, T; Kobayashi, S; Rosenblum, ML, 1984) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "Thirty-five patients with solid tumors received 44 courses of bis-chlorethylnitrosourea (BCNU) at doses ranging between 600 and 1,400 mg/m2 with cryopreserved or fresh autologous bone-marrow support." | 1.27 | Autologous bone-marrow transplantation: host effects of high-dose BCNU. ( Canellos, GP; Hochberg, FH; Parker, LM; Takvorian, T, 1983) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| " BCNU in combination with Vincristine and Procarbazine every 6 weeks." | 1.27 | Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors. ( Balsys, R; Bremer, AM; Duarte, P; Gonzalez, N; Kleriga, E; Miller, RI; Nguyen, TQ; Northup, HM, 1984) |
| "She developed progressive, pulmonary fibrosis as a consequence of chemotherapy, which lead to her death." | 1.27 | Chemotherapy-induced fatal pulmonary fibrosis. ( Révész, T; Somló, P, 1984) |
| "In addition, four nongliomatous primary brain tumors were treated in this fashion." | 1.27 | Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. ( Aldama-Leubbert, A; Bryan, RN; DeSantos, L; Ehni, G; Horowitz, B; Lehane, DE; Mahoney, D; Moiel, R; Rudolph, L; Zubler, MA, 1983) |
| "Thirty-one patients with metastatic brain tumors that either failed to respond or recurred after conventional therapy were treated by intra-arterial infusion of 100 mg/m2 of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) into either a carotid or vertebral artery." | 1.27 | Intra-arterial BCNU in the treatment of metastatic brain tumors. ( Byrne, TN; Cascino, TL; Deck, MD; Posner, JB, 1983) |
| "Two human brain tumors which were previously established in nude mice were used to determine antitumor efficacy of various therapeutic agents." | 1.27 | Human brain tumor xenografts in nude mice as a chemotherapy model. ( Houchens, DP; Ovejera, AA; Riblet, SM; Slagel, DE, 1983) |
| "The occurrence of pulmonary disease associated with long-term BCNU therapy is reported in two patients treated for astrocytoma grade II whose clinical presentations of pulmonary complications and corresponding tissue alterations showed striking differences." | 1.27 | BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes. ( Banerji, B; Greenwald, ES; Koss, LG; Mitsudo, SM, 1984) |
| "During this period, partial seizures occurred." | 1.27 | Decreased phenytoin level during antineoplastic therapy: a case report. ( Albani, F; Baruzzi, A; Bollini, C; Bollini, P; Cacciari, L; Ida, N; Riva, R, 1983) |
| "A combination chemotherapy regimen for brain tumors was developed, based on investigations of the survival of animals harboring the intracerebral 9L rat brain-tumor model and on analyses of their clonogenic tumor cells." | 1.27 | Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil. ( Dougherty, DV; Gerosa, MA; Rosenblum, ML; Wilson, CB, 1983) |
| "Fatal leukoencephalopathy occurred in two patients." | 1.27 | Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. ( Bashir, R; Hochberg, FH; Hottleman, K; Linggood, RM, 1988) |
| " In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40." | 1.27 | Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ( Ali-Osman, F; Dougherty, D; Giblin, J; Rosenblum, ML, 1987) |
| " The shapes of the dose-response curves indicated complete cross-resistance between BCNU and CCNU, i." | 1.27 | In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. ( Bricolo, A; Della Corte, V; Gerosa, MA; Licata, C; Marcon, C; Rosenblum, ML; Stevanoni, G; Tridente, G, 1986) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 1.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| " Comparison of the slope of the regression line for the dose-response curve and the interpolated ID90 for each drug showed that U251-MG was equally sensitive to aziridinylbenzoquinone and dianhydrogalactitol in all three assays." | 1.27 | Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours. ( Berens, ME; Dougherty, DV; Giblin, JR; Hoifodt, HK; Rosenblum, ML; Tveit, K, 1988) |
| "Malignant oligodendroglioma is a uniquely chemosensitive glial tumor." | 1.27 | Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988) |
| "Caffeine treatment potentiated the BCNU-induced accumulation of cells in late-S-G2-M phase of the cell cycle." | 1.27 | Effect of caffeine on cytotoxicity and sister chromatid exchange induction in sensitive and resistant rat brain tumor cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Aida, T; Bodell, WJ, 1987) |
| "Four of 11 patients with brain metastases had a response and 2 had stable disease." | 1.27 | Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. ( Charnsangavej, C; Feun, LG; Lee, YY; Savaraj, N; Tang, RA; Wallace, S; Yung, WK, 1986) |
| "Treatment of brain tumors by intra-arterial (IA) chemotherapy is occasionally complicated by sites of focal toxicity in the brain and retina." | 1.27 | Drug streaming during intra-arterial chemotherapy. ( Blacklock, JB; Blasberg, RG; Dedrick, RL; Doppman, JL; Lutz, RJ; Oldfield, EH; Wright, DC, 1986) |
| "High-grade primary and refractory brain tumors and metastases to the brain from other primary sites are associated with a grave prognosis." | 1.27 | Phase I trial of thermochemotherapy for brain malignancy. ( Benz, ML; Drury, B; Morton, DL; Rand, RW; Silberman, AW; Storm, FK, 1985) |
| " We have evaluated the dose-response curve for the i." | 1.27 | Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. ( Bigner, DD; Bigner, SH; Bullard, DE, 1985) |
| "Thirty-one patients with metastatic brain tumors (MBT) from lung cancer and ten patients with MBT from melanoma received BCNU, 100 mg/m2, every four weeks by intracarotid and/or vertebral artery infusion into each involved site." | 1.26 | Phase II study--intra-arterial BCNU therapy for metastatic brain tumors. ( Avellanosa, AM; Caracandas, J; Ghoorah, J; Jennings, E; Karakousis, C; Madajewicz, S; Park, HC; Takita, H; Vincent, R; West, CR, 1981) |
| "Glioblastoma multiforme is composed of multiple cellular compartments with different morphologic, kinetic, metabolic, vascular, and genetic properties." | 1.26 | Aggressive multimodality therapy based on a multicompartmental model of glioblastoma. ( Broadwell, RD; Ducker, TB; Kaplan, RS; Salcman, M; Samaras, GM, 1982) |
| "A dose-response relation for the cytotoxic activity of chloroethylnitrosourea cancer chemotherapeutic agents in cell culture has been developed." | 1.26 | Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture. ( Deen, DF; Weinkam, RJ, 1982) |
| "Multimodal treatment of malignant gliomas is routinely used at New York University Medical Center." | 1.26 | Malignant glioma. Results of combined modality therapy. ( Borok, TL; Carella, RJ; Cooper, JS; Ransohoff, J, 1982) |
| " The shape of the DAG dose-response curves was similar to that of those observed for most oncolytic agents." | 1.26 | Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol. ( Levin, VA; Wheeler, KT, 1982) |
| "It is concluded that BCNU causes pulmonary fibrosis that is primarily but not necessarily dose-related and may not be reversible." | 1.26 | 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis. ( Bellot, P; Cohen, M; Fisher, ER; Jacobs, SA; Moore, PB; Selker, RG; Wald, M, 1980) |
| " The patient received a cumulative dosage of 1." | 1.26 | Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy. ( Ryan, BR; Walters, TR, 1981) |
| "A clonogenic cell assay for malignant brain tumors that permits the evaluation of tumor cell sensitivity to BCNU and that correlates with patient response to BCNU has been developed." | 1.26 | Potentials and possible pitfalls of human stem cell analysis. ( Dougherty, DV; Reese, C; Rosenblum, ML; Wilson, CB, 1981) |
| "Human malignant melanoma was transplanted to the cheek pouch of immunosuppressed (corticosteroid-treated) hamsters." | 1.26 | Chemotherapy against human melanoma in the hamster cheek pouch. ( Dufour, FD; Mah, SG; Morton, DL; Okada, GT, 1980) |
| "Seven human brain tumors were transplanted into the brains (6/7 takes) and subcutaneous tissues (7/7 takes) of athymic nude mice." | 1.26 | Human brain tumor transplantation into nude mice. ( Basler, GA; Chernik, NL; Posner, JB; Shapiro, WR, 1979) |
| "Schmidt-Ruppin strain of Rous Sarcoma was inoculated intracerebrally into 27 newborn beagle dogs." | 1.26 | BCNU and steroids in the viral-induced dog brain tumor. ( Brisman, R; Gamboa, E; Goldberg, N; Hilal, S; Michelsen, JW; Schlesinger, EB; Willson, N, 1979) |
| "Six children with grade II astrocytomas were treated with combination chemotherapy consisting of 1,3 bis(2-chloroethyl) 1-nitrosourea (BCNU)." | 1.26 | Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children. ( Bremer, AM; Cohen, M; Freeman, AI; Sinks, LF; Sumer, T; Thomas, PR, 1978) |
| "Pretreatment with phenytoin, sodium methylprednisolone succinate and dexamethasone had little or no effect." | 1.26 | The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p ( Byrd, A; Finn, A; Levin, VA; Stearns, J; Weinkam, RJ, 1979) |
| " A comparison of the in vitro colony-forming capacity of treated and untreated tumor cells permits calculation of the fraction of clonogenic tumor cells surviving in vivo therapy; The plateau that we previously observed o the BCNU dose-response curve is not the result of repair of potentially lethal damage, since no change in the 0." | 1.26 | Brain-tumor therapy. Quantitative analysis using a model system. ( Knebel, KD; Rosenblum, MK; Vasquez, DA; Wilson, CB, 1977) |
| " The BCNU dose-response curve was exponential up to a dose of 0." | 1.25 | In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Barker, M; Knebel, KD; Rosenblum, ML; Wheeler, KT; Wilson, CB, 1975) |
| "The shape of dose-response curves obtained for asynchronous, exponentially growing 9L rat brain tumor cells treated in vitro with 1,3-bis(2-chloroethyl)-1-nitrosourea changed as a function of the drug exposure time." | 1.25 | Factors influencing the survival of rat brain tumor cells after in vitro treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Kabra, PM; Levin, VA; Sheppard, S; Tel, N; Wheeler, KT; Williams, ME, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 358 (38.91) | 18.7374 |
| 1990's | 188 (20.43) | 18.2507 |
| 2000's | 181 (19.67) | 29.6817 |
| 2010's | 167 (18.15) | 24.3611 |
| 2020's | 26 (2.83) | 2.80 |
| Authors | Studies |
|---|---|
| Crider, AM | 1 |
| Kolczynski, TM | 1 |
| Yates, KM | 1 |
| Kokoshka, JM | 1 |
| Ireland, CM | 1 |
| Barrows, LR | 1 |
| Clarion, L | 1 |
| Jacquard, C | 1 |
| Sainte-Catherine, O | 1 |
| Loiseau, S | 1 |
| Filippini, D | 1 |
| Hirlemann, MH | 1 |
| Volle, JN | 1 |
| Virieux, D | 1 |
| Lecouvey, M | 1 |
| Pirat, JL | 1 |
| Bakalara, N | 1 |
| Roux, A | 3 |
| Ammar, H | 1 |
| Moiraghi, A | 2 |
| Peeters, S | 1 |
| Baroud, M | 1 |
| Zah-Bi, G | 1 |
| Benzakoun, J | 1 |
| Parraga, E | 3 |
| Oppenheim, C | 2 |
| Benevello, C | 2 |
| Chretien, F | 2 |
| Varlet, P | 1 |
| Dhermain, F | 1 |
| Dezamis, E | 3 |
| Zanello, M | 3 |
| Pallud, J | 4 |
| Chen, H | 1 |
| Hu, G | 1 |
| Ouyang, D | 1 |
| Sippl, C | 3 |
| Quiring, A | 1 |
| Teping, F | 2 |
| Schulz-Schaeffer, W | 1 |
| Urbschat, S | 3 |
| Ketter, R | 4 |
| Oertel, J | 3 |
| Waqar, M | 1 |
| Trifiletti, DM | 1 |
| McBain, C | 1 |
| O'Connor, J | 1 |
| Coope, DJ | 1 |
| Akkari, L | 1 |
| Quinones-Hinojosa, A | 6 |
| Borst, GR | 1 |
| Imai, R | 1 |
| Sasaki, H | 1 |
| Fujii, Y | 1 |
| Ogiwara, T | 1 |
| Kato, H | 1 |
| Hanaoka, Y | 1 |
| Hardian, RF | 1 |
| Goto, T | 1 |
| Hongo, K | 1 |
| Horiuchi, T | 1 |
| Shibahara, I | 5 |
| Shibahara, Y | 1 |
| Hagiwara, H | 1 |
| Watanabe, T | 3 |
| Orihashi, Y | 1 |
| Handa, H | 1 |
| Inukai, M | 3 |
| Hide, T | 2 |
| Yasui, Y | 3 |
| Kumabe, T | 7 |
| Chen, S | 1 |
| Qiu, Q | 1 |
| Wang, D | 1 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| He, H | 1 |
| Wang, J | 4 |
| Park, J | 1 |
| Sim, J | 1 |
| Ahn, J | 1 |
| Kim, YJ | 3 |
| Hwang, S | 1 |
| Cho, K | 1 |
| Chang, DY | 1 |
| Jung, JH | 1 |
| Moon, JH | 1 |
| Sung, K | 1 |
| Lim, J | 1 |
| Matsuda, R | 2 |
| Maeoka, R | 1 |
| Tokuda, N | 1 |
| Nakazawa, T | 1 |
| Morimoto, T | 1 |
| Kotsugi, M | 1 |
| Takeshima, Y | 1 |
| Tamura, K | 1 |
| Yamada, S | 3 |
| Nishimura, F | 2 |
| Nakagawa, I | 1 |
| Park, YS | 2 |
| Nakase, H | 2 |
| Das, D | 1 |
| Narayanan, D | 1 |
| Ramachandran, R | 1 |
| Gowd, GS | 1 |
| Manohar, M | 1 |
| Arumugam, T | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Gulidov, I | 1 |
| Koryakin, S | 1 |
| Fatkhudinov, T | 1 |
| Gordon, K | 1 |
| Champeaux-Depond, C | 2 |
| Jecko, V | 2 |
| Weller, J | 3 |
| Constantinou, P | 2 |
| Tuppin, P | 2 |
| Metellus, P | 7 |
| Serduc, R | 1 |
| Bouchet, A | 1 |
| Aboubakr, O | 1 |
| Elia, A | 1 |
| Fathallah, H | 1 |
| Lai, JL | 1 |
| Liu, SP | 1 |
| Jiang, XX | 1 |
| Liu, J | 2 |
| Li, A | 1 |
| Li, B | 2 |
| Li, XK | 1 |
| Ye, XJ | 1 |
| Lei, KJ | 1 |
| Zhou, L | 1 |
| Yi, S | 1 |
| Yang, F | 1 |
| Jie, C | 1 |
| Zhang, G | 1 |
| Braun, L | 1 |
| Schoeneberger, L | 1 |
| List, M | 2 |
| Nakhoda, A | 1 |
| Wemmert, S | 1 |
| Zhan, W | 3 |
| Kadota, T | 1 |
| Saito, R | 4 |
| Mizusawa, J | 1 |
| Katayama, H | 1 |
| Sumi, M | 1 |
| Igaki, H | 1 |
| Kinoshita, M | 1 |
| Komori, T | 1 |
| Ichimura, K | 1 |
| Narita, Y | 1 |
| Nishikawa, R | 4 |
| Champeaux, C | 1 |
| Sun, X | 1 |
| Sun, G | 1 |
| Huang, Y | 2 |
| Zhang, S | 1 |
| Tang, X | 1 |
| Zhang, N | 1 |
| Zhao, L | 1 |
| Zhong, R | 1 |
| Peng, Y | 2 |
| Rudnick, JD | 1 |
| Sarmiento, JM | 1 |
| Uy, B | 1 |
| Nuno, M | 1 |
| Wheeler, CJ | 1 |
| Mazer, MJ | 1 |
| Wang, H | 2 |
| Hu, JL | 1 |
| Chu, RM | 1 |
| Phuphanich, S | 3 |
| Black, KL | 2 |
| Yu, JS | 1 |
| Rezaei, T | 1 |
| Hejazi, M | 1 |
| Mansoori, B | 1 |
| Mohammadi, A | 1 |
| Amini, M | 1 |
| Mosafer, J | 1 |
| Rezaei, S | 1 |
| Mokhtarzadeh, A | 1 |
| Baradaran, B | 1 |
| Erthal, LCS | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Miyasaka, K | 1 |
| Sekiguchi, A | 1 |
| Ishiyama, H | 1 |
| Sato, S | 2 |
| Iwata, H | 1 |
| Sakata, Y | 1 |
| Muramoto, K | 1 |
| Matsuoka, T | 1 |
| Bettag, C | 1 |
| Hussein, A | 1 |
| Sachkova, A | 1 |
| Bock, HC | 6 |
| Mielke, D | 1 |
| Rohde, V | 3 |
| Abboud, T | 1 |
| Klein, J | 1 |
| Juratli, TA | 2 |
| Radev, Y | 1 |
| Daubner, D | 1 |
| Soucek, S | 1 |
| Schackert, G | 2 |
| Krex, D | 2 |
| Illic, R | 1 |
| Somma, T | 1 |
| Savic, D | 1 |
| Frio, F | 1 |
| Milicevic, M | 1 |
| Solari, D | 1 |
| Nikitovic, M | 1 |
| Lavrnic, S | 1 |
| Raicevic, S | 1 |
| Milosevic, S | 1 |
| Cavallo, LM | 1 |
| Cappabianca, P | 1 |
| Grujicic, D | 4 |
| Sonoda, Y | 1 |
| Matsuda, KI | 1 |
| Kawataki, T | 1 |
| Oda, M | 1 |
| Sato, Y | 2 |
| Sadahiro, H | 1 |
| Nomura, S | 1 |
| Sasajima, T | 1 |
| Beppu, T | 1 |
| Kanamori, M | 1 |
| Sakurada, K | 1 |
| Tominaga, T | 2 |
| Kinouchi, H | 1 |
| Shimizu, H | 1 |
| Ogasawara, K | 1 |
| Suzuki, M | 1 |
| Doishita, S | 1 |
| Shimono, T | 1 |
| Yoneda, T | 1 |
| Yamada, E | 1 |
| Tsukamoto, T | 1 |
| Takemori, D | 1 |
| Kimura, D | 1 |
| Tatekawa, H | 1 |
| Sakamoto, S | 1 |
| Miki, Y | 1 |
| Nakae, S | 1 |
| Murayama, K | 1 |
| Adachi, K | 1 |
| Kumai, T | 1 |
| Abe, M | 1 |
| Hirose, Y | 2 |
| Caire, F | 2 |
| Guyotat, J | 3 |
| Menei, P | 6 |
| Sage, W | 1 |
| Guilfoyle, M | 1 |
| Luney, C | 1 |
| Young, A | 1 |
| Sinha, R | 1 |
| Sgubin, D | 1 |
| McAbee, JH | 1 |
| Ma, R | 1 |
| Jefferies, S | 1 |
| Jena, R | 1 |
| Harris, F | 1 |
| Allinson, K | 1 |
| Matys, T | 1 |
| Qian, W | 1 |
| Santarius, T | 1 |
| Price, S | 1 |
| Watts, C | 3 |
| Wang, GB | 1 |
| Liu, JH | 1 |
| Hu, J | 1 |
| Xue, K | 1 |
| Wang, CH | 4 |
| Ali, AN | 1 |
| Zhang, P | 1 |
| Yung, WKA | 1 |
| Chen, Y | 2 |
| Movsas, B | 3 |
| Urtasun, RC | 3 |
| Jones, CU | 2 |
| Choi, KN | 1 |
| Michalski, JM | 1 |
| Fischbach, AJ | 3 |
| Markoe, AM | 2 |
| Schultz, CJ | 1 |
| Penas-Prado, M | 1 |
| Garg, MK | 1 |
| Hartford, AC | 1 |
| Kim, HE | 1 |
| Won, M | 2 |
| Curran, WJ | 7 |
| Bourdillon, P | 1 |
| Boissenot, T | 1 |
| Goldwirt, L | 1 |
| Nicolas, J | 1 |
| Apra, C | 1 |
| Carpentier, A | 1 |
| Hanihara, M | 1 |
| Dan, M | 1 |
| Kuroda, H | 1 |
| Inamura, A | 1 |
| Hara, A | 1 |
| Akiyama, Y | 1 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Grangeon, L | 1 |
| Ferracci, FX | 1 |
| Fetter, D | 1 |
| Maltete, D | 1 |
| Langlois, O | 2 |
| Gilard, V | 1 |
| Tiek, DM | 1 |
| Rone, JD | 1 |
| Graham, GT | 1 |
| Pannkuk, EL | 1 |
| Haddad, BR | 1 |
| Riggins, RB | 1 |
| Matsumura, H | 1 |
| Ishikawa, E | 5 |
| Matsuda, M | 3 |
| Sakamoto, N | 2 |
| Akutsu, H | 3 |
| Takano, S | 3 |
| Matsumura, A | 3 |
| Bohr, L | 1 |
| Asano, K | 1 |
| Kurose, A | 1 |
| Kamataki, A | 1 |
| Kato, N | 1 |
| Ogawa, K | 1 |
| Katayama, K | 1 |
| Kakuta, K | 1 |
| Fumoto, T | 1 |
| Ohkuma, H | 1 |
| López-Valero, I | 1 |
| Torres, S | 1 |
| Salazar-Roa, M | 1 |
| García-Taboada, E | 1 |
| Hernández-Tiedra, S | 1 |
| Guzmán, M | 1 |
| Sepúlveda, JM | 1 |
| Velasco, G | 1 |
| Lorente, M | 1 |
| Chen, C | 2 |
| Han, G | 1 |
| Li, Y | 2 |
| Yue, Z | 2 |
| Wang, L | 2 |
| Guo, X | 1 |
| Wu, G | 1 |
| Chen, L | 1 |
| Shapira-Furman, T | 1 |
| Serra, R | 1 |
| Gorelick, N | 1 |
| Doglioli, M | 1 |
| Tagliaferri, V | 1 |
| Cecia, A | 1 |
| Peters, M | 1 |
| Kumar, A | 1 |
| Rottenberg, Y | 1 |
| Langer, R | 4 |
| Brem, H | 37 |
| Tyler, B | 5 |
| Domb, AJ | 2 |
| Tabet, A | 1 |
| Jensen, MP | 1 |
| Parkins, CC | 1 |
| Patil, PG | 1 |
| Scherman, OA | 1 |
| Ichikawa, T | 2 |
| Autran, D | 1 |
| Barrie, M | 3 |
| Matta, M | 1 |
| Monserrat, C | 1 |
| Campello, C | 1 |
| Petrirena, G | 1 |
| Boucard, C | 1 |
| Padovani, L | 1 |
| Loundou, A | 1 |
| Appay, R | 1 |
| Graillon, T | 1 |
| Dufour, H | 3 |
| Figarella-Branger, D | 3 |
| Chinot, O | 3 |
| Tabouret, E | 1 |
| Cardona, AF | 1 |
| Rojas, L | 1 |
| Wills, B | 1 |
| Ruiz-Patiño, A | 1 |
| Abril, L | 1 |
| Hakim, F | 1 |
| Jiménez, E | 1 |
| Useche, N | 1 |
| Bermúdez, S | 1 |
| Mejía, JA | 1 |
| Ramón, JF | 1 |
| Carranza, H | 1 |
| Vargas, C | 2 |
| Otero, J | 1 |
| Archila, P | 1 |
| Rodríguez, J | 2 |
| Behaine, J | 1 |
| González, D | 1 |
| Jacobo, J | 1 |
| Cifuentes, H | 1 |
| Feo, O | 1 |
| Penagos, P | 1 |
| Pineda, D | 1 |
| Ricaurte, L | 1 |
| Pino, LE | 1 |
| Marquez, JC | 1 |
| Mantilla, MI | 1 |
| Ortiz, LD | 1 |
| Balaña, C | 2 |
| Rosell, R | 1 |
| Zatarain-Barrón, ZL | 1 |
| Arrieta, O | 2 |
| Rahmathulla, G | 1 |
| Marko, NF | 1 |
| Weil, RJ | 1 |
| Gutenberg, A | 2 |
| Lumenta, CB | 1 |
| Braunsdorf, WE | 1 |
| Sabel, M | 3 |
| Mehdorn, HM | 8 |
| Westphal, M | 8 |
| Giese, A | 7 |
| Brück, W | 1 |
| Doerner, L | 1 |
| Roggendorf, W | 1 |
| Felsberg, J | 1 |
| Reifenberger, G | 1 |
| Mullins, CS | 1 |
| Schneider, B | 1 |
| Stockhammer, F | 1 |
| Krohn, M | 1 |
| Classen, CF | 1 |
| Linnebacher, M | 1 |
| Aoki, T | 3 |
| Brem, S | 5 |
| Meyers, CA | 1 |
| Palmer, G | 1 |
| Booth-Jones, M | 1 |
| Jain, S | 1 |
| Ewend, MG | 5 |
| Yan, YR | 1 |
| Xie, Q | 2 |
| Li, F | 1 |
| Zhang, Y | 1 |
| Ma, JW | 1 |
| Xie, SM | 1 |
| Li, HY | 1 |
| Zhong, XY | 1 |
| Bregy, A | 1 |
| Shah, AH | 1 |
| Diaz, MV | 1 |
| Pierce, HE | 1 |
| Ames, PL | 1 |
| Diaz, D | 1 |
| Komotar, RJ | 1 |
| Chamberlain, MC | 2 |
| Hanson, T | 1 |
| Zhang, J | 3 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 1 |
| Isik, G | 1 |
| Hänggi, D | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 1 |
| Steiger, HJ | 1 |
| Shah, RS | 1 |
| Homapour, B | 1 |
| Casselden, E | 1 |
| Barr, JG | 1 |
| Grundy, PL | 1 |
| Brydon, HL | 1 |
| Yamamoto, T | 5 |
| Satomi, K | 1 |
| Shibuya, M | 1 |
| Nakai, K | 2 |
| Liu, HL | 5 |
| Fan, CH | 3 |
| Ting, CY | 3 |
| Yeh, CK | 3 |
| Sugiyama, K | 1 |
| Nonoguchi, N | 1 |
| Kawabata, N | 1 |
| Mishima, K | 1 |
| Adachi, J | 1 |
| Kurisu, K | 1 |
| Yamasaki, F | 1 |
| Ueki, K | 1 |
| Higuchi, F | 1 |
| Takeshima, H | 2 |
| Yamashita, S | 1 |
| Arita, K | 1 |
| Hirano, H | 1 |
| Matsutani, M | 4 |
| Olson, JJ | 3 |
| Nayak, L | 2 |
| Ormond, DR | 1 |
| Wen, PY | 3 |
| Kalkanis, SN | 1 |
| Yan, Y | 1 |
| Huang, Z | 1 |
| Zhong, X | 1 |
| Huang, L | 1 |
| Lombardi, G | 3 |
| Della Puppa, A | 4 |
| Zustovich, F | 1 |
| Pambuku, A | 1 |
| Farina, P | 1 |
| Fiduccia, P | 1 |
| Roma, A | 1 |
| Zagonel, V | 2 |
| Sai, K | 1 |
| Zhong, MG | 1 |
| Chen, YS | 1 |
| Mou, YG | 1 |
| Ke, C | 1 |
| Zhang, XH | 1 |
| Yang, QY | 1 |
| Lin, FH | 1 |
| Guo, CC | 1 |
| Chen, ZH | 1 |
| Zeng, J | 1 |
| Lv, YC | 1 |
| Li, X | 3 |
| Gao, WC | 1 |
| Chen, ZP | 3 |
| Mack, F | 1 |
| Schäfer, N | 1 |
| Kebir, S | 1 |
| Stuplich, M | 1 |
| Schaub, C | 1 |
| Niessen, M | 1 |
| Scheffler, B | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Rahman, R | 1 |
| Hempfling, K | 1 |
| Norden, AD | 1 |
| Reardon, DA | 4 |
| Rinne, ML | 1 |
| Beroukhim, R | 1 |
| Doherty, L | 1 |
| Ruland, S | 1 |
| Rai, A | 1 |
| Rifenburg, J | 1 |
| LaFrankie, D | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Lee, EQ | 1 |
| Patil, AA | 1 |
| Sayal, P | 1 |
| Depondt, ML | 1 |
| Beveridge, RD | 1 |
| Roylance, A | 1 |
| Kriplani, DH | 1 |
| Myers, KN | 1 |
| Cox, A | 1 |
| Jellinek, D | 1 |
| Fernando, M | 1 |
| Carroll, TA | 1 |
| Collis, SJ | 1 |
| Adair, JE | 1 |
| Johnston, SK | 1 |
| Mrugala, MM | 1 |
| Beard, BC | 1 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Hawkins-Daarud, A | 1 |
| Gori, JL | 1 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Rockne, RC | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 1 |
| Swanson, KR | 1 |
| Kiem, HP | 1 |
| Blumenthal, DT | 2 |
| Rankin, C | 2 |
| Stelzer, KJ | 2 |
| Spence, AM | 4 |
| Sloan, AE | 1 |
| Moore, DF | 1 |
| Padula, GD | 1 |
| Schulman, SB | 1 |
| Wade, ML | 1 |
| Rushing, EJ | 2 |
| Venur, VA | 1 |
| Peereboom, DM | 1 |
| Ahluwalia, MS | 1 |
| Mu, F | 1 |
| Lucas, JT | 1 |
| Watts, JM | 1 |
| Johnson, AJ | 1 |
| Daniel Bourland, J | 1 |
| Laxton, AW | 1 |
| Chan, MD | 1 |
| Tatter, SB | 2 |
| Chang, YC | 1 |
| Wei, KC | 5 |
| Chowdhary, SA | 1 |
| Ryken, T | 2 |
| Newton, HB | 2 |
| Wait, SD | 1 |
| Prabhu, RS | 2 |
| Burri, SH | 2 |
| Atkins, TG | 1 |
| Asher, AL | 2 |
| Chaichana, KL | 5 |
| Kone, L | 1 |
| Bettegowda, C | 2 |
| Weingart, JD | 10 |
| Olivi, A | 14 |
| Lim, M | 2 |
| Gallia, GL | 3 |
| Sumrall, AL | 1 |
| Brick, W | 1 |
| Blaker, BD | 1 |
| Heideman, BE | 1 |
| Boltes, P | 1 |
| Kelly, R | 1 |
| Symanowski, JT | 1 |
| Wiggins, WF | 1 |
| Ashby, L | 2 |
| Norton, HJ | 1 |
| Judy, K | 3 |
| Stukov, AN | 1 |
| Filatova, LV | 2 |
| Latipova, DKh | 1 |
| Bespalov, VG | 1 |
| Belyaeva, OA | 1 |
| Kireeva, GS | 1 |
| Vasilieva, IN | 1 |
| Alexandrov, VA | 1 |
| Maidin, MA | 1 |
| Semenov, AL | 1 |
| Vershinina, SF | 1 |
| Markochev, AB | 1 |
| Abduloeva, NKh | 1 |
| Chubenko, VA | 1 |
| Semiglazova, TY | 1 |
| Yoshida, M | 1 |
| Yamaguchi, S | 1 |
| Ishi, Y | 1 |
| Endo, S | 1 |
| Motegi, H | 1 |
| Kobayashi, H | 1 |
| Asaoka, K | 1 |
| Kamoshima, Y | 1 |
| Terasaka, S | 1 |
| Houkin, K | 1 |
| Xing, WK | 1 |
| Shao, C | 1 |
| Qi, ZY | 1 |
| Yang, C | 1 |
| Wang, Z | 2 |
| Audureau, E | 1 |
| Noel, G | 3 |
| Corns, R | 1 |
| Lechapt-Zalcman, E | 2 |
| Duntze, J | 2 |
| Pavlov, V | 1 |
| Hieu, PD | 1 |
| Le Reste, PJ | 1 |
| Faillot, T | 1 |
| Litre, CF | 2 |
| Desse, N | 1 |
| Petit, A | 1 |
| Emery, E | 3 |
| Voirin, J | 1 |
| Peltier, J | 1 |
| Vignes, JR | 1 |
| Barat, JL | 1 |
| Nader, E | 1 |
| Lefranc, M | 1 |
| Bauchet, L | 1 |
| Devaux, B | 1 |
| Tseng, YY | 3 |
| Wang, YC | 1 |
| Su, CH | 1 |
| Yang, TC | 1 |
| Chang, TM | 1 |
| Kau, YC | 2 |
| Liu, SJ | 3 |
| Nakase, K | 1 |
| Nakamura, M | 1 |
| Motoyama, Y | 1 |
| Grossman, R | 2 |
| Burger, P | 5 |
| Soudry, E | 1 |
| Weingart, J | 5 |
| Sidransky, D | 1 |
| Ye, X | 3 |
| Schnurman, Z | 1 |
| Kondziolka, D | 2 |
| Ohue, S | 1 |
| Kohno, S | 1 |
| Inoue, A | 1 |
| Yamashita, D | 1 |
| Suehiro, S | 1 |
| Seno, T | 1 |
| Kumon, Y | 1 |
| Kikuchi, K | 1 |
| Ohnishi, T | 1 |
| Chakrabarti, M | 1 |
| Ray, SK | 1 |
| Stupp, R | 1 |
| Taillibert, S | 1 |
| Kanner, AA | 1 |
| Kesari, S | 2 |
| Steinberg, DM | 1 |
| Toms, SA | 1 |
| Taylor, LP | 1 |
| Lieberman, F | 1 |
| Silvani, A | 10 |
| Fink, KL | 4 |
| Barnett, GH | 2 |
| Zhu, JJ | 1 |
| Henson, JW | 1 |
| Engelhard, HH | 3 |
| Chen, TC | 1 |
| Tran, DD | 1 |
| Sroubek, J | 1 |
| Tran, ND | 1 |
| Hottinger, AF | 1 |
| Landolfi, J | 1 |
| Desai, R | 1 |
| Caroli, M | 1 |
| Kew, Y | 1 |
| Honnorat, J | 2 |
| Idbaih, A | 1 |
| Kirson, ED | 1 |
| Weinberg, U | 1 |
| Palti, Y | 1 |
| Hegi, ME | 1 |
| Ram, Z | 4 |
| Masuda, Y | 1 |
| Kohzuki, H | 1 |
| Okamoto, E | 1 |
| Masumoto, T | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Lu, Y | 1 |
| Grossman, SA | 7 |
| Paul-Samojedny, M | 1 |
| Pudełko, A | 1 |
| Kowalczyk, M | 1 |
| Fila-Daniłow, A | 1 |
| Suchanek-Raif, R | 1 |
| Borkowska, P | 1 |
| Kowalski, J | 1 |
| Saha, P | 1 |
| Amico, AL | 1 |
| Olopade, OI | 1 |
| Shimato, S | 1 |
| Nishizawa, T | 1 |
| Ohshima, T | 1 |
| Imai, T | 1 |
| Goto, S | 1 |
| Kato, K | 1 |
| Saito, K | 1 |
| Yamasaki, K | 1 |
| Yokogami, K | 1 |
| Ivanova, A | 1 |
| Takeishi, G | 1 |
| Hasegawa, Y | 1 |
| Iuchi, T | 1 |
| Sakaida, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Murai, S | 1 |
| Kurozumi, K | 1 |
| Shimazu, Y | 1 |
| Oka, T | 1 |
| Otani, Y | 1 |
| Shimizu, T | 1 |
| Date, I | 1 |
| Arakawa, Y | 1 |
| Ashby, LS | 2 |
| Smith, KA | 3 |
| Stea, B | 1 |
| Liu, C | 3 |
| Yao, S | 1 |
| Wang, F | 2 |
| Jiang, Y | 1 |
| Rossetto, M | 3 |
| Rustemi, O | 1 |
| Berti, F | 4 |
| Cecchin, D | 1 |
| Gardiman, MP | 1 |
| Rolma, G | 1 |
| Persano, L | 1 |
| Scienza, R | 3 |
| Ohba, S | 1 |
| Mathios, D | 1 |
| Kim, JE | 1 |
| Mangraviti, A | 1 |
| Phallen, J | 1 |
| Park, CK | 1 |
| Jackson, CM | 1 |
| Garzon-Muvdi, T | 1 |
| Kim, E | 1 |
| Theodros, D | 1 |
| Polanczyk, M | 1 |
| Martin, AM | 1 |
| Suk, I | 1 |
| Pardoll, DM | 2 |
| Arifin, DY | 3 |
| Lee, TK | 1 |
| Eyre, HJ | 3 |
| Livingston, RB | 2 |
| Berger, MS | 4 |
| Rivkin, SE | 1 |
| Cohn, AL | 1 |
| Petersdorf, SH | 1 |
| Juillerat-Jeanneret, L | 1 |
| Bernasconi, CC | 1 |
| Bricod, C | 1 |
| Gros, S | 1 |
| Trepey, S | 1 |
| Benhattar, J | 1 |
| Janzer, RC | 1 |
| Kang, MK | 1 |
| Kang, SK | 2 |
| Esther Gil-Alegre, M | 1 |
| González-Alvarez, I | 1 |
| Gutiérrez-Paúls, L | 1 |
| Torres-Suárez, AI | 1 |
| Monfared, P | 1 |
| Winkeler, A | 1 |
| Klein, M | 1 |
| Li, H | 2 |
| Klose, A | 1 |
| Hoesel, M | 1 |
| Waerzeggers, Y | 1 |
| Korsching, S | 1 |
| Jacobs, AH | 1 |
| Attenello, FJ | 2 |
| Mukherjee, D | 1 |
| Datoo, G | 1 |
| McGirt, MJ | 4 |
| Bohan, E | 1 |
| Hart, MG | 2 |
| Grant, R | 2 |
| Garside, R | 4 |
| Rogers, G | 4 |
| Somerville, M | 4 |
| Stein, K | 4 |
| McKenzie, E | 1 |
| Skurski-Martin, M | 1 |
| Zhang, Z | 3 |
| Brat, D | 2 |
| Kang, GS | 1 |
| Wang, XD | 1 |
| Mohler, ML | 1 |
| Kirichenko, OV | 1 |
| Patil, R | 1 |
| Orr, WE | 1 |
| Miller, DD | 1 |
| Geisert, EE | 1 |
| Pédeboscq, S | 1 |
| L'Azou, B | 1 |
| Passagne, I | 1 |
| De Giorgi, F | 1 |
| Ichas, F | 1 |
| Pometan, JP | 1 |
| Cambar, J | 1 |
| Finlay, JL | 6 |
| Dhall, G | 1 |
| Boyett, JM | 5 |
| Dunkel, IJ | 3 |
| Gardner, SL | 1 |
| Goldman, S | 4 |
| Yates, AJ | 2 |
| Rosenblum, MK | 3 |
| Stanley, P | 2 |
| Zimmerman, RA | 1 |
| Wallace, D | 1 |
| Pollack, IF | 2 |
| Packer, RJ | 1 |
| Gathinji, M | 1 |
| Than, K | 1 |
| Quiñones-Hinojosa, AR | 1 |
| Kartashev, AV | 1 |
| Vinogradov, VM | 1 |
| Gershanovich, ML | 1 |
| Quetin, P | 1 |
| Heymann, S | 1 |
| Karamanoukian, D | 1 |
| Schott, R | 2 |
| Bajolet, O | 1 |
| Theret, E | 1 |
| Eap, C | 1 |
| Peruzzi, P | 1 |
| Rousseaux, P | 1 |
| Gonzalez, LF | 1 |
| Gonzalez, F | 1 |
| Brachman, DG | 1 |
| Thomas, T | 1 |
| Coons, SW | 1 |
| Battaglia, M | 1 |
| Scheck, A | 1 |
| Kang, C | 2 |
| Yuan, X | 2 |
| Zhong, Y | 2 |
| Pu, P | 2 |
| Guo, Y | 1 |
| Albadany, A | 1 |
| Yu, S | 1 |
| Chang, J | 1 |
| Sheng, J | 1 |
| Quinn, JA | 2 |
| Jiang, SX | 1 |
| Carter, J | 3 |
| Desjardins, A | 2 |
| Vredenburgh, JJ | 2 |
| Rich, JN | 3 |
| Gururangan, S | 2 |
| Friedman, AH | 6 |
| Bigner, DD | 16 |
| Sampson, JH | 2 |
| McLendon, RE | 3 |
| Herndon, JE | 4 |
| Threatt, S | 1 |
| Friedman, HS | 11 |
| van den Bent, MJ | 2 |
| Brandes, AA | 8 |
| Rampling, R | 2 |
| Kouwenhoven, MC | 1 |
| Kros, JM | 1 |
| Carpentier, AF | 1 |
| Clement, PM | 1 |
| Frenay, M | 1 |
| Campone, M | 1 |
| Baurain, JF | 1 |
| Armand, JP | 1 |
| Taphoorn, MJ | 1 |
| Tosoni, A | 5 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Lacombe, D | 1 |
| Gorlia, T | 1 |
| La Rocca, RV | 2 |
| Gaviani, P | 3 |
| Lamperti, EA | 1 |
| Eoli, M | 3 |
| Falcone, C | 1 |
| Dimeco, F | 5 |
| Milanesi, IM | 1 |
| Erbetta, A | 1 |
| Boiardi, A | 7 |
| Fariselli, L | 4 |
| Salmaggi, A | 7 |
| Asthagiri, AR | 1 |
| Baggenstos, M | 1 |
| Lonser, RR | 1 |
| Lee, KY | 2 |
| Affronti, ML | 1 |
| Heery, CR | 1 |
| Corn, BW | 2 |
| Wang, M | 3 |
| Fox, S | 1 |
| Michalski, J | 1 |
| Purdy, J | 1 |
| Simpson, J | 1 |
| Kresl, J | 2 |
| Diaz, A | 1 |
| Mehta, M | 3 |
| Coulibaly, B | 1 |
| Nanni, I | 1 |
| Fina, F | 1 |
| Eudes, N | 1 |
| Giorgi, R | 1 |
| Fuentes, S | 1 |
| Ouafik, L | 1 |
| Jaeckle, KA | 5 |
| Ballman, KV | 2 |
| Giannini, C | 1 |
| Schomberg, PJ | 7 |
| Ames, MM | 2 |
| Reid, JM | 2 |
| McGovern, RM | 1 |
| Safgren, SL | 1 |
| Galanis, E | 1 |
| Uhm, JH | 1 |
| Brown, PD | 1 |
| Hammack, JE | 1 |
| Arusell, R | 1 |
| Nikcevich, DA | 1 |
| Morton, RF | 3 |
| Wender, DB | 1 |
| Buckner, JC | 11 |
| Jenkinson, MD | 1 |
| Smith, TS | 1 |
| Haylock, B | 1 |
| Husband, D | 1 |
| Shenoy, A | 1 |
| Vinjamuri, S | 1 |
| Walker, C | 1 |
| Pietronigro, D | 3 |
| Warnke, PC | 2 |
| Kantelhardt, SR | 3 |
| Kosteljanetz, M | 2 |
| Poulsen, HS | 2 |
| Reithmeier, T | 1 |
| Graf, E | 1 |
| Piroth, T | 1 |
| Trippel, M | 1 |
| Pinsker, MO | 1 |
| Nikkhah, G | 2 |
| Balossier, A | 1 |
| Dörner, L | 4 |
| Heese, O | 1 |
| Singh, J | 1 |
| Galbán, CJ | 1 |
| Bhojani, MS | 1 |
| Lee, KC | 4 |
| Meyer, CR | 4 |
| Van Dort, ME | 1 |
| Kuszpit, KK | 1 |
| Koeppe, RA | 1 |
| Ranga, R | 1 |
| Moffat, BA | 6 |
| Johnson, TD | 7 |
| Chenevert, TL | 12 |
| Rehemtulla, A | 10 |
| Ross, BD | 13 |
| Morandi, L | 1 |
| Franceschi, E | 2 |
| de Biase, D | 1 |
| Marucci, G | 1 |
| Ermani, M | 4 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Brandes, A | 1 |
| Recinos, VR | 1 |
| Tyler, BM | 8 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 1 |
| Feng, X | 1 |
| Zhang, B | 1 |
| Xu, X | 1 |
| Lin, N | 1 |
| Liu, H | 1 |
| Hua, MY | 2 |
| Chen, PY | 2 |
| Chu, PC | 2 |
| Pan, CH | 1 |
| Yang, HW | 2 |
| Huang, CY | 3 |
| Wang, JJ | 2 |
| Yen, TC | 3 |
| Parot-Schinkel, E | 1 |
| Loiseau, H | 1 |
| Capelle, L | 1 |
| Jacquet, G | 2 |
| Jin, G | 1 |
| Cook, S | 1 |
| Cui, B | 1 |
| Chen, WC | 1 |
| Keir, ST | 3 |
| Killela, P | 1 |
| Di, C | 1 |
| Payne, CA | 2 |
| Gregory, SG | 1 |
| McLendon, R | 1 |
| Yan, H | 1 |
| Kunwar, S | 1 |
| Chang, S | 1 |
| Vogelbaum, M | 1 |
| Sampson, J | 1 |
| Barnett, G | 1 |
| Shaffrey, M | 1 |
| Piepmeier, J | 2 |
| Prados, M | 4 |
| Croteau, D | 1 |
| Pedain, C | 1 |
| Leland, P | 1 |
| Husain, SR | 1 |
| Joshi, BH | 1 |
| Puri, RK | 1 |
| Márquez-Rivas, J | 4 |
| Ramirez, G | 2 |
| Ollero-Ortiz, A | 1 |
| Giménez-Pando, J | 1 |
| Emmerich, J | 1 |
| Quiroga-Cantero, E | 2 |
| Rivas, E | 2 |
| Gómez-González, E | 1 |
| Jacot, W | 1 |
| Gerlotto-Borne, MC | 1 |
| Thezenas, S | 1 |
| Pouderoux, S | 1 |
| Poujol, S | 1 |
| About, M | 1 |
| Romieu, G | 1 |
| Lyu, LA | 1 |
| Tseng, IC | 1 |
| Feng, LY | 1 |
| Tsai, HC | 1 |
| Chen, SM | 1 |
| Lu, YJ | 1 |
| Ma, YH | 1 |
| Wu, T | 1 |
| Chen, JP | 1 |
| Chuang, JI | 1 |
| Shin, JW | 1 |
| Hsueh, C | 1 |
| Ciccarino, P | 2 |
| Del Moro, G | 2 |
| Rotilio, A | 4 |
| Manara, R | 2 |
| Paola Gardiman, M | 1 |
| Denaro, L | 2 |
| d'Avella, D | 3 |
| Kong, DS | 1 |
| Kim, ST | 1 |
| Lee, JI | 1 |
| Suh, YL | 1 |
| Lim, DH | 1 |
| Kim, WS | 1 |
| Kwon, KH | 1 |
| Park, K | 1 |
| Kim, JH | 2 |
| Nam, DH | 1 |
| Puchner, MJ | 1 |
| Lohmann, F | 1 |
| Schütze, M | 1 |
| Koll, S | 1 |
| Buchalla, R | 1 |
| Rainov, N | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 4 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 3 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, MY | 1 |
| Clark, AJ | 1 |
| Chan, DC | 1 |
| Ware, JL | 1 |
| Holt, SE | 1 |
| Chidambaram, A | 1 |
| Fillmore, HL | 1 |
| Broaddus, WC | 2 |
| Nagaiah, G | 1 |
| Almubarak, M | 1 |
| Khan, M | 1 |
| Altaha, R | 1 |
| Chaichana, KK | 1 |
| Bennett, R | 1 |
| Li, J | 2 |
| Shaw, EG | 1 |
| Coughlin, C | 2 |
| Mehta, MP | 5 |
| Zhou, Y | 1 |
| Li, W | 1 |
| Xu, Q | 1 |
| Figueiredo, EG | 1 |
| Faria, JW | 1 |
| Teixeira, MJ | 1 |
| O'Brien, D | 1 |
| Cotter, M | 1 |
| Lim, CH | 1 |
| Sattar, MT | 1 |
| Smyth, E | 1 |
| Fitzpatrick, F | 1 |
| Yao, D | 1 |
| Zhao, H | 1 |
| Zhang, F | 1 |
| Chen, J | 1 |
| Jiang, X | 1 |
| Zhu, X | 1 |
| Colvin, DC | 1 |
| Loveless, ME | 1 |
| Does, MD | 1 |
| Yankeelov, TE | 1 |
| Gore, JC | 1 |
| Cohnen, J | 1 |
| Keric, N | 1 |
| Ulmer, S | 2 |
| Rohr, A | 2 |
| Nabavi, A | 3 |
| Kuo, YC | 1 |
| Liang, CT | 1 |
| Chansriwong, P | 1 |
| Sirisinha, T | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Dixit, S | 2 |
| Hingorani, M | 2 |
| Achawal, S | 2 |
| Scott, I | 2 |
| Zhao, O | 1 |
| Stummer, W | 1 |
| Rezazadeh, A | 1 |
| Gilman, AL | 1 |
| Jacobsen, C | 1 |
| Bunin, N | 1 |
| Levine, J | 1 |
| Goldman, F | 1 |
| Bendel, A | 1 |
| Joyce, M | 1 |
| Anderson, P | 1 |
| Rozans, M | 1 |
| Wall, DA | 1 |
| Macdonald, TJ | 1 |
| Simon, S | 1 |
| Kadota, RP | 1 |
| Zaidi, H | 1 |
| Pendleton, C | 1 |
| Muntasser, H | 1 |
| Liaquat, I | 1 |
| Barlow, A | 1 |
| Whittle, I | 1 |
| Kim, BS | 1 |
| Kang, KS | 1 |
| Choi, JI | 1 |
| Jung, JS | 1 |
| Im, YB | 1 |
| Meshechkin, AV | 1 |
| Korytova, LI | 1 |
| Zhabina, RM | 2 |
| Suvorova, IuV | 1 |
| Han, L | 1 |
| Ren, Y | 1 |
| Long, L | 1 |
| Shen, C | 1 |
| Duri, S | 1 |
| Milanesi, I | 5 |
| Casali, C | 2 |
| Di Meco, F | 1 |
| Catalán-Uribarrena, G | 1 |
| Bilbao-Barandica, G | 1 |
| Pomposo-Gaztelu, I | 1 |
| Undabeitia-Huertas, J | 1 |
| Ruiz de Gopegui-Ruiz, E | 1 |
| Galbarriatu-Gutiérrez, L | 1 |
| Canales-Llantada, M | 1 |
| Aurrecoechea-Obieta, J | 1 |
| Igartua-Azkune, A | 1 |
| Carbayo-Lozano, G | 1 |
| Rivero-Garvía, M | 3 |
| Mayorga-Buiza, MJ | 1 |
| Rueda-Torres, AB | 1 |
| Pascual-Argente, D | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Spalek, K | 1 |
| Schultka, S | 1 |
| Levallet, G | 1 |
| Dugué, AE | 1 |
| Vital, A | 1 |
| Diebold, MD | 1 |
| Colin, P | 1 |
| Peruzzy, P | 1 |
| Bernaudin, M | 1 |
| Chapon, F | 1 |
| Guillamo, JS | 1 |
| Nagpal, S | 1 |
| McPherson, CM | 1 |
| Gerena-Lewis, M | 1 |
| Breneman, JC | 2 |
| Warnick, RE | 3 |
| Price, SJ | 1 |
| Whittle, IR | 3 |
| Ashkan, K | 2 |
| Grundy, P | 1 |
| Cruickshank, G | 1 |
| Papageorgiou, SG | 1 |
| Diamantopoulos, P | 1 |
| Levidou, G | 1 |
| Angelopoulou, MK | 1 |
| Economopoulou, P | 1 |
| Efthimiou, A | 1 |
| Constantinou, N | 1 |
| Katsigiannis, A | 1 |
| Korkolopoulou, P | 1 |
| Pappa, V | 1 |
| Economopoulou, C | 1 |
| Georgiou, G | 1 |
| Dimou, M | 1 |
| Tsirigotis, P | 1 |
| Kyrtsonis, MC | 1 |
| Kotsianidis, I | 1 |
| Kalpadakis, C | 1 |
| Dimopoulos, MA | 1 |
| Beris, P | 1 |
| Meletis, J | 1 |
| Pangalis, GA | 1 |
| Dervenoulas, J | 1 |
| Panayiotidis, P | 1 |
| Vassilakopoulos, TP | 1 |
| Cho, KT | 1 |
| Kim, DG | 1 |
| Paek, SH | 1 |
| Chung, HT | 1 |
| Jung, HW | 2 |
| Park, HW | 1 |
| DellaPuppa, A | 1 |
| De Bonis, P | 1 |
| Anile, C | 1 |
| Pompucci, A | 1 |
| Fiorentino, A | 1 |
| Balducci, M | 1 |
| Chiesa, S | 1 |
| Maira, G | 1 |
| Mangiola, A | 1 |
| Kuhnhenn, J | 1 |
| Kowalski, T | 1 |
| Steenken, S | 1 |
| Ostermann, K | 1 |
| Schlegel, U | 1 |
| Sorrentino, BP | 1 |
| He, P | 1 |
| Fang, L | 1 |
| Su, Z | 1 |
| Antunes, IF | 1 |
| Haisma, HJ | 1 |
| Elsinga, PH | 1 |
| Di Gialleonardo, V | 1 |
| van Waarde, A | 1 |
| Willemsen, AT | 1 |
| Dierckx, RA | 1 |
| de Vries, EF | 1 |
| Dunn, L | 1 |
| Jenkinson, M | 1 |
| Smith, P | 1 |
| Safdar, S | 1 |
| Tu, NH | 1 |
| Taite, LJ | 1 |
| Yuan, S | 1 |
| Chen, G | 1 |
| Zhang, H | 1 |
| Feng, L | 1 |
| Colman, H | 1 |
| Keating, MJ | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Medina-López, D | 1 |
| Hsieh, HY | 1 |
| Liao, JY | 1 |
| Chen, WA | 1 |
| Kao, YC | 1 |
| Mustafa, A | 1 |
| Marchetti, M | 1 |
| Solero, CL | 4 |
| Maccagnano, C | 1 |
| Guzzetti, S | 1 |
| Pollo, B | 2 |
| Ciusani, E | 1 |
| Khoshyomn, S | 1 |
| Nathan, D | 1 |
| Manske, GC | 1 |
| Osler, TM | 1 |
| Penar, PL | 2 |
| Chakravarti, A | 1 |
| Chakladar, A | 1 |
| Delaney, MA | 1 |
| Latham, DE | 1 |
| Loeffler, JS | 1 |
| Selker, RG | 5 |
| Shapiro, WR | 22 |
| Blackwood, MS | 1 |
| Arena, VC | 1 |
| Gilder, JC | 1 |
| Malkin, MG | 3 |
| Mealey, JJ | 1 |
| Neal, JH | 1 |
| Olson, J | 1 |
| Robertson, JT | 3 |
| Bloomfield, S | 1 |
| Albright, R | 1 |
| Hochberg, FH | 7 |
| Hiesiger, E | 2 |
| Green, S | 1 |
| Silber, JR | 3 |
| Bobola, MS | 3 |
| Blank, A | 1 |
| Schoeler, KD | 1 |
| Haroldson, PD | 1 |
| Huynh, MB | 1 |
| Kolstoe, DD | 1 |
| Cutts, J | 1 |
| Lee, G | 1 |
| Berarducci, M | 1 |
| Thomas, C | 1 |
| Dempsey, PK | 1 |
| Kadish, SP | 1 |
| Vitanovics, D | 1 |
| Sipos, L | 1 |
| Afra, D | 2 |
| Beech, DJ | 1 |
| Madan, AK | 1 |
| Aliabadi-Wahle, S | 1 |
| Hays, AN | 1 |
| Long, WP | 1 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 2 |
| Bessell, EM | 3 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Graus, F | 2 |
| Rhines, LD | 3 |
| Sampath, P | 5 |
| Lawson, HC | 2 |
| Hanes, J | 2 |
| Shibamoto, Y | 4 |
| Tomita, N | 1 |
| Kono, T | 1 |
| Tsuji, H | 1 |
| Nankoh, S | 1 |
| Taniguchi, H | 1 |
| Hilt, DC | 2 |
| Bortey, E | 2 |
| Delavault, P | 1 |
| Olivares, R | 1 |
| Jääskeläinen, J | 1 |
| Hammoud, DA | 1 |
| Belden, CJ | 1 |
| Ho, AC | 1 |
| Dal Pan, GJ | 1 |
| Herskovits, EH | 1 |
| Pomper, MG | 1 |
| Houghton, PJ | 3 |
| Tatter, S | 1 |
| Barker, F | 1 |
| Olsen, J | 1 |
| Bruce, J | 2 |
| Hilt, D | 4 |
| Fisher, J | 1 |
| Piantadosi, S | 5 |
| Fine, HA | 2 |
| Maher, EA | 1 |
| Viscosi, E | 1 |
| Batchelor, T | 1 |
| Lakhani, N | 1 |
| Figg, WD | 1 |
| Purow, BW | 1 |
| Borkowf, CB | 1 |
| Zhang, YP | 2 |
| Xu, XN | 1 |
| Wang, JH | 1 |
| Lu, G | 1 |
| Liu, P | 1 |
| Su, TF | 1 |
| Liu, HS | 1 |
| Qi, JB | 1 |
| Gao, B | 1 |
| Lamszus, K | 1 |
| Rojas-Marcos, I | 2 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Delattre, JY | 2 |
| Frazier, JL | 1 |
| Wang, PP | 1 |
| Case, D | 1 |
| Pradilla, G | 1 |
| Lyles, S | 1 |
| Walker, M | 2 |
| Kreklau, EL | 2 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Erickson, LC | 3 |
| Guerin, C | 1 |
| Pérez-Calvo, J | 1 |
| Fernàndez, O | 1 |
| Aristu, JJ | 2 |
| Aramendia, JM | 2 |
| Rifón, J | 1 |
| Prosper, F | 1 |
| Bendandi, M | 1 |
| Rocha, E | 1 |
| Martin-Algarra, S | 2 |
| Prados, MD | 5 |
| Yung, WK | 8 |
| Greenberg, HS | 7 |
| Junck, L | 4 |
| Chang, SM | 5 |
| Nicholas, MK | 1 |
| Robins, HI | 3 |
| Kuhn, J | 2 |
| Hess, KR | 1 |
| Schold, SC | 12 |
| Kucinski, T | 1 |
| Knopp, U | 1 |
| Goldbrunner, R | 1 |
| Hamel, W | 1 |
| Tonn, JC | 5 |
| Kleinberg, LR | 2 |
| Carson, K | 1 |
| Li, K | 1 |
| Wharam, MD | 1 |
| Abrey, LE | 2 |
| Fine, H | 1 |
| Greenberg, H | 1 |
| Hess, K | 1 |
| Schold, C | 4 |
| Rosenthal, MA | 1 |
| Ashley, DL | 1 |
| Cher, L | 1 |
| Horvath, Z | 2 |
| Höchtl, T | 1 |
| Bauer, W | 2 |
| Fritzer-Szekeres, M | 2 |
| Elford, HL | 1 |
| Szekeres, T | 2 |
| Tihan, T | 2 |
| Storm, PB | 1 |
| Renard, VM | 1 |
| Moriarity, JL | 1 |
| Wilentz, RE | 1 |
| Seiferheld, W | 2 |
| Curran, W | 3 |
| Share, R | 1 |
| Atkins, J | 1 |
| Choucair, A | 2 |
| Thoron, L | 1 |
| Cairncross, G | 2 |
| Gilbert, M | 2 |
| Bahary, JP | 1 |
| Dolinskas, C | 1 |
| Louis, DN | 1 |
| Bushunow, P | 1 |
| Buckner, J | 1 |
| Barger, G | 2 |
| Raizer, JJ | 1 |
| Kleber, M | 1 |
| Paz, MF | 1 |
| Yaya-Tur, R | 1 |
| Reynes, G | 1 |
| Pollan, M | 1 |
| Aguirre-Cruz, L | 1 |
| García-Lopez, JL | 1 |
| Piquer, J | 1 |
| Safont, MJ | 1 |
| Sanchez-Cespedes, M | 1 |
| García-Villanueva, M | 1 |
| Arribas, L | 1 |
| Esteller, M | 2 |
| Lytle, RA | 2 |
| Jiang, Z | 2 |
| Zheng, X | 3 |
| Rich, KM | 4 |
| Lohani, S | 1 |
| O'Driscoll, BR | 4 |
| Woodcock, AA | 4 |
| Bacolod, MD | 1 |
| Johnson, SP | 2 |
| Pegg, AE | 6 |
| Dolan, ME | 8 |
| Moschel, RC | 5 |
| Bullock, NS | 1 |
| Fang, Q | 1 |
| Colvin, OM | 4 |
| Modrich, P | 1 |
| Amistà, P | 4 |
| Nicolardi, L | 3 |
| Grosso, D | 1 |
| Bringas, J | 1 |
| Mirek, H | 1 |
| Bankiewicz, KS | 1 |
| Basso, U | 2 |
| Reni, M | 1 |
| Valduga, F | 1 |
| Monfardini, S | 4 |
| Sotti, G | 1 |
| Hoechtl, T | 1 |
| Saiko, P | 1 |
| Hall, DE | 5 |
| Stojanovska, J | 3 |
| Li, Z | 2 |
| Hamstra, DA | 3 |
| Post, DE | 1 |
| Devi, NS | 1 |
| Brat, DJ | 2 |
| Kaur, B | 1 |
| Nicholson, A | 1 |
| Van Meir, EG | 1 |
| Hua, XM | 1 |
| Ren, XW | 1 |
| Liu, FL | 1 |
| Liu, Y | 1 |
| Zhang, CJ | 1 |
| Li, ZJ | 1 |
| Xu, L | 1 |
| Liu, JY | 1 |
| Liu, YG | 1 |
| Rao, RD | 1 |
| Krishnan, S | 1 |
| Fitch, TR | 1 |
| Dinapoli, RP | 7 |
| Nordstrom, K | 1 |
| Scheithauer, B | 1 |
| O'Fallon, JR | 6 |
| Maurer, MJ | 1 |
| Chen, LF | 1 |
| Ke, YQ | 1 |
| Yang, ZL | 1 |
| Wang, SQ | 1 |
| Xu, RX | 1 |
| Schepkin, VD | 3 |
| Sharma, S | 2 |
| Kumar, M | 2 |
| Weber, EL | 1 |
| Goebel, EA | 1 |
| Xu, GW | 1 |
| Mymryk, JS | 1 |
| Cairncross, JG | 7 |
| Liau, CT | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Couprie, C | 1 |
| Muracciole, X | 1 |
| Hoang-Xuan, K | 1 |
| Braguer, D | 1 |
| Martin, PM | 1 |
| Peragut, JC | 2 |
| Grisoli, F | 1 |
| Limentani, SA | 1 |
| Asher, A | 1 |
| Heafner, M | 1 |
| Kim, JW | 1 |
| Fraser, R | 1 |
| LaRocca, R | 1 |
| Fadeev, BP | 1 |
| Bandres, E | 1 |
| Andion, E | 2 |
| Escalada, A | 1 |
| Honorato, B | 1 |
| Catalan, V | 1 |
| Cubedo, E | 1 |
| Cordeu, L | 1 |
| Garcia, F | 1 |
| Zarate, R | 1 |
| Zabalegui, N | 1 |
| Garcia-Foncillas, J | 2 |
| Young, JM | 1 |
| Desmond, TJ | 1 |
| Frey, KA | 1 |
| Chae, GS | 1 |
| Lee, JS | 1 |
| Kim, SH | 1 |
| Seo, KS | 1 |
| Kim, MS | 1 |
| Lee, HB | 1 |
| Khang, G | 1 |
| Tsao, MN | 1 |
| Whelan, TJ | 1 |
| Morris, DE | 1 |
| Hayman, JA | 1 |
| Flickinger, JC | 1 |
| Mills, M | 1 |
| Rogers, CL | 1 |
| Souhami, L | 1 |
| Yuan, L | 2 |
| Choi, K | 2 |
| Khosla, C | 2 |
| Higashikubo, R | 2 |
| Chicoine, MR | 1 |
| Finn, LS | 1 |
| Ellenbogen, RG | 1 |
| Geyer, JR | 2 |
| Braga, JM | 1 |
| Meade, EH | 1 |
| Gross, ME | 1 |
| Marshall, NE | 1 |
| Michalak, JC | 1 |
| Burton, GV | 1 |
| Sandler, HM | 1 |
| Cascino, TL | 8 |
| Schönmayr, R | 3 |
| Kraemer, HP | 3 |
| DeAngelis, LM | 2 |
| Duntsch, C | 1 |
| Divi, MK | 1 |
| Jones, T | 1 |
| Zhou, Q | 1 |
| Krishnamurthy, M | 1 |
| Boehm, P | 1 |
| Wood, G | 1 |
| Sills, A | 1 |
| Moore, BM | 1 |
| Shibui, S | 1 |
| Hank, NC | 2 |
| Shapiro, JR | 9 |
| Scheck, AC | 3 |
| Pineda, B | 1 |
| Estrada-Parra, S | 1 |
| Pedraza-Medina, B | 1 |
| Rodriguez-Ropon, A | 1 |
| Pérez, R | 1 |
| Riddle, V | 1 |
| Sotelo, J | 2 |
| Briceño, E | 1 |
| López-González, MA | 1 |
| Chen, M | 1 |
| Kariaapper, MS | 1 |
| Blaivas, M | 1 |
| Kuszpit, K | 2 |
| Park, MC | 1 |
| Hoff, BA | 2 |
| Leopold, WR | 1 |
| Mazurchuk, RV | 1 |
| McKeever, PE | 3 |
| Simon, M | 1 |
| Voss, D | 1 |
| Park-Simon, TW | 1 |
| Mahlberg, R | 1 |
| Köster, G | 1 |
| Diedrich, A | 1 |
| König, F | 1 |
| Schulz, TG | 1 |
| Ludwig, HC | 1 |
| Herken, R | 1 |
| Quondamatteo, F | 1 |
| Muthuswami, M | 1 |
| Fruehauf, JP | 1 |
| Sloan, A | 1 |
| Huang, W | 1 |
| Parker, R | 1 |
| Perry, K | 1 |
| Clark, WD | 1 |
| Bodell, WJ | 7 |
| Bodell, AP | 1 |
| Giannini, DD | 2 |
| Dyke, JP | 1 |
| Sanelli, PC | 1 |
| Voss, HU | 1 |
| Serventi, JV | 1 |
| Stieg, PE | 1 |
| Schwartz, TH | 1 |
| Ballon, D | 1 |
| Shungu, DC | 1 |
| Pannullo, SC | 1 |
| Van Meter, TE | 1 |
| Cash, D | 1 |
| Fillmore, H | 1 |
| Siegel, M | 1 |
| Miller, CR | 1 |
| Jackson, EN | 1 |
| Piwnica-Worms, D | 1 |
| Redjal, N | 1 |
| Chan, JA | 1 |
| Segal, RA | 1 |
| Kung, AL | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Segura Ibáñez, JM | 1 |
| Sáez Castán, J | 1 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Ng, WH | 1 |
| Wan, GQ | 1 |
| Too, HP | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Delaney, SM | 1 |
| Rosenblum, ML | 24 |
| Lustig, RA | 1 |
| Berkey, B | 1 |
| Yung, AW | 1 |
| Scarantino, C | 1 |
| Simpson, JR | 1 |
| Fishbach, J | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Ducray, F | 1 |
| Gomez, GG | 1 |
| Kruse, CA | 1 |
| Jordan, JT | 1 |
| Sun, W | 1 |
| Hussain, SF | 1 |
| DeAngulo, G | 1 |
| Prabhu, SS | 1 |
| Heimberger, AB | 1 |
| Goodkin, R | 1 |
| Varia, M | 1 |
| Cush, S | 2 |
| Carey, LA | 1 |
| Pitt, M | 2 |
| Anderson, R | 2 |
| Dyer, M | 2 |
| Mealing, S | 2 |
| Price, A | 1 |
| Hashimoto, N | 1 |
| Darakchiev, BJ | 1 |
| Albright, RE | 1 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Lin, SH | 1 |
| Pan, E | 1 |
| Mitchell, SB | 1 |
| Tsai, JS | 1 |
| Kobiakov, GL | 1 |
| Sardi, I | 1 |
| Sanzo, M | 1 |
| Giordano, F | 1 |
| Sandri, A | 1 |
| Mussa, F | 1 |
| Donati, PA | 1 |
| Genitori, L | 1 |
| Smith, BH | 3 |
| Vaughan, M | 1 |
| Greenwood, MA | 1 |
| Kornblith, PL | 5 |
| Robinson, A | 1 |
| Shitara, N | 2 |
| Mortimer, JE | 1 |
| Hewlett, JS | 1 |
| Bay, J | 1 |
| Kobayashi, S | 1 |
| Hoshino, T | 13 |
| Dougherty, DV | 10 |
| Kessinger, A | 2 |
| Gerosa, M | 1 |
| Reese, C | 2 |
| Barger, GR | 2 |
| Davis, RL | 4 |
| Levin, VA | 20 |
| Wilson, CB | 29 |
| Yamamoto, YL | 6 |
| Thompson, CJ | 1 |
| Diksic, M | 7 |
| Meyer, E | 1 |
| Feindel, WH | 1 |
| Muraoka, I | 2 |
| Ogashiwa, M | 1 |
| Weizsaecker, M | 1 |
| Deen, DF | 33 |
| Gutin, PH | 7 |
| Barker, M | 8 |
| Nomura, K | 3 |
| Pentecost, SM | 1 |
| Vats, TS | 3 |
| Kimler, BF | 6 |
| Henderson, SD | 2 |
| Morantz, RA | 5 |
| Kuwamura, K | 6 |
| Kokunai, T | 6 |
| Kanazawa, Y | 1 |
| Yamada, T | 1 |
| Dietz, R | 1 |
| Burger, L | 1 |
| Schimrigk, K | 1 |
| Merkel, KH | 1 |
| Kelly, KA | 1 |
| Kirkwood, JM | 1 |
| Kapp, DS | 1 |
| Mahaley, MS | 15 |
| Urso, MB | 1 |
| Whaley, RA | 3 |
| Williams, TE | 1 |
| Guaspari, A | 1 |
| Grimson, BS | 1 |
| Dubey, HD | 1 |
| Dudka, L | 2 |
| Osieka, R | 1 |
| Glatte, P | 1 |
| Pannenbäcker, R | 1 |
| Schmidt, CG | 2 |
| Dara, P | 1 |
| Slater, LM | 1 |
| Talreja, D | 1 |
| Armentrout, SA | 1 |
| Dougherty, DA | 2 |
| Steinbok, P | 3 |
| Aronin, P | 1 |
| Zinn, D | 1 |
| Parker, LM | 2 |
| Takvorian, T | 2 |
| Canellos, GP | 2 |
| Zervas, NT | 1 |
| Madajewicz, S | 1 |
| West, CR | 3 |
| Park, HC | 2 |
| Ghoorah, J | 2 |
| Avellanosa, AM | 2 |
| Takita, H | 2 |
| Karakousis, C | 1 |
| Vincent, R | 1 |
| Caracandas, J | 1 |
| Jennings, E | 1 |
| Duffner, PK | 2 |
| Cohen, ME | 2 |
| Heffner, RR | 1 |
| Freeman, AI | 3 |
| Carella, AM | 1 |
| Giordano, D | 1 |
| Santini, G | 1 |
| Frassoni, F | 1 |
| Podestà, M | 1 |
| Van Lint, MT | 1 |
| Bacigalupo, A | 1 |
| Nati, S | 1 |
| Vimercati, R | 1 |
| Occhini, D | 1 |
| Bistolfi, F | 1 |
| Lucarelli, G | 1 |
| Lercari, G | 1 |
| Marmont, AM | 1 |
| Lieberman, AN | 1 |
| Foo, SH | 4 |
| Ransohoff, J | 10 |
| Wise, A | 3 |
| George, A | 2 |
| Gordon, W | 1 |
| Walker, R | 1 |
| Salcman, M | 6 |
| Kaplan, RS | 2 |
| Ducker, TB | 2 |
| Abdo, H | 1 |
| Montgomery, E | 1 |
| Samaras, GM | 1 |
| Broadwell, RD | 1 |
| Salazar, OM | 1 |
| VanHoutte, PJ | 1 |
| Bennett, JM | 1 |
| Rubin, P | 3 |
| Wheeler, KT | 17 |
| Gamel-Bentzel, C | 1 |
| Phillips, TW | 1 |
| Chandler, WF | 2 |
| Kindt, GW | 3 |
| Ensminger, WD | 3 |
| Seeger, JF | 1 |
| Doan, KM | 1 |
| Gyves, JW | 1 |
| Robustelli della Cuna, G | 2 |
| Paoletti, P | 10 |
| Bernardo, G | 1 |
| Knerich, R | 6 |
| Butti, G | 4 |
| Cuzzoni, Q | 1 |
| Vincent, FM | 1 |
| Pertuiset, BF | 2 |
| Poisson, M | 1 |
| Hauw, JJ | 1 |
| Buge, A | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Kapp, JP | 8 |
| Vance, R | 3 |
| Rana, SR | 1 |
| Haddy, TB | 1 |
| Ashayeri, E | 1 |
| Goldson, AL | 1 |
| Green, SB | 4 |
| Byar, DP | 2 |
| Walker, MD | 11 |
| Pistenmaa, DA | 1 |
| Alexander, E | 3 |
| Batzdorf, U | 2 |
| Brooks, WH | 2 |
| Hunt, WE | 3 |
| Mealey, J | 3 |
| Odom, GL | 1 |
| Smith, KR | 2 |
| Strike, TA | 4 |
| Nelson, DF | 8 |
| Schoenfeld, D | 4 |
| Weinstein, AS | 3 |
| Nelson, JS | 6 |
| Wasserman, T | 1 |
| Goodman, RL | 1 |
| Carabell, S | 2 |
| Chang, CH | 4 |
| Horton, J | 3 |
| Salazer, O | 1 |
| Perez-Tamayo, R | 1 |
| Kramer, S | 1 |
| Weinstein, A | 1 |
| Tsukada, Y | 1 |
| Phillips, GL | 3 |
| Fay, JW | 2 |
| Herzig, GP | 3 |
| Herzig, RH | 3 |
| Weiner, RS | 1 |
| Wolff, SN | 4 |
| Lazarus, HM | 2 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Preussmann, R | 1 |
| Fingert, HJ | 1 |
| Tanghetti, B | 1 |
| Adinolfi, D | 1 |
| Gaetani, P | 3 |
| Buoncristiani, P | 1 |
| Stewart, DJ | 5 |
| Grahovac, Z | 3 |
| Benoit, B | 4 |
| Addison, D | 1 |
| Richard, MT | 3 |
| Dennery, J | 1 |
| Hugenholtz, H | 5 |
| Russell, N | 4 |
| Peterson, E | 1 |
| Maroun, JA | 2 |
| Bjerkvig, R | 1 |
| Oredsson, SM | 5 |
| Marton, LJ | 18 |
| Linden, M | 1 |
| Tofilon, PJ | 8 |
| Feuerstein, BG | 3 |
| Sano, Y | 3 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| Alhonen-Hongisto, L | 1 |
| Silberman, AW | 2 |
| Morgan, DF | 1 |
| Storm, FK | 2 |
| Rand, RW | 2 |
| Benz, M | 1 |
| Drury, B | 2 |
| Morton, DL | 3 |
| Bremer, AM | 4 |
| Nguyen, TQ | 2 |
| Balsys, R | 2 |
| Kleriga, E | 1 |
| Northup, HM | 1 |
| Gonzalez, N | 1 |
| Duarte, P | 1 |
| Miller, RI | 1 |
| Bernstein, M | 1 |
| Somló, P | 2 |
| Révész, T | 2 |
| Hung, DT | 2 |
| Lehane, DE | 1 |
| Bryan, RN | 1 |
| Horowitz, B | 1 |
| DeSantos, L | 1 |
| Ehni, G | 1 |
| Zubler, MA | 1 |
| Moiel, R | 1 |
| Rudolph, L | 1 |
| Aldama-Leubbert, A | 1 |
| Mahoney, D | 1 |
| Feun, LG | 6 |
| Wallace, S | 4 |
| Lee, YY | 4 |
| Leavens, ME | 1 |
| Moser, R | 1 |
| Savaraj, N | 4 |
| Burgess, MA | 2 |
| Plager, C | 2 |
| Benjamin, RS | 2 |
| Chadduck, WM | 1 |
| Sako, K | 2 |
| Feindel, W | 8 |
| Kato, A | 1 |
| Farrokhzad, S | 2 |
| Thompson, C | 1 |
| Ruggiero, G | 1 |
| Finizio, FS | 1 |
| Manfredini, M | 1 |
| Spagnolli, F | 1 |
| Matozzi, F | 1 |
| Amodio, C | 1 |
| Bradley, NJ | 1 |
| Darling, JL | 3 |
| Oktar, N | 1 |
| Bloom, HJ | 3 |
| Thomas, DG | 2 |
| Davies, AJ | 1 |
| Byrne, TN | 1 |
| Deck, MD | 1 |
| Posner, JB | 4 |
| Gillespie, GY | 1 |
| Houchens, DP | 2 |
| Ovejera, AA | 2 |
| Riblet, SM | 1 |
| Slagel, DE | 2 |
| Rawlings, CE | 1 |
| Bigner, SH | 3 |
| vanAnkeren, SC | 1 |
| Dedrick, RL | 4 |
| Oldfield, EH | 4 |
| Collins, JM | 1 |
| Eagan, RT | 2 |
| Hermann, RC | 2 |
| Groover, RV | 2 |
| Layton, DD | 2 |
| Trovó, MG | 1 |
| De Paoli, A | 1 |
| Franchin, G | 1 |
| Roncadin, M | 1 |
| Veronesi, A | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Wallen, CA | 3 |
| Wolf, KL | 1 |
| Siemann, DW | 2 |
| Wolf, K | 1 |
| Morrissey, S | 1 |
| Williams, ME | 5 |
| Mitsudo, SM | 1 |
| Greenwald, ES | 1 |
| Banerji, B | 1 |
| Koss, LG | 1 |
| Rupniak, HT | 1 |
| Rasmussen, J | 2 |
| Morgan, WF | 2 |
| Layton, PB | 3 |
| Knake, J | 1 |
| Vine, AK | 1 |
| Thomas, MR | 1 |
| Robinson, WA | 1 |
| Glode, LM | 2 |
| Dantas, ME | 1 |
| Koeppler, H | 1 |
| Morton, N | 1 |
| Sutherland, J | 1 |
| Weiss, RB | 2 |
| Issell, BF | 1 |
| Seidenfeld, J | 1 |
| Hervatin, SJ | 1 |
| Koch-Weser, J | 1 |
| McCann, PP | 1 |
| Sjoerdsma, A | 1 |
| Bollini, P | 1 |
| Riva, R | 1 |
| Albani, F | 1 |
| Ida, N | 1 |
| Cacciari, L | 1 |
| Bollini, C | 1 |
| Baruzzi, A | 1 |
| Gerosa, MA | 5 |
| Siddiqi, TS | 1 |
| Buchheit, WA | 1 |
| de Tribolet, N | 2 |
| Ross, RL | 1 |
| Hochberg, F | 2 |
| Krull, IS | 1 |
| Ding, XD | 1 |
| Selavka, C | 1 |
| Weizsäcker, M | 1 |
| Nagamune, A | 1 |
| Winkelströter, R | 1 |
| Vieten, H | 1 |
| Wechsler, W | 2 |
| Knebel, KD | 4 |
| Zeller, WJ | 2 |
| Ivankovic, S | 1 |
| Habs, M | 1 |
| Schmähl, D | 2 |
| MacCarty, CS | 2 |
| Owens, G | 2 |
| Vestnys, PS | 1 |
| Volkin, RL | 1 |
| Shadduck, RK | 1 |
| Winkelstein, A | 1 |
| Zeigler, ZR | 1 |
| Weinkam, RJ | 3 |
| Feola, J | 1 |
| Wilson, KS | 1 |
| Brigden, ML | 1 |
| Alexander, S | 1 |
| Worth, A | 1 |
| Cooper, JS | 1 |
| Borok, TL | 1 |
| Carella, RJ | 1 |
| Scott, M | 1 |
| Tamaki, N | 1 |
| Matsumoto, S | 1 |
| Kapp, J | 1 |
| Parker, JL | 2 |
| Smith, RR | 1 |
| Witman, G | 1 |
| Cadman, E | 1 |
| Kapp, D | 1 |
| Wagner, F | 1 |
| Kaufman, K | 4 |
| Geraci, JP | 1 |
| Jacobs, SA | 1 |
| Moore, PB | 1 |
| Wald, M | 1 |
| Fisher, ER | 1 |
| Cohen, M | 2 |
| Bellot, P | 1 |
| Klein, RC | 1 |
| Paddison, RM | 1 |
| Bullard, DE | 2 |
| Ryan, BR | 1 |
| Walters, TR | 1 |
| Schacht, RG | 1 |
| Feiner, HD | 1 |
| Gallo, GR | 1 |
| Lieberman, A | 2 |
| Baldwin, DS | 1 |
| Yung, WA | 1 |
| Basler, GA | 2 |
| Tel, E | 1 |
| Patten, GA | 1 |
| Billi, JE | 1 |
| Rotman, HH | 1 |
| Allen, N | 1 |
| U, R | 2 |
| Varia, MA | 1 |
| Lipper, S | 2 |
| Mahaley, J | 1 |
| Dalzell, JG | 1 |
| Shafer, RH | 1 |
| Chase, ES | 1 |
| Dufour, FD | 1 |
| Okada, GT | 1 |
| Mah, SG | 1 |
| Leonard, LA | 1 |
| Kirby, S | 1 |
| Brothers, M | 1 |
| Irish, W | 1 |
| Florell, R | 1 |
| Macdonald, D | 1 |
| Roosen, N | 1 |
| Doz, F | 1 |
| Yeomans, KL | 1 |
| Jeremic, B | 3 |
| Antunovic, V | 3 |
| Djuric, L | 3 |
| Nutt, CL | 1 |
| Costello, JF | 1 |
| Bambrick, LL | 1 |
| Yarosh, DB | 2 |
| Swinnen, LJ | 1 |
| Chambers, AF | 1 |
| Shi, X | 1 |
| Burger, PC | 7 |
| Selker, R | 1 |
| Vick, NA | 4 |
| Black, K | 1 |
| Sisti, M | 3 |
| Mohr, G | 2 |
| Kalra, S | 1 |
| Gattamaneni, HR | 2 |
| Steen, RG | 1 |
| Kitagishi, K | 1 |
| Morgan, K | 1 |
| Röttinger, EM | 1 |
| Murray, KJ | 2 |
| Scott, C | 2 |
| Porter, A | 1 |
| Farnan, N | 1 |
| Stojanovic, M | 2 |
| Brown, LD | 2 |
| Kugler, JW | 1 |
| Krook, JE | 3 |
| Mailliard, JA | 2 |
| Kardinal, CG | 1 |
| Tschetter, LK | 3 |
| Scheithauer, BW | 4 |
| Judy, KD | 1 |
| Buahin, KG | 2 |
| Domb, A | 1 |
| Epstein, JI | 3 |
| Sipos, EP | 3 |
| Aas, AT | 2 |
| Brun, A | 2 |
| Pero, RW | 2 |
| Salford, LG | 2 |
| Yousem, DM | 1 |
| Scott, CB | 3 |
| Rotman, M | 3 |
| Asbell, SO | 3 |
| Martin, L | 1 |
| De Witte, O | 2 |
| Hildebrand, J | 3 |
| Luxen, A | 1 |
| Kuratsu, J | 1 |
| Ushio, Y | 2 |
| Ebert, PS | 2 |
| Plowman, J | 2 |
| Waud, WR | 1 |
| Koutsoukos, AD | 1 |
| Rubinstein, LV | 1 |
| Moore, TD | 1 |
| Grever, MR | 1 |
| Zeltzer, PM | 1 |
| Rorke, LB | 1 |
| Albright, AL | 1 |
| Wisoff, JH | 1 |
| Milstein, JM | 1 |
| Allen, JC | 2 |
| Sahmoud, T | 2 |
| Mignolet, F | 1 |
| Brucher, JM | 1 |
| Fleig, MJ | 1 |
| Basu, HS | 1 |
| Luk, GD | 1 |
| Casero, RA | 1 |
| Wu, MP | 1 |
| Tamada, JA | 1 |
| DaSilva, V | 2 |
| Belanger, G | 1 |
| Steward, W | 1 |
| Paul, J | 1 |
| Macham, MA | 1 |
| Harvey, E | 1 |
| Eckley, D | 1 |
| Schmoor, C | 1 |
| Ulm, K | 1 |
| Schumacher, M | 1 |
| Lena, H | 1 |
| Desrues, B | 1 |
| Le Coz, A | 1 |
| Quinquenel, ML | 1 |
| Delaval, P | 1 |
| Felker, GM | 1 |
| Sarkar, A | 1 |
| Gonzalez, GG | 1 |
| Archibald, YM | 1 |
| Lunn, D | 1 |
| Ruttan, LA | 1 |
| Macdonald, DR | 4 |
| Del Maestro, RF | 1 |
| Barr, HW | 1 |
| Pexman, JH | 1 |
| Fisher, BJ | 1 |
| Tamargo, RJ | 2 |
| Pinn, M | 1 |
| Wharam, M | 2 |
| Arusell, RM | 1 |
| Earle, JD | 3 |
| Maier, JA | 1 |
| Watne, K | 7 |
| Hannisdal, E | 2 |
| Nome, O | 3 |
| Hager, B | 7 |
| Hirschberg, H | 5 |
| Patterson, DL | 1 |
| Wiemann, MC | 1 |
| Lee, TH | 1 |
| Byron, WA | 1 |
| Nemoto, S | 1 |
| Bromberg, J | 1 |
| Page, MA | 1 |
| Rozental, JM | 1 |
| Cohen, JD | 1 |
| Levine, RL | 1 |
| Hanson, JM | 1 |
| Nickles, RJ | 1 |
| Pu, PY | 2 |
| Mohamed, AN | 2 |
| Galicich, JH | 1 |
| Ebrahim, SA | 3 |
| Halperin, EC | 3 |
| Gaspar, L | 2 |
| Imperato, J | 2 |
| Salter, M | 2 |
| Herndon, J | 2 |
| Dowling, S | 1 |
| Myseros, JS | 1 |
| Yang, MB | 1 |
| Chasin, M | 1 |
| Dropcho, EJ | 1 |
| Morawetz, R | 1 |
| Bergeron, C | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Evans, RG | 3 |
| Strasser, JF | 1 |
| Fung, LK | 1 |
| Eller, S | 1 |
| Saltzman, WM | 2 |
| Kiu, MC | 1 |
| Chang, CN | 1 |
| Cheng, WC | 1 |
| Lin, TK | 1 |
| Wong, CW | 1 |
| Tang, SG | 1 |
| Leung, WM | 1 |
| Chen, LH | 1 |
| Ho, YS | 1 |
| Ng, KT | 1 |
| Brown, M | 1 |
| Vick, N | 1 |
| Fischer, B | 1 |
| Dropcho, E | 1 |
| Rosenfeld, S | 1 |
| Morowitz, R | 1 |
| Hait, W | 1 |
| Byrne, T | 1 |
| Khandekar, J | 1 |
| Paleologos, N | 1 |
| Bentel, GC | 1 |
| Friedman, A | 1 |
| Kokkinakis, DM | 2 |
| Rudy, JL | 1 |
| Punt, JA | 1 |
| Firth, JL | 1 |
| Hope, DT | 1 |
| Moloney, AJ | 1 |
| Villa, S | 1 |
| Lee, SM | 1 |
| Reid, H | 1 |
| Elder, RH | 1 |
| Thatcher, N | 1 |
| Margison, GP | 2 |
| Belanich, M | 2 |
| Pastor, M | 1 |
| Randall, T | 1 |
| Guerra, D | 1 |
| Kibitel, J | 1 |
| Alas, L | 1 |
| Citron, M | 1 |
| Wasserman, P | 1 |
| White, A | 1 |
| Eyre, H | 1 |
| Jaeckle, K | 1 |
| Schulman, S | 2 |
| Rector, D | 1 |
| Coons, S | 1 |
| Shapiro, W | 1 |
| Yarosh, D | 1 |
| Takeda, N | 2 |
| Lunardi, P | 1 |
| Osman Farah, J | 1 |
| Mastronardi, L | 1 |
| Puzzilli, F | 1 |
| Lo Bianco, FM | 1 |
| Kaaijk, P | 1 |
| Troost, D | 1 |
| de Boer, OJ | 1 |
| Van Amstel, P | 1 |
| Bakker, PJ | 1 |
| Leenstra, S | 1 |
| Bosch, DA | 1 |
| Camby, I | 1 |
| Salmon, I | 1 |
| Danguy, A | 1 |
| Pasteels, JL | 1 |
| Kiss, R | 1 |
| Greenhoot, J | 1 |
| Fernández-Hidalgo, OA | 1 |
| Vanaclocha, V | 2 |
| Vieitez, JM | 1 |
| Rebollo, J | 1 |
| Gúrpide, A | 1 |
| Moreno-Palanques, R | 1 |
| Subirá, ML | 1 |
| Brugarolas, A | 1 |
| Siffert, J | 1 |
| Kawecki, S | 1 |
| Lazo, JS | 1 |
| Schlegel, J | 1 |
| Stumm, G | 1 |
| Ruschoff, J | 1 |
| Mennel, HD | 1 |
| Liang, BC | 2 |
| Mineura, K | 1 |
| Yanagisawa, T | 1 |
| Watanabe, K | 1 |
| Kowada, M | 1 |
| Yasui, N | 1 |
| Williams, JA | 2 |
| Tabassi, K | 1 |
| Babel, KM | 1 |
| Anderson, RC | 1 |
| Pinn, ML | 1 |
| Bartus, RT | 5 |
| Elliott, PJ | 1 |
| Dean, RL | 2 |
| Hayward, NJ | 1 |
| Nagle, TL | 1 |
| Huff, MR | 1 |
| Snodgrass, PA | 1 |
| Blunt, DG | 1 |
| Rigon, A | 3 |
| Zampieri, P | 3 |
| Scelzi, E | 2 |
| Gardiman, M | 1 |
| Fiorentino, MV | 2 |
| Kurpad, SN | 1 |
| Archer, GE | 1 |
| Bouffet, E | 1 |
| Khelfaoui, F | 1 |
| Philip, I | 1 |
| Biron, P | 1 |
| Brunat-Mentigny, M | 1 |
| Philip, T | 1 |
| Russell, C | 1 |
| Weissman, D | 1 |
| Evans, R | 1 |
| Cook, P | 1 |
| Burton, G | 1 |
| Eisenberg, PD | 1 |
| Valenzuela, R | 1 |
| Verkh, L | 1 |
| Beith, J | 1 |
| Hartley, J | 1 |
| Darling, J | 1 |
| Souhami, R | 1 |
| Allison, RR | 1 |
| Schulsinger, A | 1 |
| Vongtama, V | 1 |
| Barry, T | 1 |
| Shin, KH | 1 |
| Schmitz, N | 1 |
| Diehl, V | 1 |
| Elliott, TE | 1 |
| Levitt, R | 1 |
| Pfeifle, DM | 1 |
| Twito, DI | 1 |
| Nelimark, RA | 1 |
| Pozzi, A | 3 |
| Farinotti, M | 1 |
| Broggi, G | 5 |
| Valtonen, S | 1 |
| Timonen, U | 1 |
| Toivanen, P | 1 |
| Kalimo, H | 1 |
| Kivipelto, L | 1 |
| Heiskanen, O | 1 |
| Unsgaard, G | 1 |
| Kuurne, T | 1 |
| Donahue, B | 1 |
| Banker, FL | 1 |
| Fischbach, JA | 1 |
| Lote, K | 2 |
| Egeland, T | 1 |
| Stenwig, B | 1 |
| Skullerud, K | 1 |
| Berg-Johnsen, J | 1 |
| Storm-Mathisen, I | 1 |
| Larson, DA | 1 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 1 |
| Wara, WM | 4 |
| Mack, EE | 1 |
| Krouwer, HG | 2 |
| Chandler, KL | 1 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Phillips, TL | 1 |
| Carollo, C | 1 |
| Altavilla, G | 1 |
| Turazzi, S | 1 |
| Chierichetti, F | 1 |
| Florentino, MV | 1 |
| Rajkumar, SV | 3 |
| Burch, PA | 1 |
| Arguello, F | 1 |
| Alexander, MA | 1 |
| Greene, JF | 1 |
| Stinson, SF | 1 |
| Jorden, JL | 1 |
| Smith, EM | 1 |
| Kalavar, NT | 1 |
| Alvord, WG | 1 |
| Klabansky, RL | 1 |
| Sausville, EA | 1 |
| Vassal, G | 1 |
| Boland, I | 1 |
| Terrier-Lacombe, MJ | 1 |
| Watson, AJ | 1 |
| Vénuat, AM | 1 |
| Morizet, J | 1 |
| Parker, F | 1 |
| Lacroix, C | 1 |
| Lellouch-Tubiana, A | 1 |
| Pierre-Kahn, A | 1 |
| Poullain, MG | 1 |
| Gouyette, A | 1 |
| Hsu, E | 1 |
| Keene, D | 1 |
| Ventureyra, E | 1 |
| Matzinger, MA | 1 |
| Jimenez, C | 1 |
| Wang, HS | 1 |
| Grimard, L | 1 |
| Garvin, JH | 2 |
| Ettinger, LJ | 1 |
| Kaplan, AM | 1 |
| Cairo, M | 1 |
| Ullyatt, E | 1 |
| Coggins, CA | 1 |
| Elion, GB | 2 |
| Hare, CB | 1 |
| Keir, S | 1 |
| Leweke, F | 1 |
| Damian, MS | 1 |
| Schindler, C | 1 |
| Schachenmayr, W | 3 |
| McElroy, EA | 1 |
| Lewis, JE | 1 |
| McQuillan, A | 1 |
| Panasci, LC | 3 |
| Zhao, YJ | 1 |
| Neal, ER | 1 |
| Stegman, LD | 2 |
| Ercolani, M | 1 |
| Ben-Yoseph, O | 1 |
| Taylor, BV | 1 |
| Schaefer, PL | 1 |
| Schomberg, P | 1 |
| Guruangan, S | 1 |
| Rosenblum, M | 3 |
| Gardner, S | 1 |
| Merchant, TE | 1 |
| Gollamudi, S | 1 |
| Trepel, M | 1 |
| Groscurth, P | 1 |
| Malipiero, U | 1 |
| Gulbins, E | 1 |
| Dichgans, J | 2 |
| Weller, M | 3 |
| Townsend, JJ | 1 |
| Knudson, HM | 1 |
| Bearman, SI | 2 |
| Giroux, DJ | 1 |
| Kong, Q | 1 |
| Lillehei, KO | 1 |
| Kim, B | 1 |
| Bagniewski, PJ | 1 |
| Marks, RS | 1 |
| Gundersen, S | 1 |
| Pitot, HC | 1 |
| Ingle, JN | 1 |
| Nieto, Y | 1 |
| Cagnoni, PJ | 1 |
| Shpall, EJ | 1 |
| Matthes, S | 1 |
| DeBoom, T | 1 |
| Barón, A | 1 |
| Jones, RB | 1 |
| Williams, D | 1 |
| Kleinberg, L | 1 |
| Zeltzman, M | 1 |
| Israel, ZH | 1 |
| Elmalak, O | 1 |
| Teomim, D | 1 |
| Bentolila, A | 1 |
| Grovas, AC | 1 |
| Lindsley, K | 1 |
| Rolhion, C | 1 |
| Penault-Llorca, F | 1 |
| Kemeny, JL | 1 |
| Kwiatkowski, F | 1 |
| Lemaire, JJ | 1 |
| Chollet, P | 1 |
| Finat-Duclos, F | 1 |
| Verrelle, P | 1 |
| Quan, D | 1 |
| Hackney, DB | 1 |
| Pruitt, AA | 2 |
| Lenkinski, RE | 1 |
| Cecil, KM | 1 |
| Subach, BR | 1 |
| Witham, TF | 1 |
| Lunsford, LD | 1 |
| Bozik, M | 1 |
| Schiff, D | 1 |
| Fleming, DR | 1 |
| Goldsmith, GC | 1 |
| Stevens, DA | 1 |
| Biroccio, A | 1 |
| Bufalo, DD | 1 |
| Ricca, A | 1 |
| D'Angelo, C | 1 |
| D'Orazi, G | 1 |
| Sacchi, A | 1 |
| Soddu, S | 1 |
| Zupi, G | 1 |
| Wang, CC | 1 |
| Teo, CS | 1 |
| Lee, T | 1 |
| Lassen, U | 1 |
| Kristjansen, PE | 1 |
| Wagner, A | 1 |
| Kurpad, C | 1 |
| Bartussek, C | 1 |
| Naumann, U | 1 |
| Papadopoulos, KP | 1 |
| Balmaceda, C | 1 |
| Fetell, M | 1 |
| Kaufman, E | 1 |
| Vahdat, LT | 1 |
| Isaacson, S | 1 |
| De LaPaz, R | 1 |
| Savage, DG | 1 |
| Troxel, A | 1 |
| Antman, KH | 1 |
| Hesdorffer, CS | 1 |
| Bruce, JN | 1 |
| Falavigna, A | 1 |
| Johnson, JP | 1 |
| Hall, JS | 1 |
| Birch, BD | 1 |
| Yoon, JT | 1 |
| Wu, EX | 1 |
| Fine, RL | 1 |
| Parsa, AT | 1 |
| Castellino, RC | 1 |
| Khil, MS | 1 |
| Kolozsvary, A | 1 |
| Apple, M | 1 |
| Rieger, L | 1 |
| Rieger, J | 1 |
| Winter, S | 1 |
| Streffer, J | 1 |
| Esser, P | 1 |
| Meyermann, R | 1 |
| Park, SJ | 1 |
| Kaye, AH | 1 |
| Hill, JS | 1 |
| Chen, YQ | 2 |
| Hung, CF | 1 |
| Lee, A | 1 |
| DeJong, G | 1 |
| Guo, J | 1 |
| Bu, X | 1 |
| Jia, WW | 1 |
| Emerich, DF | 4 |
| Winn, SR | 3 |
| Hu, Y | 1 |
| Marsh, J | 2 |
| Snodgrass, P | 3 |
| LaFreniere, D | 3 |
| Wiens, T | 2 |
| Hasler, BP | 1 |
| Agostino, M | 1 |
| Xiong, H | 1 |
| Goodman, SN | 1 |
| Hidalgo, OF | 1 |
| Baylin, SB | 1 |
| Herman, JG | 1 |
| Weinstein, JN | 1 |
| Taylor, JM | 1 |
| Robertson, PL | 1 |
| Langer, C | 1 |
| Coia, L | 1 |
| Pink, M | 1 |
| Godard, J | 1 |
| Viennet, G | 1 |
| Raul, JS | 1 |
| Plouvier, E | 1 |
| Miny, J | 1 |
| Czorny, A | 1 |
| Potthoff, RF | 1 |
| Peterson, BL | 1 |
| George, SL | 1 |
| Joy, A | 1 |
| Panicker, S | 1 |
| Gildenberg, PL | 2 |
| Winter, PM | 1 |
| Poptani, H | 1 |
| Bansal, N | 1 |
| Palmisano, V | 1 |
| Pasetto, LM | 1 |
| Teicher, BA | 2 |
| Menon, K | 1 |
| Alvarez, E | 1 |
| Galbreath, E | 1 |
| Shih, C | 1 |
| Faul, M | 1 |
| Kuhn, JG | 1 |
| Bosik, ME | 1 |
| Fulton, D | 1 |
| Pan, J | 1 |
| Huang, Q | 1 |
| Sun, ZF | 1 |
| Zhou, LY | 1 |
| Wang, AD | 1 |
| Hoffman, RM | 1 |
| Frenkel, EP | 1 |
| Wick, JB | 1 |
| Han, Q | 1 |
| Xu, M | 1 |
| Tan, Y | 1 |
| McGinnis, WL | 1 |
| Kuross, SA | 1 |
| Hatfield, AK | 1 |
| Cole, JT | 1 |
| Steen, PD | 1 |
| Bernath, AM | 1 |
| Reyes, S | 1 |
| Herrera, LA | 1 |
| Ostrosky, P | 1 |
| Hassenbusch, S | 1 |
| Linassier, C | 1 |
| Destrieux, C | 1 |
| Benboubker, L | 1 |
| Alcaraz, L | 1 |
| Bergemer-Fouquet, AM | 1 |
| Jan, M | 1 |
| Calais, G | 1 |
| Colombat, P | 1 |
| Woo, SY | 1 |
| Qin, D | 1 |
| Mo, H | 1 |
| Ou, G | 1 |
| Lesniak, MS | 1 |
| Pluda, J | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Haglund, MM | 1 |
| Provenzale, JM | 1 |
| Tourt-Uhlig, S | 1 |
| Vogelhuber, W | 1 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Buschauer, A | 1 |
| Göpferich, A | 1 |
| Villavicencio, AT | 1 |
| Bulsara, KR | 1 |
| Fleming, AB | 1 |
| Kohno, T | 1 |
| Sano, K | 1 |
| Crafts, DC | 2 |
| Schultz, MJ | 1 |
| Boldrey, EB | 5 |
| Enot, KJ | 4 |
| Pischer, TL | 4 |
| Seager, M | 2 |
| Elashoff, RM | 1 |
| Young, DF | 1 |
| Gutin, P | 1 |
| Drafts, D | 1 |
| Weiss, HD | 1 |
| Gentry, RE | 1 |
| Vogl, SE | 1 |
| Lemon, HM | 1 |
| Foley, JF | 1 |
| Bellot, PA | 1 |
| Valdiserri, RO | 1 |
| Chernik, NL | 2 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Brambilla, C | 2 |
| Vaghi, A | 2 |
| Valagussa, P | 2 |
| Morello, G | 2 |
| Bonadonna, G | 3 |
| Davis, R | 2 |
| Irwin, L | 2 |
| Paillas, JE | 1 |
| Prince, MA | 1 |
| Hassoun, J | 1 |
| Pellet, W | 1 |
| Zinn, DC | 1 |
| Mahaley, JL | 1 |
| Wara, W | 1 |
| Brisman, R | 2 |
| Schlesinger, EB | 1 |
| Willson, N | 1 |
| Hilal, S | 1 |
| Michelsen, JW | 1 |
| Gamboa, E | 1 |
| Goldberg, N | 1 |
| Kung, FH | 1 |
| Nythan, WL | 1 |
| Cuttner, J | 1 |
| Falkson, G | 1 |
| Lanzkowsky, P | 1 |
| Del Duca, V | 1 |
| Nawabi, IU | 1 |
| Koch, K | 1 |
| Pluess, H | 1 |
| Freeman, A | 1 |
| Burgert, EO | 1 |
| Leone, LA | 1 |
| Ruymann, F | 1 |
| Patterson, RB | 1 |
| Degnan, T | 1 |
| Hakami, N | 1 |
| Pajak, TF | 1 |
| Holland, J | 1 |
| Valeriote, F | 2 |
| Lynch, R | 1 |
| Medoff, G | 2 |
| Tolen, S | 1 |
| Dieckman, J | 1 |
| Gehan, EA | 3 |
| Knebel, K | 1 |
| Norrell, HA | 1 |
| Strada, MR | 1 |
| Vogel, FS | 2 |
| Ghatak, NR | 1 |
| Baldini, M | 1 |
| Princi, L | 1 |
| Ehmann, UK | 1 |
| Spence, JD | 1 |
| Shah, S | 1 |
| Shane, SR | 1 |
| Yamada, K | 1 |
| Cigánek, L | 1 |
| Kalina, P | 1 |
| Silvanová, E | 1 |
| Feldstein, M | 1 |
| Baker, DG | 1 |
| Fumagalli, R | 3 |
| Weiss, JF | 1 |
| Pezzotta, S | 4 |
| Racca, AR | 2 |
| Sumer, T | 1 |
| Thomas, PR | 2 |
| Sinks, LF | 2 |
| Szypko, PE | 1 |
| Hoffman, W | 1 |
| Zander, E | 1 |
| Wagenknecht, L | 1 |
| Sheline, GE | 2 |
| Kabra, PA | 1 |
| Freeman-Dove, MA | 1 |
| Stearns, J | 1 |
| Byrd, A | 1 |
| Finn, A | 1 |
| Vasquez, DA | 2 |
| Garfield, JS | 1 |
| Hilton, J | 1 |
| Housepian, EM | 1 |
| Chang, C | 1 |
| Duffy, P | 1 |
| Balis, E | 1 |
| Fiebig, HH | 1 |
| Zeller, WH | 1 |
| Beretta, G | 1 |
| Cascinelli, N | 1 |
| Morabito, A | 1 |
| Veronesi, U | 1 |
| Holoye, PY | 1 |
| Jenkins, DE | 1 |
| Greenberg, SD | 1 |
| Wheeler, K | 1 |
| Gee, TS | 1 |
| Haghbin, M | 1 |
| Dowling, MD | 1 |
| Cunningham, I | 1 |
| Middleman, MP | 1 |
| Clarkson, BD | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
| Costanzi, JJ | 2 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Agradi, E | 1 |
| Tel, N | 1 |
| Sheppard, S | 1 |
| Kabra, PM | 1 |
| Calogero, J | 1 |
| Rosenberg, A | 1 |
| Wollner, N | 1 |
| Burchenal, JH | 1 |
| Lieberman, PH | 1 |
| Exelby, PR | 1 |
| D'Angio, GJ | 1 |
| Murphy, ML | 1 |
| Bradac, GB | 1 |
| Soffietti, R | 1 |
| Riva, A | 1 |
| Stura, G | 1 |
| Sales, S | 1 |
| Schiffer, D | 1 |
| Tamada, J | 1 |
| Barcellos-Hoff, MH | 2 |
| Linfoot, PA | 2 |
| Tokuda, K | 2 |
| Massin, F | 1 |
| Coudert, B | 1 |
| Foucher, P | 1 |
| Lombard, JN | 1 |
| Reybet-Degat, O | 1 |
| Jeannin, L | 1 |
| Camus, P | 1 |
| Botturi, M | 2 |
| Bobo, H | 2 |
| Kupersmith, MJ | 2 |
| Seiple, WH | 1 |
| Holopigian, K | 1 |
| Noble, K | 1 |
| Warren, F | 1 |
| Janus, TJ | 1 |
| Maor, M | 1 |
| Hoffmann, O | 1 |
| Smith, DC | 1 |
| Trump, DL | 1 |
| Purvis, J | 1 |
| Gauspari, A | 1 |
| Lange, OF | 2 |
| Scheef, W | 2 |
| Haase, KD | 2 |
| Papadopoulos, N | 1 |
| Charnsangavej, C | 3 |
| Punt, J | 1 |
| Firth, J | 1 |
| Hope, T | 1 |
| Holland, I | 1 |
| Lowe, J | 1 |
| Allalunis-Turner, MJ | 1 |
| Day, RS | 1 |
| McKean, JD | 1 |
| Petruk, KC | 1 |
| Allen, PB | 1 |
| Aronyk, KE | 1 |
| Weir, BK | 1 |
| Huyser-Wierenga, D | 1 |
| Fulton, DS | 1 |
| Mehta, BM | 1 |
| Moots, PL | 1 |
| Fiola, MR | 1 |
| Roosen, K | 1 |
| Lord, J | 1 |
| Coleman, EA | 1 |
| Wong, KH | 1 |
| Munari, L | 1 |
| Boaziz, C | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Israël, L | 1 |
| Schem, BC | 1 |
| Dahl, O | 1 |
| Mitsuki, S | 1 |
| Conway, T | 1 |
| Villemure, JG | 6 |
| Berens, ME | 2 |
| Obbens, EA | 1 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 3 |
| August, C | 1 |
| Packer, R | 1 |
| Zimmerman, R | 1 |
| Sutton, L | 1 |
| Freid, A | 1 |
| Rorke, L | 1 |
| Bayever, E | 1 |
| Kamani, N | 1 |
| Kramer, E | 1 |
| Ciric, IS | 1 |
| Eller, TW | 1 |
| Cozzens, JW | 1 |
| Arita, N | 1 |
| Hayakawa, T | 1 |
| Mogami, H | 1 |
| Hasegawa, H | 1 |
| Bitoh, S | 1 |
| Oku, Y | 1 |
| Ikeda, H | 1 |
| Kanai, N | 1 |
| Kanoh, M | 1 |
| Hasleton, PS | 2 |
| Lynch, P | 1 |
| Webster, A | 1 |
| Kalra, SJ | 1 |
| Gattamaneini, HR | 1 |
| Poulter, LW | 2 |
| Hunter, KJ | 2 |
| Pellarin, M | 1 |
| Zhang, RX | 1 |
| Silver, P | 2 |
| Hannigan, J | 1 |
| Recht, L | 1 |
| Fram, RJ | 1 |
| Strauss, G | 1 |
| Fitzgerald, TJ | 1 |
| Liepman, M | 1 |
| Lew, R | 1 |
| Kadish, S | 1 |
| Sherman, D | 1 |
| Wilson, J | 1 |
| Greenberger, J | 1 |
| Ali-Osman, F | 3 |
| Stein, DE | 1 |
| Renwick, A | 1 |
| Schipper, HM | 1 |
| Skalski, V | 2 |
| Wang, E | 1 |
| Hassenbusch, SJ | 1 |
| Anderson, JH | 1 |
| Whiting, DM | 1 |
| Heuser, K | 1 |
| Bradford, R | 1 |
| Assietti, R | 1 |
| Bowles, AP | 1 |
| Pantazis, CG | 1 |
| Wansley, W | 1 |
| Taylor, PM | 1 |
| Gattameneni, HR | 1 |
| Hamada, H | 1 |
| Asakura, T | 1 |
| Matsuda, K | 1 |
| Rathmer, K | 1 |
| Carrasco, CH | 1 |
| Gianturco, C | 1 |
| Driscoll, JS | 1 |
| Johns, DG | 1 |
| Bogdahn, U | 2 |
| Zapf, J | 2 |
| Weber, H | 2 |
| Dünisch, G | 2 |
| Löbering, HG | 2 |
| Martin, R | 1 |
| Mertens, HG | 2 |
| Richard, M | 2 |
| Iwata, K | 1 |
| Fields, WS | 1 |
| Geier, JM | 3 |
| Rodriguez, L | 1 |
| Chamberlain, M | 2 |
| Levin, V | 1 |
| Elsås, T | 1 |
| Fostad, K | 1 |
| Zamorano, L | 1 |
| Katanick, D | 1 |
| Dujovny, M | 1 |
| Yakar, D | 1 |
| Malik, G | 1 |
| Ausman, JI | 1 |
| Caughlan, J | 1 |
| Gray, GS | 1 |
| Wu, ZL | 1 |
| Arnold, DL | 2 |
| Shoubridge, EA | 2 |
| Emrich, J | 2 |
| Fischer, H | 1 |
| Schwechheimer, K | 1 |
| Hutter, KJ | 1 |
| Wowra, B | 1 |
| Kunze, S | 1 |
| Sturm, V | 1 |
| Sheidler, VR | 1 |
| Gilbert, MR | 1 |
| Clayton, PE | 2 |
| Price, DA | 2 |
| Jones, PH | 1 |
| Smith, MT | 3 |
| Evans, CG | 2 |
| Doane-Setzer, P | 2 |
| Castro, VM | 1 |
| Tahir, MK | 1 |
| Mannervik, B | 1 |
| Harris, MI | 1 |
| Bruner, JM | 1 |
| Walker, RW | 1 |
| Bashir, R | 1 |
| Linggood, RM | 1 |
| Hottleman, K | 1 |
| Mbidde, EK | 1 |
| Selby, PJ | 1 |
| Perren, TJ | 1 |
| Dearnaley, DP | 1 |
| Whitton, A | 1 |
| Ashley, S | 1 |
| Workman, P | 1 |
| McElwain, TJ | 1 |
| Mughal, TI | 1 |
| Braun, TJ | 1 |
| Klingensmith, W | 1 |
| Giblin, J | 1 |
| Dougherty, D | 1 |
| Pickrell, L | 1 |
| Purvin, V | 1 |
| Fontaine, S | 1 |
| Théron, J | 3 |
| Melanson, D | 1 |
| Raymond, J | 1 |
| Ethier, R | 1 |
| Stoeter, P | 1 |
| Prey, N | 1 |
| Scholl-Latour, R | 1 |
| Vögele, H | 1 |
| Büdingen, HJ | 1 |
| Chatterji, DC | 2 |
| Yeager, RL | 2 |
| Girton, ME | 1 |
| Doppman, JL | 4 |
| Miller, DF | 1 |
| Bay, JW | 1 |
| Lederman, RJ | 1 |
| Purvis, JD | 1 |
| Rogers, LR | 1 |
| Tomsak, RL | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vance, RB | 3 |
| Beck, DO | 2 |
| DeBrun, G | 1 |
| Davis, K | 1 |
| Stevanoni, G | 2 |
| Tommasi, M | 1 |
| Della Corte, V | 2 |
| Licata, C | 2 |
| Bricolo, A | 2 |
| Tridente, G | 2 |
| Marcon, C | 1 |
| Gebarski, S | 1 |
| Meyer, M | 1 |
| Chaffee, B | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| Eltringham, JR | 1 |
| Al-Sarraf, M | 2 |
| Talley, RW | 1 |
| Athens, JW | 1 |
| Oishi, N | 1 |
| Fletcher, WS | 1 |
| Liu, HC | 1 |
| Da Silva, V | 3 |
| Murovic, J | 1 |
| Berger, M | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Sariban, E | 1 |
| Kohn, KW | 1 |
| Zlotogorski, C | 1 |
| Laurent, G | 1 |
| D'Incalci, M | 1 |
| Day, R | 1 |
| Strayer, DR | 1 |
| Weisband, J | 1 |
| Carter, WA | 1 |
| Black, P | 1 |
| Nidzgorski, F | 1 |
| Cook, AW | 1 |
| Saunders, WM | 1 |
| Cohen, AR | 1 |
| Pietronigro, DD | 1 |
| Cravioto, H | 1 |
| Flamm, ES | 1 |
| Martin, DF | 1 |
| Campbell, RH | 1 |
| Herman, TS | 1 |
| Rose, CM | 1 |
| Wysenbeek, YS | 1 |
| Nissenkorn, I | 1 |
| Cohen, S | 1 |
| Ben-Sira, I | 1 |
| Stark, B | 1 |
| Zaizov, R | 2 |
| Aida, T | 3 |
| Di Chiro, G | 1 |
| Oldfield, E | 1 |
| Wright, DC | 2 |
| De Michele, D | 1 |
| Katz, DA | 1 |
| Patronas, NJ | 1 |
| Larson, SM | 1 |
| Ito, M | 1 |
| Kufta, CV | 1 |
| Giblin, JR | 1 |
| Hoifodt, HK | 1 |
| Tveit, K | 1 |
| Diener-West, M | 2 |
| Dodion, P | 1 |
| Sanders, C | 1 |
| Georges, P | 1 |
| Kenis, Y | 1 |
| LoRusso, PM | 1 |
| Tapazoglou, E | 1 |
| Zarbo, RJ | 1 |
| Cullis, PA | 1 |
| Austin, D | 1 |
| Silvani, V | 1 |
| Spanu, G | 1 |
| Rossi, A | 1 |
| Wolpert, SM | 3 |
| Kwan, ES | 2 |
| Heros, D | 1 |
| Kasdon, DL | 3 |
| Hedges, TR | 1 |
| Frohman, LP | 1 |
| Choi, IS | 2 |
| Hiesinger, E | 1 |
| Berenstein, A | 3 |
| Carr, RE | 1 |
| Heros, DO | 1 |
| Renkens, K | 1 |
| Adelman, LS | 1 |
| Sijens, PE | 1 |
| Bovee, WM | 1 |
| Tyler, JL | 2 |
| Worthington, C | 2 |
| Evans, AC | 1 |
| Blasberg, RG | 2 |
| Groothuis, DR | 1 |
| Sause, WT | 1 |
| Goodman, R | 1 |
| Kimmel, DW | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 2 |
| Johnson, DB | 1 |
| Thompson, JM | 1 |
| Corwin, JA | 1 |
| Mosley, KR | 1 |
| de los Reyes, RA | 1 |
| Daly, MB | 1 |
| Petty, AM | 1 |
| Lamaster, D | 1 |
| Pierson, WP | 1 |
| Donadio, D | 1 |
| Navarro, M | 1 |
| Izarn, P | 1 |
| Johnson, DW | 1 |
| Parkinson, D | 1 |
| Laucella, M | 1 |
| Anderson, ML | 1 |
| Maroun, J | 1 |
| Verma, S | 1 |
| Goebel, WE | 1 |
| Trappe, AE | 1 |
| Weinzierl, FX | 1 |
| Leclerc, DB | 1 |
| Arundel, CM | 1 |
| Lombard, CM | 1 |
| Churg, A | 1 |
| Winokur, S | 1 |
| Schlechtingen, J | 1 |
| Constine, LS | 1 |
| Woolf, PD | 1 |
| Doane, K | 1 |
| Lush, CM | 1 |
| Da Silva, VF | 1 |
| Raaphorst, GP | 1 |
| Goyal, R | 1 |
| Feeley, M | 1 |
| Gray, JW | 1 |
| Dean, PN | 1 |
| Tang, RA | 1 |
| Koslow, M | 1 |
| Lin, J | 1 |
| Feigin, I | 1 |
| Budzilovich, G | 1 |
| Pittisapu, J | 1 |
| Sanford, RA | 1 |
| Kligerman, AD | 1 |
| Erexson, GL | 1 |
| Wilmer, JL | 1 |
| Sulis, E | 1 |
| Floris, C | 1 |
| Chessa, A | 1 |
| Desogus, A | 1 |
| Muggiano, A | 1 |
| Tedde, A | 1 |
| Turno, R | 1 |
| Kieffer, SA | 1 |
| King, GA | 1 |
| King, RB | 1 |
| Cacayorin, ED | 1 |
| Cowan, B | 1 |
| Collins, GH | 1 |
| Petro, G | 1 |
| Levinsohn, EM | 1 |
| Markarian, B | 1 |
| Greene, MH | 1 |
| Boice, JD | 1 |
| Cohen, IJ | 1 |
| Vogel, R | 1 |
| Matz, S | 1 |
| Weitz, R | 1 |
| Mor, C | 1 |
| Stern, S | 1 |
| Blacklock, JB | 1 |
| Lutz, RJ | 1 |
| Kendall, LE | 1 |
| Blue, M | 1 |
| Klein, DS | 1 |
| Klein, PW | 1 |
| Choy, IS | 1 |
| Benz, ML | 1 |
| Persson, L | 1 |
| Boethius, J | 1 |
| Gronowitz, JS | 1 |
| Källander, C | 1 |
| Lindgren, L | 1 |
| Dewey, WC | 1 |
| Buckley, N | 1 |
| Tucker, EM | 1 |
| Safdari, H | 1 |
| Mompeon, B | 1 |
| Dubois, JB | 1 |
| Gros, C | 1 |
| Calvo, FA | 1 |
| Pastor, MA | 1 |
| Dy, C | 1 |
| Alegría, E | 1 |
| Antón Aparicio, LM | 1 |
| Gil, A | 1 |
| Harguindey, S | 1 |
| Zubieta, JL | 1 |
| Martinez Lage, M | 1 |
| Clark, WC | 1 |
| DeVroom, HL | 1 |
| Nagata, K | 1 |
| Gross, CE | 1 |
| Adey, GR | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Conley, FK | 1 |
| Jacobi, H | 1 |
| Hill, GJ | 1 |
| Ruess, R | 1 |
| Berris, R | 1 |
| Philpott, GW | 1 |
| Parkin, P | 1 |
| Lewis, MB | 1 |
| Nunes, LB | 1 |
| Powell, DE | 1 |
| Shnider, BI | 1 |
| Lynch, RG | 1 |
| Schlessinger, D | 1 |
| Kobayashi, GS | 1 |
| Einhorn, LH | 1 |
| Vallejos, C | 1 |
| Bodey, GP | 1 |
| Gutterman, J | 1 |
| Mavligit, G | 1 |
| Hersh, EM | 1 |
| Luce, JK | 1 |
| Frei, E | 1 |
| Freireich, EJ | 1 |
| Gottlieb, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer[NCT00525590] | Phase 2 | 69 participants (Actual) | Interventional | 2007-12-12 | Completed | ||
| Prospective and Retrospective Memory Perception Assessment in Central/Non-central Nervous System Cancers[NCT03975959] | 420 participants (Anticipated) | Interventional | 2019-05-10 | Recruiting | |||
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma[NCT00017147] | Phase 3 | 183 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196] | Phase 3 | 540 participants (Actual) | Interventional | 2019-03-22 | Active, not recruiting | ||
| Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-02-10 | Active, not recruiting | ||
| HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047] | Phase 1 | 6 participants (Actual) | Interventional | 2017-04-06 | Active, not recruiting | ||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590] | Phase 2 | 25 participants (Actual) | Interventional | 2019-02-15 | Active, not recruiting | ||
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959] | Phase 3 | 270 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789] | Phase 3 | 276 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576] | 28 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | |||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme[NCT00003417] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 1998-09-30 | Completed | ||
| Pilot And Phase II Trial Of Irinotecan And Radiation Followed By Irinotecan And BCNU In Glioblastoma Multiforme Patients[NCT00027612] | Phase 1/Phase 2 | 58 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA[NCT00004028] | Phase 1 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)[NCT00004259] | Phase 3 | 230 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)[NCT00003621] | Phase 2 | 29 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial[NCT00224978] | Phase 3 | 0 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma[NCT02432417] | Phase 2 | 0 participants (Actual) | Interventional | 2023-11-10 | Withdrawn (stopped due to The study was withdrawn due to a lack of funding. The researchers were unable to secure the necessary financial support to continue and complete the trial.) | ||
| A Phase I Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma[NCT02378532] | Phase 1 | 13 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460] | Phase 2 | 20 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| EUS-Guided Radiofrequency Ablation of Pancreatic Cysts - A Safety and Efficacy Trial[NCT05916846] | 28 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY[NCT00002620] | Phase 3 | 212 participants (Anticipated) | Interventional | 1994-11-30 | Completed | ||
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980] | 32 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas[NCT01316809] | Phase 1 | 22 participants (Actual) | Interventional | 2011-03-04 | Completed | ||
| (11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas[NCT01281982] | 2 participants (Actual) | Observational | 2011-01-13 | Terminated | |||
| Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)[NCT01468324] | Phase 1 | 14 participants (Actual) | Interventional | 2011-10-05 | Completed | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538] | 674 participants (Actual) | Observational | 2002-03-01 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neurologic Death was defined as death due to progression of neurologic disease. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | percentage of participants (Number) |
|---|---|
| GLIADEL | 1.9 |
NF was assessed as the performance of 3 neurocognitive domains:memory(MD),executive function(EFD), fine motor coordination(FMCD). For each domain, z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted and education-adjusted normative distribution of scores from an unimpaired population.Individual z-scores from related tests were averaged to determine overall z-score.If a z-score average decreased from baseline by greater than or equal to(>=)3 standard deviations(SD)in tests' normative age-adjusted distribution on 2 consecutive visits or decreased by >=3 SD on last follow-up visit, participant were considered to have significant deterioration in their NF at time of the first decrease in z-score.Deterioration in NF:demonstrated deterioration for at least two of the three neurocognitive domains based on these changes from screening.Rate of deterioration in NF was measured as estimated percentage of participants using Kaplan-Meier method. (NCT00525590)
Timeframe: Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| GLIADEL | 2.8 |
The time to neurocognitive deterioration was defined as the number of days between the date of study treatment and the date of neurocognitive deterioration based on NF assessment. This was assessed using Kaplan Meier method. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | months (Number) |
|---|---|
| GLIADEL | NA |
The correlation between recurrence (local, distant or overall) & NF was assessed by presenting change in NF domain scores (memory domain [MD], executive function domain [EFD], fine motor coordination domain [FMCD]) after tumor recurrence (Visits X, X+1, X+2, and X+3) compared to before tumor recurrence (Visit X-1). Here 'Visit X' refers to visit at which participants had tumor recurrence, Visit X-1 refers to visit immediately before the recurrence and X+1, X+2, X+3 refers to subsequent first, second & third visit after the recurrence.NF domain z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted &education-adjusted normative distribution of scores from an unimpaired population. Individual z-scores from related tests were averaged to determine overall z-score for each of NF domains. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | z-score (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Local Recurrence: MD at Visit (X-1) | Local Recurrence: MD Change at Visit (X-1) | Local Recurrence: MD Change at Visit (X+1) | Local Recurrence: MD Change at Visit (X+2) | Local Recurrence: MD Change at Visit (X+3) | Local Recurrence: EFD at Visit (X-1) | Local Recurrence: EFD Change at Visit (X-1) | Local Recurrence: EFD Change at Visit (X+1) | Local Recurrence: EFD Change at Visit (X+2) | Local Recurrence: EFD Change at Visit (X+3) | Local Recurrence: FMCD at Visit (X-1) | Local Recurrence: FMCD Change at Visit (X-1) | Local Recurrence: FMCD Change at Visit (X+1) | Local Recurrence: FMCD Change at Visit (X+2) | Local Recurrence: FMCD Change at Visit (X+3) | Distant Recurrence: MD at Visit (X-1) | Distant Recurrence: MD Change at Visit (X-1) | Distant Recurrence: MD Change at Visit (X+1) | Distant Recurrence: MD Change at Visit (X+2) | Distant Recurrence: MD Change at Visit (X+3) | Distant Recurrence: EFD at Visit (X-1) | Distant Recurrence: EFD Change at Visit (X-1) | Distant Recurrence: EFD Change at Visit (X+1) | Distant Recurrence: EFD Change at Visit (X+2) | Distant Recurrence: EFD Change at Visit (X+3) | Distant Recurrence: FMCD at Visit (X-1) | Distant Recurrence: FMCD Change at Visit (X-1) | Distant Recurrence: FMCD Change at Visit (X+1) | Distant Recurrence: FMCD Change at Visit (X+2) | Distant Recurrence: FMCD Change at Visit (X+3) | Overall Recurrence: MD at Visit (X-1) | Overall Recurrence: MD Change at Visit (X-1) | Overall Recurrence: MD Change at Visit (X+1) | Overall Recurrence: MD Change at Visit (X+2) | Overall Recurrence: MD Change at Visit (X+3) | Overall Recurrence: EFD at Visit (X-1) | Overall Recurrence: EFD Change at Visit (X-1) | Overall Recurrence: EFD Change at Visit (X+1) | Overall Recurrence: EFD Change at Visit (X+2) | Overall Recurrence: EFD Change at Visit (X+3) | Overall Recurrence: FMCD at Visit (X-1) | Overall Recurrence: FMCD Change at Visit (X-1) | Overall Recurrence: FMCD Change at Visit (X+1) | Overall Recurrence: FMCD Change at Visit (X+2) | Overall Recurrence: FMCD Change at Visit (X+3) | |
| GLIADEL | -0.9 | -1.1 | 0.7 | 0.1 | -0.8 | -0.4 | -0.5 | 0.2 | -0.0 | -1.1 | -1.5 | 0.4 | 0.5 | -0.4 | 0.3 | -1.0 | 0.2 | -0.2 | -0.2 | -0.7 | -0.2 | -0.2 | -0.5 | -0.8 | -0.8 | -1.2 | -0.1 | -0.4 | -1.1 | -0.1 | -0.9 | -0.1 | -0.1 | -0.2 | -0.7 | -0.1 | -0.3 | -0.5 | -0.6 | -0.8 | -1.2 | 0.0 | -0.3 | -0.9 | -0.1 |
Preservation of NF was defined as a decrease of less than or equal to (<=) 1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 12
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 9 | 5 | 0 | 0 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 2
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 26 | 12 | 4 | 3 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 4
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 24 | 9 | 2 | 1 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 17 | 5 | 2 | 0 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 9
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 14 | 6 | 0 | 0 |
(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Local Recurrence | Distant Recurrence | Overall Recurrence | |
| GLIADEL | 28.0 | 48.0 | 62.0 |
Neurocognitive decline was defined as any decrease in NF scores less than (<) 0 SD from baseline. Here, in category titles EFD represents Executive Function Domain and FMCD represents Fine Motor Coordination Domain. (NCT00525590)
Timeframe: Months 2, 4, 6, 9 and 12
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 2: Memory Domain, decline <0 to -1 SD | Month 2: Memory Domain, decline <-1 to -2 SD | Month 2: Memory Domain, decline <-2 to -3 SD | Month 2: Memory Domain, decline <-3 to -4 SD | Month 2: Memory Domain, decline <-4 to -5 SD | Month 2: Memory Domain, decline <-5 SD | Month 2: EFD, decline <0 to -1 SD | Month 2: EFD, decline <-1 to -2 SD | Month 2: EFD, decline <-2 to -3 SD | Month 2: EFD, decline <-3 to -4 SD | Month 2: EFD, decline <-4 to -5 SD | Month 2: EFD, decline <-5 SD | Month 2: FMCD, decline <0 to -1 SD | Month 2: FMCD, decline <-1 to -2 SD | Month 2: FMCD, decline <-2 to -3 SD | Month 2: FMCD, decline <-3 to -4 SD | Month 2: FMCD, decline <-4 to -5 SD | Month 2: FMCD, decline <-5 SD | Month 4: Memory Domain, decline <0 to -1 SD | Month 4: Memory Domain, decline <-1 to -2 SD | Month 4: Memory Domain, decline <-2 to -3 SD | Month 4: Memory Domain, decline <-3 to -4 SD | Month 4: Memory Domain, decline <-4 to -5 SD | Month 4: Memory Domain, decline <-5 SD | Month 4: EFD, decline <0 to -1 SD | Month 4: EFD, decline <-1 to -2 SD | Month 4: EFD, decline <-2 to -3 SD | Month 4: EFD, decline <-3 to -4 SD | Month 4: EFD, decline <-4 to -5 SD | Month 4: EFD, decline <-5 SD | Month 4: FMCD, decline <0 to -1 SD | Month 4: FMCD, decline <-1 to -2 SD | Month 4: FMCD, decline <-2 to -3 SD | Month 4: FMCD, decline <-3 to -4 SD | Month 4: FMCD, decline <-4 to -5 SD | Month 4: FMCD, decline <-5 SD | Month 6: Memory Domain, decline <0 to -1 SD | Month 6: Memory Domain, decline <-1 to -2 SD | Month 6: Memory Domain, decline <-2 to -3 SD | Month 6: Memory Domain, decline <-3 to -4 SD | Month 6: Memory Domain, decline <-4 to -5 SD | Month 6: Memory Domain, decline <-5 SD | Month 6: EFD, decline <0 to -1 SD | Month 6: EFD, decline <-1 to -2 SD | Month 6: EFD, decline <-2 to -3 SD | Month 6: EFD, decline <-3 to -4 SD | Month 6: EFD, decline <-4 to -5 SD | Month 6: EFD, decline <-5 SD | Month 6: FMCD, decline <0 to -1 SD | Month 6: FMCD, decline <-1 to -2 SD | Month 6: FMCD, decline <-2 to -3 SD | Month 6: FMCD, decline <-3 to -4 SD | Month 6: FMCD, decline <-4 to -5 SD | Month 6: FMCD, decline <-5 SD | Month 9: Memory Domain, decline <0 to -1 SD | Month 9: Memory Domain, decline <-1 to -2 SD | Month 9: Memory Domain, decline <-2 to -3 SD | Month 9: Memory Domain, decline <-3 to -4 SD | Month 9: Memory Domain, decline <-4 to -5 SD | Month 9: Memory Domain, decline <-5 SD | Month 9: EFD, decline <0 to -1 SD | Month 9: EFD, decline <-1 to -2 SD | Month 9: EFD, decline <-2 to -3 SD | Month 9: EFD, decline <-3 to -4 SD | Month 9: EFD, decline <-4 to -5 SD | Month 9: EFD, decline <-5 SD | Month 9: FMCD, decline <0 to -1 SD | Month 9: FMCD, decline <-1 to -2 SD | Month 9: FMCD, decline <-2 to -3 SD | Month 9: FMCD, decline <-3 to -4 SD | Month 9: FMCD, decline <-4 to -5 SD | Month 9: FMCD, decline <-5 SD | Month 12: Memory Domain, decline <0 to -1 SD | Month 12: Memory Domain, decline <-1 to -2 SD | Month 12: Memory Domain, decline <-2 to -3 SD | Month 12: Memory Domain, decline <-3 to -4 SD | Month 12: Memory Domain, decline <-4 to -5 SD | Month 12: Memory Domain, decline <-5 SD | Month 12: EFD, decline <0 to -1 SD | Month 12: EFD, decline <-1 to -2 SD | Month 12: EFD, decline <-2 to -3 SD | Month 12: EFD, decline <-3 to -4 SD | Month 12: EFD, decline <-4 to -5 SD | Month 12: EFD, decline <-5 SD | Month 12: FMCD, decline <0 to -1 SD | Month 12: FMCD, decline <-1 to -2 SD | Month 12: FMCD, decline <-2 to -3 SD | Month 12: FMCD, decline <-3 to -4 SD | Month 12: FMCD, decline <-4 to -5 SD | Month 12: FMCD, decline <-5 SD | |
| GLIADEL | 27.3 | 15.9 | 4.5 | 0 | 0 | 0 | 37.8 | 8.1 | 0 | 0 | 0 | 0 | 23.8 | 7.1 | 2.4 | 2.4 | 0 | 0 | 19.4 | 8.3 | 0 | 0 | 2.8 | 2.8 | 29.0 | 0 | 0 | 0 | 0 | 0 | 17.1 | 11.4 | 0 | 2.9 | 0 | 0 | 12.5 | 0 | 4.2 | 0 | 0 | 0 | 18.2 | 4.5 | 0 | 0 | 0 | 0 | 12.5 | 20.8 | 0 | 0 | 0 | 0 | 25.0 | 5.0 | 0 | 0 | 0 | 0 | 36.8 | 5.3 | 0 | 0 | 0 | 0 | 20.0 | 10.0 | 5.0 | 0 | 0 | 0 | 14.3 | 7.1 | 0 | 0 | 0 | 0 | 33.3 | 0 | 0 | 0 | 0 | 0 | 7.1 | 14.3 | 0 | 0 | 0 | 0 |
(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | months (Median) | ||
|---|---|---|---|
| Time to Local Recurrence | Time to Distant Recurrence | Time to Overall Recurrence | |
| GLIADEL | NA | 8.5 | 6.1 |
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 3.9 |
| RT + BCNU/CCNU | 3.8 |
Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Progression-free survival time is defined as time from randomization to date of progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 4.0 |
| Unmthylated MGMT | 2.1 |
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 7.2 |
| Unmthylated MGMT | 3.1 |
Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | months (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 45.4 |
| RT + BCNU/CCNU | 54.7 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (< 25,000 for 5 days), neutropenia (< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU. (NCT00004259)
Timeframe: From start of treatment to 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Subjects with Pulmonary DLT | Subjects with Hematologic DLT | |
| Pilot Arm #1: RT+TMZ+BCNU | 1 | 4 |
| Pilot Arm #2: RT+TMZ+BCNU | 0 | 3 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | participants (Number) | |
|---|---|---|
| Overall toxicity | Non-hematologic toxicity | |
| Radiation Therapy + Temozolomide (TMZ) | 46 | 31 |
| RT + BCNU/CCNU | 75 | 34 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
93 reviews available for carmustine and Brain Neoplasms
| Article | Year |
|---|---|
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Glioblasto | 2022 |
Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Glioblasto | 2022 |
Biocompatible copolymer formulations to treat glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Polymers; Quality of | 2021 |
Biocompatible copolymer formulations to treat glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Polymers; Quality of | 2021 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Drug Delivery Systems; Gli | 2019 |
Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Drug Delivery Systems; Gli | 2019 |
Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brachytherapy; Brain Neoplas | 2013 |
Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brachytherapy; Brain Neoplas | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as | 2013 |
Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as | 2013 |
[II. Current status of BCNU stent in the brain for treatment of glioma].
Topics: Animals; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Decanoic Acids; Drug-Eluting Stents; | 2013 |
[II. Current status of BCNU stent in the brain for treatment of glioma].
Topics: Animals; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Decanoic Acids; Drug-Eluting Stents; | 2013 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Contrast Media; Drug Delivery Systems; Glioma; Hum | 2014 |
Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Contrast Media; Drug Delivery Systems; Glioma; Hum | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Current medical treatment of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, | 2015 |
Current medical treatment of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, | 2015 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Polymeric drug delivery for the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioblastoma; Humans; | 2015 |
Polymeric drug delivery for the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioblastoma; Humans; | 2015 |
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chem | 2015 |
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chem | 2015 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Topics: Absorbable Implants; Administration, Topical; Algorithms; Antineoplastic Agents, Alkylating; Brain N | 2008 |
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Topics: Absorbable Implants; Administration, Topical; Algorithms; Antineoplastic Agents, Alkylating; Brain N | 2008 |
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Prognosis | 2009 |
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Prognosis | 2009 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modali | 2010 |
Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modali | 2010 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
[Local antitumor treatments].
Topics: Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Decanoic | 2010 |
[Local antitumor treatments].
Topics: Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Decanoic | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Prepa | 2012 |
The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Prepa | 2012 |
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
[Study on MGMT assay and tumor individual predictable chemotherapy].
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Resistance, Neo | 2004 |
[Study on MGMT assay and tumor individual predictable chemotherapy].
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Resistance, Neo | 2004 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biodegradation, E | 2005 |
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biodegradation, E | 2005 |
[Treatment for malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Treatment for malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
Positron emission tomography.
Topics: Adolescent; Adult; Aged; Aging; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebrovascular | 1984 |
Positron emission tomography.
Topics: Adolescent; Adult; Aged; Aging; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebrovascular | 1984 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Carcinogenic N-nitroso compounds and their environmental significance.
Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln | 1984 |
Clonal tumor cell heterogeneity.
Topics: Brain Neoplasms; Carmustine; Chromosome Aberrations; Cisplatin; Culture Techniques; Drug Resistance; | 1984 |
Clonal tumor cell heterogeneity.
Topics: Brain Neoplasms; Carmustine; Chromosome Aberrations; Cisplatin; Culture Techniques; Drug Resistance; | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
[Colony forming efficiency assay and human tumor (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Gl | 1981 |
[Colony forming efficiency assay and human tumor (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Gl | 1981 |
[Chemotherapy of brain tumors].
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1994 |
[Chemotherapy of brain tumors].
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
New delivery systems for brain tumor therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality | 1995 |
New delivery systems for brain tumor therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality | 1995 |
[Chemoradiation for malignant brain tumors].
Topics: Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
[Chemoradiation for malignant brain tumors].
Topics: Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Bone marrow metastasis in astrocytic gliomata.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Neoplasms; Brai | 1998 |
Bone marrow metastasis in astrocytic gliomata.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Neoplasms; Brai | 1998 |
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1998 |
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1998 |
PET reveals disruption of blood-tumor barrier.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; History, 20th Century; Humans; Magnetic Resonance | 1990 |
PET reveals disruption of blood-tumor barrier.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; History, 20th Century; Humans; Magnetic Resonance | 1990 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality | 2000 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
Pharmacokinetics of the carmustine implant.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Comput | 2002 |
Pharmacokinetics of the carmustine implant.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Comput | 2002 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Biology and therapy of glial tumors.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Division; Cell Surviva | 1992 |
Biology and therapy of glial tumors.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Division; Cell Surviva | 1992 |
[Nitrosourea-induced lung diseases].
Topics: Adult; Brain Neoplasms; Carmustine; Child; Drug Therapy, Combination; Female; Humans; Iatrogenic Dis | 1992 |
[Nitrosourea-induced lung diseases].
Topics: Adult; Brain Neoplasms; Carmustine; Child; Drug Therapy, Combination; Female; Humans; Iatrogenic Dis | 1992 |
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas.
Topics: Aneuploidy; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Geneti | 1991 |
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas.
Topics: Aneuploidy; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Geneti | 1991 |
Chemotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Fluorouracil; Humans; Methotrexate; N | 1991 |
Chemotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Fluorouracil; Humans; Methotrexate; N | 1991 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl | 1991 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl | 1991 |
Brain tumors.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioma; | 1991 |
Brain tumors.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioma; | 1991 |
Polymers to treat brain tumours.
Topics: Animals; Biocompatible Materials; Biodegradation, Environmental; Brain Neoplasms; Carmustine; Delaye | 1990 |
Polymers to treat brain tumours.
Topics: Animals; Biocompatible Materials; Biodegradation, Environmental; Brain Neoplasms; Carmustine; Delaye | 1990 |
New drugs and new delivery techniques.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoqui | 1985 |
New drugs and new delivery techniques.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoqui | 1985 |
Decreased phenytoin levels in patients receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1989 |
Decreased phenytoin levels in patients receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1989 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Recent and current investigations of radiation therapy of malignant gliomas.
Topics: Brachytherapy; Brain; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Glioma; Helium; Humans; Hyperb | 1986 |
Recent and current investigations of radiation therapy of malignant gliomas.
Topics: Brachytherapy; Brain; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Glioma; Helium; Humans; Hyperb | 1986 |
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature.
Topics: Adult; Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glial Fibrillary Acidic Prote | 1988 |
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature.
Topics: Adult; Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glial Fibrillary Acidic Prote | 1988 |
Therapy of adult malignant brain tumors: what have the clinical trials taught us?
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality T | 1986 |
Therapy of adult malignant brain tumors: what have the clinical trials taught us?
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality T | 1986 |
Chemotherapy of brain tumors: physiological and pharmacokinetic considerations.
Topics: Antineoplastic Agents; Autoradiography; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; | 1986 |
Chemotherapy of brain tumors: physiological and pharmacokinetic considerations.
Topics: Antineoplastic Agents; Autoradiography; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; | 1986 |
In vitro drug sensitivity testing in human gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; G | 1987 |
In vitro drug sensitivity testing in human gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; G | 1987 |
Proceedings: Chemotherapy of malignant glioma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Evaluation Studies as Topic | 1972 |
Proceedings: Chemotherapy of malignant glioma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Evaluation Studies as Topic | 1972 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
Nitrosoureas in central nervous system tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclohexanes; Glioma; Humans; Injections, Intrav | 1973 |
Nitrosoureas in central nervous system tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclohexanes; Glioma; Humans; Injections, Intrav | 1973 |
151 trials available for carmustine and Brain Neoplasms
| Article | Year |
|---|---|
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Carmustine | 2020 |
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Carmustine | 2020 |
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2015 |
Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2008 |
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2008 |
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Combined Mo | 2008 |
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Combined Mo | 2008 |
Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; DNA Modification Met | 2008 |
Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; DNA Modification Met | 2008 |
[Postoperative chemoradiotherapy for cerebral glioblastoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 2008 |
[Postoperative chemoradiotherapy for cerebral glioblastoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 2008 |
Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblas
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2008 |
Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblas
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2008 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therap | 2009 |
Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therap | 2009 |
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2009 |
Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2009 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Mapping; Brain Neoplasms; Carmustine; Cerebrovascular | 2010 |
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Mapping; Brain Neoplasms; Carmustine; Cerebrovascular | 2010 |
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Catheters, Indwelling; | 2010 |
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Catheters, Indwelling; | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine | 2011 |
Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine | 2011 |
[Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results].
Topics: Adult; Angiography; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Breast Neoplasms; Car | 2011 |
[Regional chemoinfusion and radiation therapy to patients with breast cancer metastases to the brain: preliminary results].
Topics: Adult; Angiography; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Breast Neoplasms; Car | 2011 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality The | 2002 |
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality The | 2002 |
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Topics: Adult; Aged; Biocompatible Materials; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Doub | 2003 |
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Topics: Adult; Aged; Biocompatible Materials; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Doub | 2003 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Ca | 2004 |
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Ca | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2004 |
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2004 |
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
[Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; | 2005 |
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; | 2005 |
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Carriers; | 2007 |
Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Carriers; | 2007 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
Bleomycin and brain tumors. A review.
Topics: Adult; Aged; Animals; Bleomycin; Brain; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combi | 1983 |
Bleomycin and brain tumors. A review.
Topics: Adult; Aged; Animals; Bleomycin; Brain; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combi | 1983 |
Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Topics: Adjuvants, Immunologic; Alpharetrovirus; Animals; Brain Neoplasms; Carmustine; Clinical Trials as To | 1981 |
Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Topics: Adjuvants, Immunologic; Alpharetrovirus; Animals; Brain Neoplasms; Carmustine; Clinical Trials as To | 1981 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Topics: Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Glioma; H | 1980 |
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Topics: Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Glioma; H | 1980 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Evaluating glioma therapies: modeling treatments and predicting outcomes.
Topics: Adolescent; Adult; Aged; Brachytherapy; Brain Neoplasms; Carmustine; Child; Combined Modality Therap | 1995 |
Evaluating glioma therapies: modeling treatments and predicting outcomes.
Topics: Adolescent; Adult; Aged; Brachytherapy; Brain Neoplasms; Carmustine; Child; Combined Modality Therap | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Male; M | 1995 |
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Male; M | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Topics: Brain; Brain Neoplasms; Carmustine; Dose-Response Relationship, Radiation; Female; Glioma; Humans; M | 1994 |
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Topics: Brain; Brain Neoplasms; Carmustine; Dose-Response Relationship, Radiation; Female; Glioma; Humans; M | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 1994 |
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 1994 |
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1993 |
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1993 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clin | 1993 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clin | 1993 |
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1993 |
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carm | 1993 |
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carm | 1993 |
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1995 |
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1995 |
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1996 |
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1996 |
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1996 |
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1996 |
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mod | 1996 |
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mod | 1996 |
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Carmustine; Chemother | 1996 |
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Carmustine; Chemother | 1996 |
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain N | 1995 |
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain N | 1995 |
High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Brain Neoplasms; | 1996 |
High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Damage, Chronic; Brain Neoplasms; | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
High-dose carmustine for high-grade gliomas in childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Brain Neoplasms; Carmust | 1997 |
High-dose carmustine for high-grade gliomas in childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Brain Neoplasms; Carmust | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Mo | 1997 |
Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Mo | 1997 |
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblast | 1997 |
Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblast | 1997 |
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1998 |
Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1998 |
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1998 |
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1998 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1998 |
High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neopl | 1998 |
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 1998 |
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 1998 |
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carbop | 1998 |
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carbop | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustin | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustin | 1998 |
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1999 |
Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1999 |
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1999 |
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1999 |
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose Frac | 2000 |
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose Frac | 2000 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relations | 2000 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relations | 2000 |
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
[Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chil | 2001 |
[Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chil | 2001 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Brain Tumor Study Group: a survey of current activities.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Glioma; Humans; National Ins | 1977 |
Brain Tumor Study Group: a survey of current activities.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Glioma; Humans; National Ins | 1977 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Treatment of malignant glioma. A controlled study of chemotherapy and irradiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glioblasto | 1976 |
Treatment of malignant glioma. A controlled study of chemotherapy and irradiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glioblasto | 1976 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Glioblastoma; Humans; Lomustine; Male | 1979 |
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Glioblastoma; Humans; Lomustine; Male | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Prognostic factors for patients with brain tumors.
Topics: Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Male; Prognosis; | 1977 |
Prognostic factors for patients with brain tumors.
Topics: Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Male; Prognosis; | 1977 |
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Clinical Trials as Topic; Evaluation St | 1978 |
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Clinical Trials as Topic; Evaluation St | 1978 |
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu | 1978 |
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu | 1978 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System | 1976 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
The development of polyanhydrides for drug delivery applications.
Topics: Alzheimer Disease; Anhydrides; Animals; Bethanechol; Bethanechol Compounds; Biocompatible Materials; | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Eto | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Eto | 1992 |
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem | 1992 |
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem | 1992 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Carcinom | 1991 |
Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Carcinom | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Intra-arterial chemotherapy for brain tumors.
Topics: Analysis of Variance; Animals; Brain Neoplasms; Carmustine; Ethanol; Fluorocarbons; Humans; Infusion | 1990 |
Intra-arterial chemotherapy for brain tumors.
Topics: Analysis of Variance; Animals; Brain Neoplasms; Carmustine; Ethanol; Fluorocarbons; Humans; Infusion | 1990 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glio | 1986 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glio | 1986 |
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention.
Topics: Adult; Aged; Ambroxol; Brain Neoplasms; Bromhexine; Carmustine; Clinical Trials as Topic; Double-Bli | 1987 |
Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention.
Topics: Adult; Aged; Ambroxol; Brain Neoplasms; Bromhexine; Carmustine; Clinical Trials as Topic; Double-Bli | 1987 |
Therapy of adult malignant brain tumors: what have the clinical trials taught us?
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality T | 1986 |
Therapy of adult malignant brain tumors: what have the clinical trials taught us?
Topics: Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality T | 1986 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Gliom | 1986 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Gliom | 1986 |
Reevaluating the efficacy of intra-arterial BCNU.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Humans; Infusions, In | 1987 |
Reevaluating the efficacy of intra-arterial BCNU.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Humans; Infusions, In | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Carmustine as a cause of acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Humans; Leukemia; Male; | 1985 |
Carmustine as a cause of acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Humans; Leukemia; Male; | 1985 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
Topics: Adult; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cyclohe | 1974 |
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
Topics: Adult; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cyclohe | 1974 |
681 other studies available for carmustine and Brain Neoplasms
| Article | Year |
|---|---|
Synthesis and anticancer activity of nitrosourea derivatives of phensuximide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Ependymoma; Leukemia L1210; Mice; Neoplasms, Experi | 1980 |
Synthesis and anticancer activity of nitrosourea derivatives of phensuximide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Ependymoma; Leukemia L1210; Mice; Neoplasms, Experi | 1980 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Cysts; Gliobla | 2022 |
Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Cysts; Gliobla | 2022 |
A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma.
Topics: Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Humans; Reproducibili | 2022 |
A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma.
Topics: Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Humans; Reproducibili | 2022 |
MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioblastoma; Humans; MicroRNAs; Pro | 2022 |
MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioblastoma; Humans; MicroRNAs; Pro | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Immunom | 2022 |
Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Immunom | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Molecular characteristics of incidental lower-grade glioma for treatment decision-making.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Retrospe | 2023 |
Molecular characteristics of incidental lower-grade glioma for treatment decision-making.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Retrospe | 2023 |
Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2023 |
Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2023 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
External Beam Fast Neutron Therapy: Russian Clinical Experience and Prospects for Further Development.
Topics: Boron Neutron Capture Therapy; Brain Neoplasms; Carmustine; Etoposide; Fast Neutrons; Humans; Neutro | 2023 |
External Beam Fast Neutron Therapy: Russian Clinical Experience and Prospects for Further Development.
Topics: Boron Neutron Capture Therapy; Brain Neoplasms; Carmustine; Etoposide; Fast Neutrons; Humans; Neutro | 2023 |
Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.
Topics: Animals; Brain Neoplasms; Carmustine; Dose Fractionation, Radiation; Glioma; Radiotherapy; Rats; Syn | 2023 |
MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.
Topics: Animals; Brain Neoplasms; Carmustine; Dose Fractionation, Radiation; Glioma; Radiotherapy; Rats; Syn | 2023 |
Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cohort Studies; C | 2023 |
Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cohort Studies; C | 2023 |
Can Optical Surface Imaging Replace Non-coplanar Cone-beam Computed Tomography for Non-coplanar Set-up Verification in Single-isocentre Non-coplanar Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Single and Multiple Brain Met
Topics: Brain Neoplasms; Carmustine; Cone-Beam Computed Tomography; Etoposide; Humans; Radiosurgery; Radioth | 2023 |
Can Optical Surface Imaging Replace Non-coplanar Cone-beam Computed Tomography for Non-coplanar Set-up Verification in Single-isocentre Non-coplanar Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Single and Multiple Brain Met
Topics: Brain Neoplasms; Carmustine; Cone-Beam Computed Tomography; Etoposide; Humans; Radiosurgery; Radioth | 2023 |
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Gliom | 2019 |
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Gliom | 2019 |
miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Fema | 2019 |
miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Fema | 2019 |
Convection enhanced delivery of anti-angiogenic and cytotoxic agents in combination therapy against brain tumour.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2020 |
Convection enhanced delivery of anti-angiogenic and cytotoxic agents in combination therapy against brain tumour.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2020 |
Implantation of carmustine wafers (Gliadel
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusi | 2020 |
Implantation of carmustine wafers (Gliadel
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusi | 2020 |
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2020 |
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2020 |
microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Mo | 2020 |
microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Mo | 2020 |
Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Coho | 2021 |
Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Coho | 2021 |
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Humans; Japa | 2021 |
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Humans; Japa | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2017 |
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cerebral Ventric | 2017 |
Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cerebral Ventric | 2017 |
In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Fema | 2018 |
In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Fema | 2018 |
Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus.
Topics: Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Human | 2018 |
Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus.
Topics: Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Human | 2018 |
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliobla | 2018 |
Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliobla | 2018 |
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.
Topics: Antagomirs; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.
Topics: Antagomirs; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Convection enhanced delivery of chemotherapeutic drugs into brain tumour.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Computer Simulation; Convection; Doxo | 2018 |
Convection enhanced delivery of chemotherapeutic drugs into brain tumour.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; Computer Simulation; Convection; Doxo | 2018 |
Incomplete copolymer degradation of in situ chemotherapy.
Topics: Absorbable Implants; Adsorption; Aged; Brain Neoplasms; Carmustine; Disease Progression; Drug Delive | 2018 |
Incomplete copolymer degradation of in situ chemotherapy.
Topics: Absorbable Implants; Adsorption; Aged; Brain Neoplasms; Carmustine; Disease Progression; Drug Delive | 2018 |
Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain | 2018 |
Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
How safe are carmustine wafers?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cysts; Drug Implants; Glioblastoma; | 2018 |
How safe are carmustine wafers?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cysts; Drug Implants; Glioblastoma; | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Central Nervous System Cysts; | 2018 |
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Central Nervous System Cysts; | 2018 |
[Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2018 |
[Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2018 |
MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2019 |
MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chem | 2019 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; Camphanes; Carmustine; Cell Line, T | 2019 |
Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; Camphanes; Carmustine; Cell Line, T | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
[BCNU wafer].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Humans | 2016 |
[BCNU wafer].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Humans | 2016 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Topics: AC133 Antigen; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neopl | 2019 |
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Topics: AC133 Antigen; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neopl | 2019 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Accelerated hazards model based on parametric families generalized with Bernstein polynomials.
Topics: Bayes Theorem; Brain Neoplasms; Carmustine; Computer Simulation; Data Interpretation, Statistical; G | 2014 |
Accelerated hazards model based on parametric families generalized with Bernstein polynomials.
Topics: Bayes Theorem; Brain Neoplasms; Carmustine; Computer Simulation; Data Interpretation, Statistical; G | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2014 |
MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2014 |
The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combined Modalit | 2015 |
Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combined Modalit | 2015 |
Drug-loaded bubbles with matched focused ultrasound excitation for concurrent blood-brain barrier opening and brain-tumor drug delivery.
Topics: Acoustics; Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Surviva | 2015 |
Drug-loaded bubbles with matched focused ultrasound excitation for concurrent blood-brain barrier opening and brain-tumor drug delivery.
Topics: Acoustics; Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Surviva | 2015 |
Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Co | 2015 |
Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Co | 2015 |
[Therapeutic activity of gemcitabine in intracranial tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brai | 2015 |
[Therapeutic activity of gemcitabine in intracranial tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brai | 2015 |
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2015 |
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Gliobla | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Gliobla | 2015 |
[A Case of Symptomatic Cyst Formation after BCNU Wafer Implantation for Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cysts; Fe | 2015 |
[A Case of Symptomatic Cyst Formation after BCNU Wafer Implantation for Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cysts; Fe | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
Evaluating innovation. Part 2: Development in neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Deep Brain Stimulation; Depression; | 2016 |
Evaluating innovation. Part 2: Development in neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Deep Brain Stimulation; Depression; | 2016 |
Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2016 |
Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2016 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Female; Gl | 2016 |
Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Female; Gl | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
[Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Surveys and Question | 2016 |
[Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Surveys and Question | 2016 |
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Delivery Systems; Dr | 2017 |
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Delivery Systems; Dr | 2017 |
The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Cysts; Female; Gl | 2016 |
The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Cysts; Female; Gl | 2016 |
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine | 2016 |
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine | 2016 |
[Long-Term Efficacy of BCNU Wafers for Malignant Gliomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
[Long-Term Efficacy of BCNU Wafers for Malignant Gliomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Topics: Adult; Aged; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Al | 2017 |
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Topics: Adult; Aged; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Al | 2017 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Diffusion; Drug Deli | 2017 |
Mathematical Modelling of Convection Enhanced Delivery of Carmustine and Paclitaxel for Brain Tumour Therapy.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Diffusion; Drug Deli | 2017 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antineoplastic Agents; Apoptosis; Brain Neoplasms; | 2008 |
Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antineoplastic Agents; Apoptosis; Brain Neoplasms; | 2008 |
Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Drug Carriers; Gliobl | 2008 |
Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Drug Carriers; Gliobl | 2008 |
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc | 2008 |
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
[Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
[Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
[Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature].
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Clostridium Infection | 2009 |
[Clostridial brain abscess after glioblastoma resection: case report and critical review of the literature].
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Carmustine; Clostridium Infection | 2009 |
Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Lactic Acid; Male; Nanoparticles; Po | 2009 |
Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Lactic Acid; Male; Nanoparticles; Po | 2009 |
Chemotherapeutic drug transport to brain tumor.
Topics: Antineoplastic Agents; Biological Transport; Brain; Brain Neoplasms; Carmustine; Computer Simulation | 2009 |
Chemotherapeutic drug transport to brain tumor.
Topics: Antineoplastic Agents; Biological Transport; Brain; Brain Neoplasms; Carmustine; Computer Simulation | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Brain Neoplasms; Carmustine; DNA Methylation; Drug Impl | 2009 |
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Brain Neoplasms; Carmustine; DNA Methylation; Drug Impl | 2009 |
Role of convective flow in carmustine delivery to a brain tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Computer Simulation; Decanoic Acids; Drug | 2009 |
Role of convective flow in carmustine delivery to a brain tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Computer Simulation; Decanoic Acids; Drug | 2009 |
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free Survival; | 2010 |
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free Survival; | 2010 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Diffusion Magnetic Reson | 2010 |
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Diffusion Magnetic Reson | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell | 2011 |
Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell | 2011 |
Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid; Con | 2010 |
Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid; Con | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle Proteins; Child; Drug | 2010 |
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle Proteins; Child; Drug | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 2010 |
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 2010 |
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Drug Delivery Syst | 2010 |
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Drug Delivery Syst | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Carmu | 2011 |
Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Carmu | 2011 |
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
Topics: Aged; Aged, 80 and over; Aging; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2011 |
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
Topics: Aged; Aged, 80 and over; Aging; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2011 |
Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Car | 2011 |
Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Car | 2011 |
Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG44 to BCNU.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain N | 2010 |
Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG44 to BCNU.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain N | 2010 |
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; | 2010 |
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; | 2010 |
Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants.
Topics: Biocompatible Materials; Brain Neoplasms; Candidiasis; Carmustine; Combined Modality Therapy; Decano | 2011 |
Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants.
Topics: Biocompatible Materials; Brain Neoplasms; Candidiasis; Carmustine; Combined Modality Therapy; Decano | 2011 |
Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; An | 2010 |
Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; An | 2010 |
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion | 2011 |
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion | 2011 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Ne | 2011 |
Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Ne | 2011 |
Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor.
Topics: Anions; Brain Neoplasms; Carmustine; Cations; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proli | 2011 |
Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor.
Topics: Anions; Brain Neoplasms; Carmustine; Cations; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proli | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
A new semiparametric estimation method for accelerated hazard model.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Data Interpretation, Statistical; Humans; Outcom | 2011 |
A new semiparametric estimation method for accelerated hazard model.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Data Interpretation, Statistical; Humans; Outcom | 2011 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Carmustine-impregnated wafers and their impact in the management of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Carri | 2011 |
Carmustine-impregnated wafers and their impact in the management of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Carri | 2011 |
The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2011 |
The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2011 |
Gliadel wafers acting as a lattice for bacterial growth: a case illustration.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Central Nervous System | 2011 |
Gliadel wafers acting as a lattice for bacterial growth: a case illustration.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Central Nervous System | 2011 |
Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell Move | 2011 |
Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell Move | 2011 |
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2012 |
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat O
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Fema | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat O
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Fema | 2011 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Treatment of glioblastoma multiforme with high doses of carmustine intracavitary, in an infant.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infant | 2012 |
Treatment of glioblastoma multiforme with high doses of carmustine intracavitary, in an infant.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infant | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Abscess; Brain Neoplasms; C | 2012 |
Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Abscess; Brain Neoplasms; C | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Fem | 2012 |
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Fem | 2012 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined | 2012 |
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Chemoprotection in brain tumor patients: another success for stem cell gene therapy.
Topics: Brain Neoplasms; Carmustine; Genetic Therapy; Humans; Stem Cells | 2012 |
Chemoprotection in brain tumor patients: another success for stem cell gene therapy.
Topics: Brain Neoplasms; Carmustine; Genetic Therapy; Humans; Stem Cells | 2012 |
A sequential testing approach to detecting multiple change points in the proportional hazards model.
Topics: Antineoplastic Agents, Alkylating; Biostatistics; Brain Neoplasms; Carmustine; Clinical Trials as To | 2013 |
A sequential testing approach to detecting multiple change points in the proportional hazards model.
Topics: Antineoplastic Agents, Alkylating; Biostatistics; Brain Neoplasms; Carmustine; Clinical Trials as To | 2013 |
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2013 |
Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Primary cerebral radiotherapy-induced rhabdomyosarcoma: treatment with intraoperative carmustine implants.
Topics: Brain Neoplasms; Carmustine; Child; Female; Humans; Intraoperative Period; Neoplasms, Radiation-Indu | 2013 |
Primary cerebral radiotherapy-induced rhabdomyosarcoma: treatment with intraoperative carmustine implants.
Topics: Brain Neoplasms; Carmustine; Child; Female; Humans; Intraoperative Period; Neoplasms, Radiation-Indu | 2013 |
Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms | 2013 |
Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms | 2013 |
Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies.
Topics: Absorbable Implants; Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biological | 2013 |
Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies.
Topics: Absorbable Implants; Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biological | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmu | 2002 |
Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmu | 2002 |
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Combined Modality Therapy | 2002 |
The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Combined Modality Therapy | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
Goosebumps.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Dexamethasone; Diagnosis, Differential; Frontal Lobe; Huma | 2002 |
Goosebumps.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Dexamethasone; Diagnosis, Differential; Frontal Lobe; Huma | 2002 |
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Topics: Animals; Biodegradation, Environmental; Biological Availability; Brain Neoplasms; Carmustine; Chondr | 2003 |
Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Topics: Animals; Biodegradation, Environmental; Biological Availability; Brain Neoplasms; Carmustine; Chondr | 2003 |
[Study on drug delivery of the 3H-BCNU polylacties acid released agents on gliosarcoma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliosarcoma; Male; | 2003 |
[Study on drug delivery of the 3H-BCNU polylacties acid released agents on gliosarcoma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Gliosarcoma; Male; | 2003 |
Intracavitary chemotherapy for glioblastoma: present status and future directions.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 2003 |
Intracavitary chemotherapy for glioblastoma: present status and future directions.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2003 |
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2003 |
Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompa | 2003 |
Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompa | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Topics: Absorbable Implants; Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; B | 2004 |
Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Topics: Absorbable Implants; Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; B | 2004 |
Advancing the treatment of malignant glioma: act local, think global.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2004 |
Advancing the treatment of malignant glioma: act local, think global.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2004 |
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 2004 |
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 2004 |
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gli | 2004 |
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gli | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Brain Neopl | 2004 |
BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Brain Neopl | 2004 |
25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Disease Pr | 2004 |
25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Disease Pr | 2004 |
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Deoxyguanosine; Drug Resistanc | 2004 |
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Deoxyguanosine; Drug Resistanc | 2004 |
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Culture Techniques; Ce | 2004 |
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Culture Techniques; Ce | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2004 |
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2004 |
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2004 |
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2004 |
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Gliosarc | 2005 |
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Gliosarc | 2005 |
Cerebral edema associated with Gliadel wafers: two case studies.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Edema; Brain Neoplasms; Carmustine | 2005 |
Cerebral edema associated with Gliadel wafers: two case studies.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Edema; Brain Neoplasms; Carmustine | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2005 |
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2005 |
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Carmustine; Ethanol; | 2005 |
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Carmustine; Ethanol; | 2005 |
Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dru | 2005 |
Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dru | 2005 |
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
Topics: Animals; Apoptosis Regulatory Proteins; Azo Compounds; Bcl-2-Like Protein 11; Brain Neoplasms; Cadav | 2005 |
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
Topics: Animals; Apoptosis Regulatory Proteins; Azo Compounds; Bcl-2-Like Protein 11; Brain Neoplasms; Cadav | 2005 |
Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2005 |
Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2005 |
Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Blotting, Western; Brain; Brain Neoplasms; Car | 2005 |
Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Blotting, Western; Brain; Brain Neoplasms; Car | 2005 |
Resistance of human malignant intracranial tumors in vitro: potential guidelines to clinical therapy?
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Division; Drug Resistance, Neoplasm; Humans | 1989 |
Resistance of human malignant intracranial tumors in vitro: potential guidelines to clinical therapy?
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Division; Drug Resistance, Neoplasm; Humans | 1989 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cannabinoids; Carmustine; Cell Line, Tumor; Dronabi | 2006 |
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cannabinoids; Carmustine; Cell Line, Tumor; Dronabi | 2006 |
Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Chromosomes, H | 2006 |
Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Chromosomes, H | 2006 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Summaries for patients. Adding chloroquine to conventional chemotherapy and radiotherapy for glioblastoma multiforme.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Carm | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Carm | 2006 |
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmu | 2006 |
Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmu | 2006 |
Dynamic imaging of emerging resistance during cancer therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Diffusion Magnetic Resonance Imaging; Drug Administration Sche | 2006 |
Dynamic imaging of emerging resistance during cancer therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Diffusion Magnetic Resonance Imaging; Drug Administration Sche | 2006 |
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2006 |
Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carmustine; C | 2006 |
Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carmustine; C | 2006 |
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Female; Genotype; Glioblastoma; Glu | 2006 |
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Female; Genotype; Glioblastoma; Glu | 2006 |
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion; Drug Resis | 2006 |
Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion; Drug Resis | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2006 |
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Proliferation; Cell Survival; Drug Therapy, | 2006 |
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Proliferation; Cell Survival; Drug Therapy, | 2006 |
Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid | 2007 |
Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chromatography, High Pressure Liquid | 2007 |
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Caspases; Cell Survival; Chemotherap | 2006 |
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Caspases; Cell Survival; Chemotherap | 2006 |
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Extracellular Matrix; Female; Fibron | 2007 |
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Extracellular Matrix; Female; Fibron | 2007 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Edema; Brain Neoplasms; Carmustine; Com | 2006 |
Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Edema; Brain Neoplasms; Carmustine; Com | 2006 |
[Local chemotherapy for brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans | 2006 |
[Local chemotherapy for brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans | 2006 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Communication; Cell Count; Cell | 2007 |
Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Communication; Cell Count; Cell | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calcium; Carmustine; Cell Adhesion; C | 2007 |
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calcium; Carmustine; Cell Adhesion; C | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Cost-Ben | 2008 |
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Cost-Ben | 2008 |
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust | 2008 |
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Brain; Brain Neoplasms; Carm | 2008 |
Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Brain; Brain Neoplasms; Carm | 2008 |
Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines.
Topics: Adult; Brain Neoplasms; Carmustine; Cell Line; Cell Membrane; Cytoplasm; Drug Resistance; Female; Gl | 1983 |
Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines.
Topics: Adult; Brain Neoplasms; Carmustine; Cell Line; Cell Membrane; Cytoplasm; Drug Resistance; Female; Gl | 1983 |
High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Res | 1983 |
High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Res | 1983 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
[Effects of surgery on remaining brain tumor cells (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Mitosis; Neoplasms, Experimental; Rats; Time Factors | 1980 |
[Effects of surgery on remaining brain tumor cells (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Mitosis; Neoplasms, Experimental; Rats; Time Factors | 1980 |
The 9L rat brain tumor: description and application of an animal model.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Cells, Cultured; Neoplasm Transp | 1981 |
The 9L rat brain tumor: description and application of an animal model.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Cells, Cultured; Neoplasm Transp | 1981 |
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Kinetics; Male; Neoplasms, Experimental; Rats | 1981 |
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Kinetics; Male; Neoplasms, Experimental; Rats | 1981 |
Combination chemotherapy for the 9L rat brain tumor model system.
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Drug Administration Schedule | 1982 |
Combination chemotherapy for the 9L rat brain tumor model system.
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Drug Administration Schedule | 1982 |
[High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Glioma; Huma | 1982 |
[High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Glioma; Huma | 1982 |
Complications after combination of chemotherapy and radiation for malignant brain tumours.
Topics: Adult; Bleomycin; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Huma | 1982 |
Complications after combination of chemotherapy and radiation for malignant brain tumours.
Topics: Adult; Bleomycin; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Huma | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
Topics: Animals; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; Glioma; Male; Neopla | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
Topics: Animals; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; Glioma; Male; Neopla | 1982 |
Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Interferons; Mi | 1984 |
Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Interferons; Mi | 1984 |
Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine).
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Central Nervous System Diseases; | 1981 |
Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine).
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Central Nervous System Diseases; | 1981 |
Visual-evoked responses. A new abnormality with focal retinal damage.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Evoked Potentials, Visual; Female; Humans; Middle Aged; Pa | 1981 |
Visual-evoked responses. A new abnormality with focal retinal damage.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Evoked Potentials, Visual; Female; Humans; Middle Aged; Pa | 1981 |
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Long-term survivors of high-grade malignant astrocytomas.
Topics: Adult; Age Factors; Astrocytoma; Brain Neoplasms; Carmustine; Evaluation Studies as Topic; Glioblast | 1980 |
Long-term survivors of high-grade malignant astrocytomas.
Topics: Adult; Age Factors; Astrocytoma; Brain Neoplasms; Carmustine; Evaluation Studies as Topic; Glioblast | 1980 |
Analysis of clonogenic human brain tumour cells: preliminary results of tumour sensitivity testing with BCNU.
Topics: Aged; Brain; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Female; Glioblastoma; Humans; | 1980 |
Analysis of clonogenic human brain tumour cells: preliminary results of tumour sensitivity testing with BCNU.
Topics: Aged; Brain; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Female; Glioblastoma; Humans; | 1980 |
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1981 |
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1981 |
Phase II study--intra-arterial BCNU therapy for metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carmu | 1981 |
Phase II study--intra-arterial BCNU therapy for metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carmu | 1981 |
Primitive neuroectodermal tumors of childhood. An approach to therapy.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Dexamethasone; Drug Therapy, | 1981 |
Primitive neuroectodermal tumors of childhood. An approach to therapy.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Dexamethasone; Drug Therapy, | 1981 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
High dose BCNU followed by autologous bone marrow infusion in glioblastoma multiforme.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Middle Aged | 1981 |
High dose BCNU followed by autologous bone marrow infusion in glioblastoma multiforme.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Middle Aged | 1981 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Doxorubicin; | 1982 |
Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Doxorubicin; | 1982 |
Aggressive multimodality therapy based on a multicompartmental model of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Drug Therapy, Combination; Glioblastoma; Hot Temper | 1982 |
Aggressive multimodality therapy based on a multicompartmental model of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Drug Therapy, Combination; Glioblastoma; Hot Temper | 1982 |
High-dose radiation therapy with low-dose (pulsed) BCNU in malignant gliomas: an Eastern Cooperative Oncology Group (ECOG) report.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cobalt Radioisotopes; Female; Glioblastoma; Humans; Male; | 1982 |
High-dose radiation therapy with low-dose (pulsed) BCNU in malignant gliomas: an Eastern Cooperative Oncology Group (ECOG) report.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cobalt Radioisotopes; Female; Glioblastoma; Humans; Male; | 1982 |
Nursing management of the patient receiving high-dose BCNU with autologous bone marrow harvest.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1982 |
Nursing management of the patient receiving high-dose BCNU with autologous bone marrow harvest.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1982 |
New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Carotid Arteries; Chemotherapy, | 1982 |
New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Carotid Arteries; Chemotherapy, | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Spinal leptomeningeal invasion from intracranial glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Cauda Equina; Cerebrospinal Fluid; Child, Preschool; Cobalt Radioisotop | 1983 |
Spinal leptomeningeal invasion from intracranial glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Cauda Equina; Cerebrospinal Fluid; Child, Preschool; Cobalt Radioisotop | 1983 |
[Kinetics of multicellular spheroids developed from a human glioblastoma, and effect of 1,3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Glioma; Humans; Kinetics | 1983 |
[Kinetics of multicellular spheroids developed from a human glioblastoma, and effect of 1,3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Glioma; Humans; Kinetics | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Intraoperative radiotherapy in childhood malignant astrocytoma.
Topics: Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioblastoma; Humans; Intraoperative | 1984 |
Intraoperative radiotherapy in childhood malignant astrocytoma.
Topics: Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioblastoma; Humans; Intraoperative | 1984 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Autologous bone-marrow transplantation: host effects of high-dose BCNU.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Hematopoiesis; | 1983 |
Autologous bone-marrow transplantation: host effects of high-dose BCNU.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Hematopoiesis; | 1983 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Cell cycle age response of 9L cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and modification by alpha-difluoromethylornithine.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Eflornithine; Ki | 1983 |
Cell cycle age response of 9L cells to 1,3-bis(2-chloroethyl)-1-nitrosourea and modification by alpha-difluoromethylornithine.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Eflornithine; Ki | 1983 |
Differential potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine in chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Drug Resistance; Drug Synerg | 1983 |
Differential potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine in chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Drug Resistance; Drug Synerg | 1983 |
Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Line; Cell Surviva | 1983 |
Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Line; Cell Surviva | 1983 |
Effects of alpha-difluoromethylornithine on the growth of 9L rat brain tumor multicellular spheroids and their response to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Drug Ther | 1984 |
Effects of alpha-difluoromethylornithine on the growth of 9L rat brain tumor multicellular spheroids and their response to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Drug Ther | 1984 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Time dependence of the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity caused by alpha-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Drug Synergism; Eflornithine; Kinetics; Ornithine; | 1984 |
Time dependence of the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity caused by alpha-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Drug Synergism; Eflornithine; Kinetics; Ornithine; | 1984 |
Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy. Animal experience and two case reports.
Topics: Animals; Brain Neoplasms; Carmustine; Chordoma; Combined Modality Therapy; Diathermy; Female; Fronta | 1984 |
Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy. Animal experience and two case reports.
Topics: Animals; Brain Neoplasms; Carmustine; Chordoma; Combined Modality Therapy; Diathermy; Female; Fronta | 1984 |
Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Craniopharyngiom | 1984 |
Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Craniopharyngiom | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Heterogeneity of tumor cell DNA content.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Tum | 1984 |
Heterogeneity of tumor cell DNA content.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Tum | 1984 |
Feasibility of microwave hyperthermia for brain tumor therapy.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Diathermy; Hot Temperature; Humans; Microwav | 1984 |
Feasibility of microwave hyperthermia for brain tumor therapy.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Diathermy; Hot Temperature; Humans; Microwav | 1984 |
Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Topics: Animals; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Frontal Lobe; Glioma | 1984 |
Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Topics: Animals; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Frontal Lobe; Glioma | 1984 |
Chemotherapy-induced fatal pulmonary fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Epend | 1984 |
Chemotherapy-induced fatal pulmonary fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Epend | 1984 |
Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in 9L rat brain tumor cells by methylglyoxal-bis(guanylhydrazone), an inhibitor of S-adenosyl-L-methionine decarboxylase.
Topics: Adenosylmethionine Decarboxylase; Animals; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Surviva | 1984 |
Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in 9L rat brain tumor cells by methylglyoxal-bis(guanylhydrazone), an inhibitor of S-adenosyl-L-methionine decarboxylase.
Topics: Adenosylmethionine Decarboxylase; Animals; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Surviva | 1984 |
Detection of heterogeneity in the chemosensitivity of 9L brain tumor cell lines to 1,3-bis (2-chloroethyl)-1-nitrosourea by the sister chromatid exchange assay.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Count; Cell Line; Crossing Over, Genetic; Drug Resistance | 1984 |
Detection of heterogeneity in the chemosensitivity of 9L brain tumor cell lines to 1,3-bis (2-chloroethyl)-1-nitrosourea by the sister chromatid exchange assay.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Count; Cell Line; Crossing Over, Genetic; Drug Resistance | 1984 |
Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors.
Topics: Brain; Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Humans; Infusions, Intra-Arterial; | 1983 |
Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors.
Topics: Brain; Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Humans; Infusions, Intra-Arterial; | 1983 |
Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Malignant anorexia after nitrosourea therapy: case report.
Topics: Adult; Anorexia; Brain Neoplasms; Carmustine; Feeding and Eating Disorders; Glioma; Humans; Male | 1984 |
Malignant anorexia after nitrosourea therapy: case report.
Topics: Adult; Anorexia; Brain Neoplasms; Carmustine; Feeding and Eating Disorders; Glioma; Humans; Male | 1984 |
Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography.
Topics: Brain Neoplasms; Carmustine; Humans; Kinetics; Tomography, Emission-Computed | 1984 |
Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography.
Topics: Brain Neoplasms; Carmustine; Humans; Kinetics; Tomography, Emission-Computed | 1984 |
Tomodensitometric evaluation of the results of radiochemotherapy of cerebral metastases.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Humans; Outcome and Process Assessment, Heal | 1983 |
Tomodensitometric evaluation of the results of radiochemotherapy of cerebral metastases.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Humans; Outcome and Process Assessment, Heal | 1983 |
The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 1983 |
The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 1983 |
Intra-arterial BCNU in the treatment of metastatic brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Humans; Infusions, Intr | 1983 |
Intra-arterial BCNU in the treatment of metastatic brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Humans; Infusions, Intr | 1983 |
New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Blood-Brain Barrier; Brain Neoplasms; C | 1983 |
New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Blood-Brain Barrier; Brain Neoplasms; C | 1983 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Interphase; Rats; Time Factors | 1984 |
Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Interphase; Rats; Time Factors | 1984 |
Relationship between the repair of radiation-induced DNA damage and recovery from potentially lethal damage in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Combined Modality Therapy; DNA Repair; DNA Replicat | 1984 |
Relationship between the repair of radiation-induced DNA damage and recovery from potentially lethal damage in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Combined Modality Therapy; DNA Repair; DNA Replicat | 1984 |
BCNU-induced sister chromatid exchanges are increased by X irradiation.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Crossing Over, Genetic; Dose-R | 1984 |
BCNU-induced sister chromatid exchanges are increased by X irradiation.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Crossing Over, Genetic; Dose-R | 1984 |
Arterial drug infusion with extracorporeal removal. I. Theoretic basis with particular reference to the brain.
Topics: Animals; Anthropometry; Brain Neoplasms; Carmustine; Cats; Cattle; Chemotherapy, Cancer, Regional Pe | 1984 |
Arterial drug infusion with extracorporeal removal. I. Theoretic basis with particular reference to the brain.
Topics: Animals; Anthropometry; Brain Neoplasms; Carmustine; Cats; Cattle; Chemotherapy, Cancer, Regional Pe | 1984 |
Carmustine and Baker's antifol combination chemotherapy for primary brain tumors progressive after irradiation and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Count; Brain Neoplasm | 1984 |
Carmustine and Baker's antifol combination chemotherapy for primary brain tumors progressive after irradiation and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Count; Brain Neoplasm | 1984 |
[Fatal pulmonary fibrosis induced by cytotoxic therapy].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Ependymoma; Female; Hum | 1984 |
[Fatal pulmonary fibrosis induced by cytotoxic therapy].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Ependymoma; Female; Hum | 1984 |
Treatment of grade III and IV astrocytoma with high-dose irradiation: schedule and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1984 |
Treatment of grade III and IV astrocytoma with high-dose irradiation: schedule and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1984 |
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Drug Synergism; Misonidazole; | 1984 |
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Drug Synergism; Misonidazole; | 1984 |
The effects of X rays on BCNU-induced DNA crosslinking.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relatio | 1984 |
The effects of X rays on BCNU-induced DNA crosslinking.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relatio | 1984 |
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Humans; Lung; Lung Diseases; Male; Pulmonary Fibros | 1984 |
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Humans; Lung; Lung Diseases; Male; Pulmonary Fibros | 1984 |
Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells.
Topics: Alkylation; Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Chemical Phenomena; Chem | 1984 |
Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells.
Topics: Alkylation; Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Chemical Phenomena; Chem | 1984 |
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; | 1984 |
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; | 1984 |
BCNU treatment of astrocytomas: erratum.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Humans | 1984 |
BCNU treatment of astrocytomas: erratum.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Humans | 1984 |
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; | 1982 |
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; | 1982 |
Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cell Survival; Dose-Response Relationsh | 1981 |
Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cell Survival; Dose-Response Relationsh | 1981 |
Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Co | 1981 |
Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Co | 1981 |
An approach to the use of polyamine inhibitors for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Ef | 1981 |
An approach to the use of polyamine inhibitors for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Ef | 1981 |
Decreased phenytoin level during antineoplastic therapy: a case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Interactions; Drug Therapy, Combination; Hu | 1983 |
Decreased phenytoin level during antineoplastic therapy: a case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Interactions; Drug Therapy, Combination; Hu | 1983 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Disseminated intravascular coagulation--a complication of 1,3-bis(2-chlorethyl)-nitrosourea therapy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Disseminated Intravascular Coagulation; Female; Hum | 1983 |
Disseminated intravascular coagulation--a complication of 1,3-bis(2-chlorethyl)-nitrosourea therapy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Disseminated Intravascular Coagulation; Female; Hum | 1983 |
Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.
Topics: Biological Assay; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Glioma; Humans | 1983 |
Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.
Topics: Biological Assay; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Glioma; Humans | 1983 |
Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Male; Rats; Rats, Inbred | 1983 |
Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Male; Rats; Rats, Inbred | 1983 |
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial; Osmolar Concentration; Solub | 1983 |
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial; Osmolar Concentration; Solub | 1983 |
Radiation and drug response of the rat glioma RG2.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Glioma; Male; Neopl | 1982 |
Radiation and drug response of the rat glioma RG2.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Glioma; Male; Neopl | 1982 |
Development of a 9L rat brain tumor cell multicellular spheroid system and its response to 1,3-bis(2-chloroethyl)-1-nitrosourea and radiation.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Adhesion; Cell Division; Cell Survival; Cells, Cultured; | 1980 |
Development of a 9L rat brain tumor cell multicellular spheroid system and its response to 1,3-bis(2-chloroethyl)-1-nitrosourea and radiation.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Adhesion; Cell Division; Cell Survival; Cells, Cultured; | 1980 |
Rational planning of brain tumour therapy based on laboratory investigations: comparison of single- and multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Administration Schedule; Glioma; Humans; N | 1980 |
Rational planning of brain tumour therapy based on laboratory investigations: comparison of single- and multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Administration Schedule; Glioma; Humans; N | 1980 |
Is cell survival a determinant of the in situ response of 9L tumours?
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Ra | 1980 |
Is cell survival a determinant of the in situ response of 9L tumours?
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Ra | 1980 |
Experimental chemical production of brain tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Ethylnitrosourea; Methylnitrosourea; Neoplasms, Experimental; | 1982 |
Experimental chemical production of brain tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Ethylnitrosourea; Methylnitrosourea; Neoplasms, Experimental; | 1982 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
Topics: Animals; Biotransformation; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Respon | 1982 |
Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
Topics: Animals; Biotransformation; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Respon | 1982 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
Fatal pneumothorax in "BCNU lung".
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Humans; Parietal Lobe; Pneumo | 1982 |
Fatal pneumothorax in "BCNU lung".
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Humans; Parietal Lobe; Pneumo | 1982 |
Malignant glioma. Results of combined modality therapy.
Topics: Adult; Aged; Anaplasia; Brain; Brain Neoplasms; Carmustine; Glioma; Humans; Middle Aged; Postoperati | 1982 |
Malignant glioma. Results of combined modality therapy.
Topics: Adult; Aged; Anaplasia; Brain; Brain Neoplasms; Carmustine; Glioma; Humans; Middle Aged; Postoperati | 1982 |
Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
Topics: Animals; Brain Neoplasms; Carmustine; Cells, Cultured; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
Topics: Animals; Brain Neoplasms; Carmustine; Cells, Cultured; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Synergistic effect of perfluorochemicals on BCNU chemotherapy. Experimental study in a 9L rat brain-tumor model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Drug Therapy, Combinati | 1982 |
Synergistic effect of perfluorochemicals on BCNU chemotherapy. Experimental study in a 9L rat brain-tumor model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Drug Therapy, Combinati | 1982 |
Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Infusions, Intra-Arterial; Ma | 1982 |
Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Infusions, Intra-Arterial; Ma | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a rat brain-tumor model].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Fluorocarbons; Glioma; | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a rat brain-tumor model].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Fluorocarbons; Glioma; | 1982 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
[Possibility of the use of perfluorochemicals (fluorocarbons) as adjuvants in chemotherapy of cancer].
Topics: Animals; Blood Substitutes; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; M | 1982 |
[Possibility of the use of perfluorochemicals (fluorocarbons) as adjuvants in chemotherapy of cancer].
Topics: Animals; Blood Substitutes; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; M | 1982 |
The use of cisplatinum for treatment of malignant glioma.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Male; Middle Aged; Tomography, X-Ray Compute | 1982 |
The use of cisplatinum for treatment of malignant glioma.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Male; Middle Aged; Tomography, X-Ray Compute | 1982 |
Influence of fractionation schedules on the response of a rat brain tumor to therapy with BCNU and radiation.
Topics: Animals; Brain Neoplasms; Carmustine; Chemical Fractionation; Dose-Response Relationship, Drug; Dose | 1980 |
Influence of fractionation schedules on the response of a rat brain tumor to therapy with BCNU and radiation.
Topics: Animals; Brain Neoplasms; Carmustine; Chemical Fractionation; Dose-Response Relationship, Drug; Dose | 1980 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Biopsy; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Lung; Male; Mi | 1980 |
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Biopsy; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Lung; Male; Mi | 1980 |
Chemosensitivity testing for human brain tumors.
Topics: Brain Neoplasms; Carmustine; Cell Separation; Cell Survival; Clone Cells; Glioma; Humans | 1980 |
Chemosensitivity testing for human brain tumors.
Topics: Brain Neoplasms; Carmustine; Cell Separation; Cell Survival; Clone Cells; Glioma; Humans | 1980 |
Failure of corticosteroids to prevent carmustine-induced pulmonary fibrosis in a woman with astrocytoma.
Topics: Adrenal Cortex Hormones; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Huma | 1981 |
Failure of corticosteroids to prevent carmustine-induced pulmonary fibrosis in a woman with astrocytoma.
Topics: Adrenal Cortex Hormones; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Huma | 1981 |
Efficacy of continuous treatment with radiation in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Male; Neoplasms, Experimental; Radiati | 1981 |
Efficacy of continuous treatment with radiation in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Male; Neoplasms, Experimental; Radiati | 1981 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Topics: Brain Neoplasms; Carmustine; Child, Preschool; Humans; Medulloblastoma; Pulmonary Fibrosis; Risk | 1981 |
Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
Topics: Brain Neoplasms; Carmustine; Child, Preschool; Humans; Medulloblastoma; Pulmonary Fibrosis; Risk | 1981 |
Nephrotoxicity of nitrosoureas.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Urea Nitrogen; Brain Neoplasms; Carmustine; Child; Creatinine | 1981 |
Nephrotoxicity of nitrosoureas.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Urea Nitrogen; Brain Neoplasms; Carmustine; Child; Creatinine | 1981 |
Brain tumor therapy: prospects for combining BCNU with conventional radiotherapy schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cesium Radioisotopes; Gamma Rays; Male; Neoplasms, Experimenta | 1981 |
Brain tumor therapy: prospects for combining BCNU with conventional radiotherapy schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cesium Radioisotopes; Gamma Rays; Male; Neoplasms, Experimenta | 1981 |
Potentials and possible pitfalls of human stem cell analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Aggregation; Cells, Cultured; Clone Cells; | 1981 |
Potentials and possible pitfalls of human stem cell analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Aggregation; Cells, Cultured; Clone Cells; | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Potentials and limitations of a clonogenic cell assay for human brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cells, Cultured; Clone Cells; Dose-Response Relationship, | 1981 |
Potentials and limitations of a clonogenic cell assay for human brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cells, Cultured; Clone Cells; Dose-Response Relationship, | 1981 |
Review of factors influencing the response of experimental brain tumors to therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Kinetics; Neoplasms, Experimental; Rats | 1981 |
Review of factors influencing the response of experimental brain tumors to therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Kinetics; Neoplasms, Experimental; Rats | 1981 |
Effect of surgery on BCNU chemotherapy in a rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Mitosis; Neoplasm Transplantation; Neoplasms, Expe | 1980 |
Effect of surgery on BCNU chemotherapy in a rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Mitosis; Neoplasm Transplantation; Neoplasms, Expe | 1980 |
Rapidly progressive, fatal pulmonary fibrosis induced by carmustine.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Female; Humans; Lung; Middle Aged; Postoperative Care; Pul | 1980 |
Rapidly progressive, fatal pulmonary fibrosis induced by carmustine.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Female; Humans; Lung; Middle Aged; Postoperative Care; Pul | 1980 |
Experimental therapy of brain tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Methods; Metronidazole; Misonidazole; Neoplasms, Ex | 1980 |
Experimental therapy of brain tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Methods; Metronidazole; Misonidazole; Neoplasms, Ex | 1980 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
DNA damage in rat 9L cells treated with nitrogen mustard and 1,3-bis(2-chloroethyl)-1-nitrosourea assayed by viscoelastometry and S1 nuclease.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cross-Linking Reagents; Deoxyribonucleases; DNA, Ne | 1980 |
DNA damage in rat 9L cells treated with nitrogen mustard and 1,3-bis(2-chloroethyl)-1-nitrosourea assayed by viscoelastometry and S1 nuclease.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cross-Linking Reagents; Deoxyribonucleases; DNA, Ne | 1980 |
Chemotherapy against human melanoma in the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Da | 1980 |
Chemotherapy against human melanoma in the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Da | 1980 |
Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.
Topics: Adult; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; Female; Glioma; H | 1981 |
Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.
Topics: Adult; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; Female; Glioma; H | 1981 |
Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Dose-Response Relationship, Drug; | 1994 |
Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Dose-Response Relationship, Drug; | 1994 |
The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carmustine; C | 1994 |
The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carmustine; C | 1994 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
Topics: Adult; Animals; Astrocytes; Brain Neoplasms; Carmustine; Cell Differentiation; Cell Survival; Female | 1995 |
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
Topics: Adult; Animals; Astrocytes; Brain Neoplasms; Carmustine; Cell Differentiation; Cell Survival; Female | 1995 |
[Analysis of three-year survivors in patients with glioblastoma].
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; China; Combined Modality Therapy; Female; Fol | 1995 |
[Analysis of three-year survivors in patients with glioblastoma].
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; China; Combined Modality Therapy; Female; Fol | 1995 |
Late carmustine lung fibrosis. Age at treatment may influence severity and survival.
Topics: Adolescent; Age Factors; Brain Neoplasms; Carmustine; Child; Child, Preschool; Follow-Up Studies; Hu | 1995 |
Late carmustine lung fibrosis. Age at treatment may influence severity and survival.
Topics: Adolescent; Age Factors; Brain Neoplasms; Carmustine; Child; Child, Preschool; Follow-Up Studies; Hu | 1995 |
In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.
Topics: Animals; Brain Neoplasms; Carmustine; Cerebrovascular Circulation; Gliosarcoma; Hemoglobins; Oxygen; | 1994 |
In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.
Topics: Animals; Brain Neoplasms; Carmustine; Cerebrovascular Circulation; Gliosarcoma; Hemoglobins; Oxygen; | 1994 |
[Survival of children with primitive neuroectodermal tumors and malignant ependymomas of the central nervous system after treatment with 8 cytostatic agents in one day. A report of the Children's Cancer Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabine; Ependymoma; | 1995 |
[Survival of children with primitive neuroectodermal tumors and malignant ependymomas of the central nervous system after treatment with 8 cytostatic agents in one day. A report of the Children's Cancer Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabine; Ependymoma; | 1995 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclophosphamide; Decanoic Acids; Delay | 1995 |
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclophosphamide; Decanoic Acids; Delay | 1995 |
The role of minocycline in the treatment of intracranial 9L glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modal | 1995 |
The role of minocycline in the treatment of intracranial 9L glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modal | 1995 |
Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth.
Topics: Animals; Body Weight; Brain Neoplasms; Calmodulin; Carmustine; Cell Division; Chlorpromazine; Drug S | 1994 |
Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth.
Topics: Animals; Body Weight; Brain Neoplasms; Calmodulin; Carmustine; Cell Division; Chlorpromazine; Drug S | 1994 |
Acute effect of carmustine on glucose metabolism in brain and glioblastoma.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glucose; Humans; Male; Middle | 1994 |
Acute effect of carmustine on glucose metabolism in brain and glioblastoma.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glucose; Humans; Male; Middle | 1994 |
Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bucladesine; Butyrates; Butyric Acid; Carmustine; C | 1994 |
Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bucladesine; Butyrates; Butyric Acid; Carmustine; C | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1994 |
Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Cyclophospha | 1994 |
Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Cyclophospha | 1994 |
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Topics: Animals; Body Weight; Brain Neoplasms; Carmustine; Cell Division; Colonic Neoplasms; Drug Screening | 1994 |
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Topics: Animals; Body Weight; Brain Neoplasms; Carmustine; Cell Division; Colonic Neoplasms; Drug Screening | 1994 |
In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.
Topics: Animals; Biodegradation, Environmental; Brain Neoplasms; Carmustine; Cellulose, Oxidized; Decanoic A | 1994 |
In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.
Topics: Animals; Biodegradation, Environmental; Brain Neoplasms; Carmustine; Cellulose, Oxidized; Decanoic A | 1994 |
Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).
Topics: Acute Disease; Adult; Brain Neoplasms; Carmustine; Fatal Outcome; Humans; Lung Diseases, Interstitia | 1994 |
Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).
Topics: Acute Disease; Adult; Brain Neoplasms; Carmustine; Fatal Outcome; Humans; Lung Diseases, Interstitia | 1994 |
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Drug Synergism | 1993 |
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Drug Synergism | 1993 |
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Hypoxia; Combined Modality Therapy; Drug Resi | 1993 |
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Hypoxia; Combined Modality Therapy; Drug Resi | 1993 |
Cognitive functioning in long-term survivors of high-grade glioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cognition; Fem | 1994 |
Cognitive functioning in long-term survivors of high-grade glioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cognition; Fem | 1994 |
Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Topics: Animals; Brain Edema; Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinat | 1994 |
Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Topics: Animals; Brain Edema; Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinat | 1994 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Carmustine toxicity presenting as a lobar infiltrate.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Pulmonary Fibrosis; Vital Capacity | 1993 |
Carmustine toxicity presenting as a lobar infiltrate.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Pulmonary Fibrosis; Vital Capacity | 1993 |
[Intravascular surgery for brain tumors].
Topics: Brain Neoplasms; Carmustine; Chemoembolization, Therapeutic; Humans; Meningeal Neoplasms; Meningioma | 1993 |
[Intravascular surgery for brain tumors].
Topics: Brain Neoplasms; Carmustine; Chemoembolization, Therapeutic; Humans; Meningeal Neoplasms; Meningioma | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.
Topics: Biological Transport, Active; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality | 1993 |
Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.
Topics: Biological Transport, Active; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality | 1993 |
Chromosome number and carmustine sensitivity in human gliomas.
Topics: Adolescent; Adult; Aged; Aneuploidy; Astrocytoma; Brain Neoplasms; Carmustine; Child; Chromosome Abe | 1993 |
Chromosome number and carmustine sensitivity in human gliomas.
Topics: Adolescent; Adult; Aged; Aneuploidy; Astrocytoma; Brain Neoplasms; Carmustine; Child; Chromosome Abe | 1993 |
BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clone Cells; Diploidy; Drug Resistance; Drug Screening Ass | 1993 |
BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clone Cells; Diploidy; Drug Resistance; Drug Screening Ass | 1993 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ca | 1993 |
Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ca | 1993 |
Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants.
Topics: Animals; Antipyrine; Autoradiography; Biodegradation, Environmental; Brain; Brain Neoplasms; Carmust | 1995 |
Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants.
Topics: Animals; Antipyrine; Autoradiography; Biodegradation, Environmental; Brain; Brain Neoplasms; Carmust | 1995 |
Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Death; De | 1996 |
Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Death; De | 1996 |
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Glio | 1996 |
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Glio | 1996 |
The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bromodeoxyuridine; Carmustine; DNA; Fem | 1996 |
The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bromodeoxyuridine; Carmustine; DNA; Fem | 1996 |
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 1996 |
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 1996 |
Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.
Topics: Brain Neoplasms; Carcinogens; Carmustine; Cell Count; Cell Death; Cell Division; Cell Survival; Colo | 1996 |
Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.
Topics: Brain Neoplasms; Carcinogens; Carmustine; Cell Count; Cell Death; Cell Division; Cell Survival; Colo | 1996 |
Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 1995 |
Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 1995 |
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Topics: Alkaloids; Brain Neoplasms; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibito | 1996 |
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Topics: Alkaloids; Brain Neoplasms; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibito | 1996 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcin | 1996 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcin | 1996 |
Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7.
Topics: Animals; Autoradiography; Biomarkers; Blood-Brain Barrier; Bradykinin; Brain Neoplasms; Capillaries; | 1996 |
Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7.
Topics: Animals; Autoradiography; Biomarkers; Blood-Brain Barrier; Bradykinin; Brain Neoplasms; Capillaries; | 1996 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Scre | 1997 |
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Scre | 1997 |
Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Carmustine; Cell Line; Con | 1997 |
Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Carmustine; Cell Line; Con | 1997 |
Radiation and chemotherapy improve outcome in oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1997 |
Radiation and chemotherapy improve outcome in oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1997 |
Carmustine and the lungs .
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Female; Hodgkin Disease; Huma | 1997 |
Carmustine and the lungs .
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Female; Hodgkin Disease; Huma | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Chil | 1997 |
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Chil | 1997 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1998 |
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 1998 |
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 1998 |
Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17.
Topics: Apoptosis; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Chromatin; Enzyme Inhibitors; | 1998 |
Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17.
Topics: Apoptosis; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Chromatin; Enzyme Inhibitors; | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member | 1998 |
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
Topics: Brain Neoplasms; Carmustine; Colorimetry; DNA Helicases; DNA Repair; DNA-Binding Proteins; DNA, Neop | 1998 |
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
Topics: Brain Neoplasms; Carmustine; Colorimetry; DNA Helicases; DNA Repair; DNA-Binding Proteins; DNA, Neop | 1998 |
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Death; Cell Division; | 1998 |
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Death; Cell Division; | 1998 |
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brai | 1998 |
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brai | 1998 |
Gliadel wafers for treatment of brain tumors.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Implants; | 1998 |
Gliadel wafers for treatment of brain tumors.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Implants; | 1998 |
Malignant glioma: who benefits from adjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1998 |
Malignant glioma: who benefits from adjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1998 |
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carmustine; Combi | 1998 |
Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carmustine; Combi | 1998 |
Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cath | 1998 |
Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cath | 1998 |
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Water; Brain Neoplasms; Carmustine; Cell Count; Cel | 1997 |
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Water; Brain Neoplasms; Carmustine; Cell Count; Cel | 1997 |
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Carmustine; Cell Division; | 1995 |
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Carmustine; Cell Division; | 1995 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain | 1998 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Biodegradation, Environmental; B | 1999 |
Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Biodegradation, Environmental; B | 1999 |
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci | 1999 |
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci | 1999 |
Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors.
Topics: Anhydrides; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; | 1999 |
Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors.
Topics: Anhydrides; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; | 1999 |
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
Topics: Animals; Antineoplastic Agents; Autoradiography; Brain; Brain Neoplasms; Carmustine; Cell Line; Fema | 1999 |
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
Topics: Animals; Antineoplastic Agents; Autoradiography; Brain; Brain Neoplasms; Carmustine; Cell Line; Fema | 1999 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combi | 1999 |
Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combi | 1999 |
Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studi | 1999 |
Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studi | 1999 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplati | 1999 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplati | 1999 |
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Sc | 1999 |
Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Sc | 1999 |
The delivery of BCNU to brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capillary Permeability; Carmustine; Drug Deliver | 1999 |
The delivery of BCNU to brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capillary Permeability; Carmustine; Drug Deliver | 1999 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain N | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain N | 1999 |
Intracerebral clysis in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Dextrans; Drug Deliv | 2000 |
Intracerebral clysis in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Dextrans; Drug Deliv | 2000 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camp | 2000 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camp | 2000 |
Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuva | 2000 |
Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuva | 2000 |
Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Carmustine; Cobalt Radiois | 2000 |
Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Carmustine; Cobalt Radiois | 2000 |
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2000 |
Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2000 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2000 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2000 |
Estimating a treatment effect with the accelerated hazards models.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2000 |
Estimating a treatment effect with the accelerated hazards models.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Delayed-Action Preparation | 2000 |
Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Delayed-Action Preparation | 2000 |
Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Corpus Striatum; Delayed-A | 2000 |
Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Corpus Striatum; Delayed-A | 2000 |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free S | 2000 |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free S | 2000 |
Pharmacogenomics--teaching old drugs new tricks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; DNA Methylation; DNA, Neoplasm; Gene | 2000 |
Pharmacogenomics--teaching old drugs new tricks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; DNA Methylation; DNA, Neoplasm; Gene | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain.
Topics: Animals; Antineoplastic Agents; Autoradiography; Blood-Brain Barrier; Bradykinin; Brain; Brain Neopl | 2000 |
Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain.
Topics: Animals; Antineoplastic Agents; Autoradiography; Blood-Brain Barrier; Bradykinin; Brain; Brain Neopl | 2000 |
[Intramedullary spread of a cerebral oligodendroglioma. Two case reports].
Topics: Abducens Nerve Diseases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2000 |
[Intramedullary spread of a cerebral oligodendroglioma. Two case reports].
Topics: Abducens Nerve Diseases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2000 |
Detecting treatment-by-centre interaction in multi-centre clinical trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Com | 2001 |
Detecting treatment-by-centre interaction in multi-centre clinical trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Com | 2001 |
Altered nuclear localization of bax protein in BCNU-resistant glioma cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; | 2000 |
Altered nuclear localization of bax protein in BCNU-resistant glioma cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Chemot | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Chemot | 2000 |
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Gli | 2001 |
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Gli | 2001 |
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 2001 |
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell | 2001 |
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carr | 2001 |
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carr | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Quinacrine enhances carmustine therapy of experimental rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 2001 |
Quinacrine enhances carmustine therapy of experimental rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 2001 |
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Chemistry; Brain Neoplasms; Carmustine; Chromat | 2001 |
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Chemistry; Brain Neoplasms; Carmustine; Chromat | 2001 |
Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carm | 2002 |
Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carm | 2002 |
Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain | 2002 |
Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain | 2002 |
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Car | 2002 |
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Car | 2002 |
[Scheduled combination chemotherapy of adriamycin and BCNU to malignant brain tumors (author's transl)].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child, Preschool; Doxorubicin; Drug Therapy, C | 1976 |
[Scheduled combination chemotherapy of adriamycin and BCNU to malignant brain tumors (author's transl)].
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child, Preschool; Doxorubicin; Drug Therapy, C | 1976 |
[Perturbation of cell kinetics on 9L rat brain tumor treated with BCNU, in vitro and in vivo (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cells, Cultured; Kinetics; Mitosis; Neoplasms, Experimental; R | 1978 |
[Perturbation of cell kinetics on 9L rat brain tumor treated with BCNU, in vitro and in vivo (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cells, Cultured; Kinetics; Mitosis; Neoplasms, Experimental; R | 1978 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Glioblastoma; Humans; Vincristine | 1977 |
Glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Glioblastoma; Humans; Vincristine | 1977 |
Immunobiology of primary intracranial tumors.
Topics: Alpharetrovirus; Animals; Astrocytoma; BCG Vaccine; Brain Neoplasms; Carmustine; Disease Models, Ani | 1977 |
Immunobiology of primary intracranial tumors.
Topics: Alpharetrovirus; Animals; Astrocytoma; BCG Vaccine; Brain Neoplasms; Carmustine; Disease Models, Ani | 1977 |
[Polychemotherapy of glioblastoma multiforme].
Topics: Adult; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Male | 1977 |
[Polychemotherapy of glioblastoma multiforme].
Topics: Adult; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Male | 1977 |
Acute leukemia complicating treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child, Preschool; Dexamethasone; Drug Therapy, C | 1978 |
Acute leukemia complicating treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child, Preschool; Dexamethasone; Drug Therapy, C | 1978 |
Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain.
Topics: Brain Neoplasms; Carmustine; Drug Administration Schedule; Glioblastoma; Humans; Teniposide; Vomitin | 1978 |
Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain.
Topics: Brain Neoplasms; Carmustine; Drug Administration Schedule; Glioblastoma; Humans; Teniposide; Vomitin | 1978 |
Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lung Diseases; Male; Middle Aged | 1979 |
Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lung Diseases; Male; Middle Aged | 1979 |
Human brain tumor transplantation into nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantati | 1979 |
Human brain tumor transplantation into nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Transplantati | 1979 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Nitrosourea Compounds; Semustine | 1978 |
Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Nitrosourea Compounds; Semustine | 1978 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
Topics: Animals; Avian Sarcoma Viruses; Brain Neoplasms; Carmustine; Glioma; Neoplasms, Experimental; Rats | 1979 |
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
Topics: Animals; Avian Sarcoma Viruses; Brain Neoplasms; Carmustine; Glioma; Neoplasms, Experimental; Rats | 1979 |
BCNU and steroids in the viral-induced dog brain tumor.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Disease Models, Animal; | 1979 |
BCNU and steroids in the viral-induced dog brain tumor.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dexamethasone; Disease Models, Animal; | 1979 |
Growth and rejection of leukemia cells in individual mice after combined treatment with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Amphotericin B; Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Clone Cells; Drug | 1978 |
Growth and rejection of leukemia cells in individual mice after combined treatment with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Amphotericin B; Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Clone Cells; Drug | 1978 |
BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells.
Topics: Animals; Autoradiography; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cytological Techniques | 1978 |
BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells.
Topics: Animals; Autoradiography; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cytological Techniques | 1978 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Cinemicrographic determination of cell progression and division abnormalities after treatment with 1, 3 bis(2-chloroethyl)-l-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Mot | 1979 |
Cinemicrographic determination of cell progression and division abnormalities after treatment with 1, 3 bis(2-chloroethyl)-l-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Mot | 1979 |
BCNU and malignant glioma.
Topics: Brain Neoplasms; Carmustine; Drug Evaluation; Follow-Up Studies; Glioma; Humans | 1979 |
BCNU and malignant glioma.
Topics: Brain Neoplasms; Carmustine; Drug Evaluation; Follow-Up Studies; Glioma; Humans | 1979 |
Pulmonary toxicity from carmustine (BCNU): a case report.
Topics: Autopsy; Brain Neoplasms; Carmustine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Meta | 1979 |
Pulmonary toxicity from carmustine (BCNU): a case report.
Topics: Autopsy; Brain Neoplasms; Carmustine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Meta | 1979 |
Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma: a preliminary report.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Humans; Infusions, Intra-Arteria | 1979 |
Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma: a preliminary report.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Humans; Infusions, Intra-Arteria | 1979 |
[Treatment of intracranial tumors with Nitrumon (Litrumon; BCNU; 1,3-bis (2-chlorethyl)-1-nitrosourea)].
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Child; Female; Humans; Male; Middle Age | 1979 |
[Treatment of intracranial tumors with Nitrumon (Litrumon; BCNU; 1,3-bis (2-chlorethyl)-1-nitrosourea)].
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Child; Female; Humans; Male; Middle Age | 1979 |
Comparison of the CCNU and BCNU modification of the in vitro radiation response in 9L brain tumor cells of rats.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr | 1979 |
Comparison of the CCNU and BCNU modification of the in vitro radiation response in 9L brain tumor cells of rats.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr | 1979 |
Response of a rat brain tumor to fractionated therapy with low doses of BCNU and irradiation.
Topics: Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Male; Neoplasms, Experimenta | 1979 |
Response of a rat brain tumor to fractionated therapy with low doses of BCNU and irradiation.
Topics: Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Male; Neoplasms, Experimenta | 1979 |
BCNU and X-ray therapy of intracerebral 9L rat tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Male; Neoplasms, Experimental; Pulmonary Fibrosis; Radiation I | 1979 |
BCNU and X-ray therapy of intracerebral 9L rat tumors.
Topics: Animals; Brain Neoplasms; Carmustine; Male; Neoplasms, Experimental; Pulmonary Fibrosis; Radiation I | 1979 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Chemotherapy of human nervous system tumors: influence on cerebrospinal fluid sterols.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Humans; | 1977 |
Chemotherapy of human nervous system tumors: influence on cerebrospinal fluid sterols.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Humans; | 1977 |
Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethas | 1978 |
Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethas | 1978 |
Variations in response of human brain tumors to BCNU in vitro.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Glioma; Humans; Meningeal Neoplasms; Meningioma | 1978 |
Variations in response of human brain tumors to BCNU in vitro.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Glioma; Humans; Meningeal Neoplasms; Meningioma | 1978 |
Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.
Topics: Body Composition; Brain Neoplasms; Carmustine; Female; Half-Life; Humans; Male; Mass Spectrometry; M | 1978 |
Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.
Topics: Body Composition; Brain Neoplasms; Carmustine; Female; Half-Life; Humans; Male; Mass Spectrometry; M | 1978 |
Carmustine (BiCNU).
Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma | 1978 |
Carmustine (BiCNU).
Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma | 1978 |
Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioma; Humans; Male; M | 1978 |
Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioma; Humans; Male; M | 1978 |
Where are we heading--heat and otherwise.
Topics: Animals; Body Temperature; Brain Neoplasms; Carmustine; Glioma; Hot Temperature; Humans; Radiotherap | 1978 |
Where are we heading--heat and otherwise.
Topics: Animals; Body Temperature; Brain Neoplasms; Carmustine; Glioma; Hot Temperature; Humans; Radiotherap | 1978 |
Immunotherapy of brain tumors--is there a future?
Topics: Antibodies, Neoplasm; BCG Vaccine; Brain Neoplasms; Carmustine; Cytotoxicity, Immunologic; Glioma; H | 1978 |
Immunotherapy of brain tumors--is there a future?
Topics: Antibodies, Neoplasm; BCG Vaccine; Brain Neoplasms; Carmustine; Cytotoxicity, Immunologic; Glioma; H | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.
Topics: Animals; Brain Neoplasms; Carmustine; DNA; Kinetics; Lomustine; Male; Neoplasm Proteins; Nitrosourea | 1978 |
Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.
Topics: Animals; Brain Neoplasms; Carmustine; DNA; Kinetics; Lomustine; Male; Neoplasm Proteins; Nitrosourea | 1978 |
The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p
Topics: Alkylating Agents; Animals; Biotransformation; Brain Neoplasms; Carmustine; Dexamethasone; Drug Inte | 1979 |
The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p
Topics: Alkylating Agents; Animals; Biotransformation; Brain Neoplasms; Carmustine; Dexamethasone; Drug Inte | 1979 |
Combination chemotherapy in recurrent medulloblastoma.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethaso | 1979 |
Combination chemotherapy in recurrent medulloblastoma.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethaso | 1979 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
Neurosurgical aspects of supratentorial malignant gliomas.
Topics: Biopsy; Brain Neoplasms; Carmustine; Craniotomy; Glioma; Methotrexate | 1976 |
Neurosurgical aspects of supratentorial malignant gliomas.
Topics: Biopsy; Brain Neoplasms; Carmustine; Craniotomy; Glioma; Methotrexate | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Dose-Response Relationship, Drug | 1976 |
In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cell Survival; Dose-Response Relationship, Drug | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
An experimental model for meningeal leukemia in rats (L5222). Effect of treatment with BCNU and cyclophosphamide.
Topics: Animals; Brain Neoplasms; Carmustine; Cyclophosphamide; Disease Models, Animal; Drug Evaluation, Pre | 1976 |
An experimental model for meningeal leukemia in rats (L5222). Effect of treatment with BCNU and cyclophosphamide.
Topics: Animals; Brain Neoplasms; Carmustine; Cyclophosphamide; Disease Models, Animal; Drug Evaluation, Pre | 1976 |
Pulmonary toxicity in long-term administration of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Humans; Male; Pulmonary Fibrosis | 1976 |
Pulmonary toxicity in long-term administration of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Humans; Male; Pulmonary Fibrosis | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Brain tumor chemotherapy: translation of laboratory experiments into clinical trials.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Neopl | 1976 |
Brain tumor chemotherapy: translation of laboratory experiments into clinical trials.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Neopl | 1976 |
Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Brain Neoplasms; Carmustine; Child; Child, Presc | 1976 |
Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.
Topics: Adolescent; Adult; Age Factors; Aged; Asparaginase; Brain Neoplasms; Carmustine; Child; Child, Presc | 1976 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Dose-Response Relatio | 1975 |
In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Dose-Response Relatio | 1975 |
The effect of BCNU, CCNU and MeCCNU in the prevention of the development of tumors of the nervous system.
Topics: Animals; Brain Neoplasms; Carmustine; Ethylnitrosourea; Neoplasms, Experimental; Nitrosourea Compoun | 1975 |
The effect of BCNU, CCNU and MeCCNU in the prevention of the development of tumors of the nervous system.
Topics: Animals; Brain Neoplasms; Carmustine; Ethylnitrosourea; Neoplasms, Experimental; Nitrosourea Compoun | 1975 |
Factors influencing the survival of rat brain tumor cells after in vitro treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr | 1975 |
Factors influencing the survival of rat brain tumor cells after in vitro treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Intracerebral chemotherapy in the 9L rat brain tumor model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; B | 1992 |
Intracerebral chemotherapy in the 9L rat brain tumor model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; B | 1992 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
Production of stable phenotypes from 9L rat brain tumor multicellular spheroids treated with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Resistance; Phenotype; Rats; Tumor Cells, Cultured | 1992 |
Production of stable phenotypes from 9L rat brain tumor multicellular spheroids treated with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Resistance; Phenotype; Rats; Tumor Cells, Cultured | 1992 |
[Effect of pretreatment with N-methyl-N-nitrosourea or streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Resistance; Drug Synergism; Ethylnitrosour | 1992 |
[Effect of pretreatment with N-methyl-N-nitrosourea or streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Resistance; Drug Synergism; Ethylnitrosour | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cisplatin; Electrophysiology; Fluorescein Angiography; Fun | 1992 |
Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cisplatin; Electrophysiology; Fluorescein Angiography; Fun | 1992 |
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Female; Glioma; Humans; | 1992 |
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Female; Glioma; Humans; | 1992 |
Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.
Topics: Adult; Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Front | 1992 |
Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.
Topics: Adult; Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Front | 1992 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 1990 |
Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 1990 |
Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1990 |
Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1990 |
Primary non-Hodgkin's lymphoma of the central nervous system: phase II study of chemotherapy (BVAM) prior to radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1991 |
Primary non-Hodgkin's lymphoma of the central nervous system: phase II study of chemotherapy (BVAM) prior to radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; | 1991 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1991 |
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1991 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Edetic Acid; Gallium Radio | 1991 |
Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Edetic Acid; Gallium Radio | 1991 |
A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Survival; Glioma; Humans; Immunohistoc | 1991 |
A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Survival; Glioma; Humans; Immunohistoc | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cisplatin; Combined Modality Therapy; Dogs; Gli | 1991 |
In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cisplatin; Combined Modality Therapy; Dogs; Gli | 1991 |
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
Topics: Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Ependymoma; Humans; Lung; Medulloblastoma; Microsc | 1991 |
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
Topics: Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Ependymoma; Humans; Lung; Medulloblastoma; Microsc | 1991 |
Effect of alpha-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Eflornit | 1990 |
Effect of alpha-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Eflornit | 1990 |
Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Brain Neo | 1990 |
Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Brain Neo | 1990 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Cisplatin; DNA, Neoplasm; Drug Resistan | 1990 |
Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Cisplatin; DNA, Neoplasm; Drug Resistan | 1990 |
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Cycle P | 1990 |
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Cycle P | 1990 |
[Chemotherapy in malignant gliomas].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cytarabine; Follow-Up | 1990 |
[Chemotherapy in malignant gliomas].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cytarabine; Follow-Up | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Cycle; DNA Damage; DNA, Neoplasm; Rats | 1990 |
Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Cycle; DNA Damage; DNA, Neoplasm; Rats | 1990 |
Intra-arterial BCNU in the treatment of recurrent medulloblastoma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Humans; Injections, Intra-Arterial; Male; Medulloblastom | 1990 |
Intra-arterial BCNU in the treatment of recurrent medulloblastoma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Humans; Injections, Intra-Arterial; Male; Medulloblastom | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Fluorescent D | 1990 |
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Fluorescent D | 1990 |
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
Topics: Acute Disease; Adolescent; Brain Neoplasms; Carmustine; Child; Female; Humans; Lung; Male; Pulmonary | 1990 |
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
Topics: Acute Disease; Adolescent; Brain Neoplasms; Carmustine; Child; Female; Humans; Lung; Male; Pulmonary | 1990 |
[Application of renal subcapsular assay to human malignant glioma--a new screening method in vivo for antitumoral drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Division; Cisplatin; Dr | 1985 |
[Application of renal subcapsular assay to human malignant glioma--a new screening method in vivo for antitumoral drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Division; Cisplatin; Dr | 1985 |
Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Carmustine; Cytarabine; Leukemia L1210 | 1985 |
Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Carmustine; Cytarabine; Leukemia L1210 | 1985 |
Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
Topics: Adolescent; Aged; Arabinonucleotides; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Child, Pr | 1987 |
Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
Topics: Adolescent; Aged; Arabinonucleotides; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Child, Pr | 1987 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells.
Topics: Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; Drug Screening | 1988 |
In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells.
Topics: Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; Drug Screening | 1988 |
The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Topics: Antineoplastic Agents; Biological Transport; Brain Neoplasms; Carmustine; Cell Line; Dose-Response R | 1989 |
The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Topics: Antineoplastic Agents; Biological Transport; Brain Neoplasms; Carmustine; Cell Line; Dose-Response R | 1989 |
Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line; Dru | 1989 |
Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9L rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line; Dru | 1989 |
Pathology of high-dose intraarterial BCNU.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Hu | 1989 |
Pathology of high-dose intraarterial BCNU.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Hu | 1989 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Glioblastoma; Glutathione; Glutathione Transf | 1989 |
Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Glioblastoma; Glutathione; Glutathione Transf | 1989 |
[Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma].
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Female; Glioma; Humans; Infusions, Int | 1989 |
[Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma].
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Female; Glioma; Humans; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Karyotyping; Ma | 1989 |
Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Karyotyping; Ma | 1989 |
Ovarian function following chemotherapy for childhood brain tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1989 |
Ovarian function following chemotherapy for childhood brain tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1989 |
Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Resistance; Glutathione Transferase; Isoenzymes; Kinetics | 1989 |
Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Drug Resistance; Glutathione Transferase; Isoenzymes; Kinetics | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme.
Topics: Adult; Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Combined Modality Ther | 1988 |
Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme.
Topics: Adult; Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Combined Modality Ther | 1988 |
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther | 1988 |
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther | 1988 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Phase I clinical trial of intracarotid bis-chloroethylnitrosourea (BCNU) and 2' dioxy-5-fluorouridine (FUDR) in malignant astrocytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Caro | 1986 |
Phase I clinical trial of intracarotid bis-chloroethylnitrosourea (BCNU) and 2' dioxy-5-fluorouridine (FUDR) in malignant astrocytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Caro | 1986 |
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Biological Assay; Brain Neoplasms; Carmustine; Cel | 1987 |
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Biological Assay; Brain Neoplasms; Carmustine; Cel | 1987 |
Ischemic optic neuropathy secondary to intracarotid infusion of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Fluorescein Angiography; Glioma; Human | 1987 |
Ischemic optic neuropathy secondary to intracarotid infusion of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Fluorescein Angiography; Glioma; Human | 1987 |
Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view.
Topics: Brain Neoplasms; Carmustine; Catheterization; Cerebral Angiography; Cerebral Arteries; Female; Gliom | 1988 |
Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view.
Topics: Brain Neoplasms; Carmustine; Catheterization; Cerebral Angiography; Cerebral Arteries; Female; Gliom | 1988 |
Transcranial Doppler monitoring of blood flow in the middle cerebral artery during angiography and drug perfusion.
Topics: Adult; Aged; Blood Flow Velocity; Brain Neoplasms; Carmustine; Cerebral Angiography; Cerebral Arteri | 1986 |
Transcranial Doppler monitoring of blood flow in the middle cerebral artery during angiography and drug perfusion.
Topics: Adult; Aged; Blood Flow Velocity; Brain Neoplasms; Carmustine; Cerebral Angiography; Cerebral Arteri | 1986 |
Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Glioblastoma; Hemoperfusion; | 1985 |
Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Glioblastoma; Hemoperfusion; | 1985 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Infusions, Intra-Arterial | 1985 |
The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Infusions, Intra-Arterial | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age.
Topics: Age Factors; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Chil | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age.
Topics: Age Factors; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Chil | 1985 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Drug Resistance; Glioblastoma; Humans; Lomu | 1986 |
In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Drug Resistance; Glioblastoma; Humans; Lomu | 1986 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.
Topics: Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Cross-Linking Re | 1987 |
DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.
Topics: Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Cross-Linking Re | 1987 |
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cell Line; Colony-Forming Units Assay; Dose-Response Relat | 1987 |
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cell Line; Colony-Forming Units Assay; Dose-Response Relat | 1987 |
Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Eflornithine; | 1986 |
Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Eflornithine; | 1986 |
Potentiation of rat brain tumor therapy by fluosol and carbogen.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon Dioxide; Carmustine | 1988 |
Potentiation of rat brain tumor therapy by fluosol and carbogen.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon Dioxide; Carmustine | 1988 |
Testicular damage after chemotherapy for childhood brain tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; Follicle Stimulating Hormone; Follow-Up Studi | 1988 |
Testicular damage after chemotherapy for childhood brain tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; Follicle Stimulating Hormone; Follow-Up Studi | 1988 |
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Carmustine; Combined Modality | 1988 |
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Carmustine; Combined Modality | 1988 |
Intraocular involvement of Burkitt's lymphoma in a Bedouin child.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Burkitt Lympho | 1987 |
Intraocular involvement of Burkitt's lymphoma in a Bedouin child.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Burkitt Lympho | 1987 |
[Mechanisms of cellular resistance to chloroethylnitrosourea in cell lines derived from human brain tumors].
Topics: Brain Neoplasms; Carmustine; Cell Line; DNA Damage; Drug Resistance; Glioma; Humans; Nimustine; Nitr | 1988 |
[Mechanisms of cellular resistance to chloroethylnitrosourea in cell lines derived from human brain tumors].
Topics: Brain Neoplasms; Carmustine; Cell Line; DNA Damage; Drug Resistance; Glioma; Humans; Nimustine; Nitr | 1988 |
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies.
Topics: Adolescent; Adult; Aged; Brain; Brain Neoplasms; Carmustine; Child; Child, Preschool; Deoxyglucose; | 1988 |
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies.
Topics: Adolescent; Adult; Aged; Brain; Brain Neoplasms; Carmustine; Child; Child, Preschool; Deoxyglucose; | 1988 |
Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Colony-Forming Units | 1988 |
Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Colony-Forming Units | 1988 |
More on the question of chemotherapy for CNS glioma.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans | 1987 |
More on the question of chemotherapy for CNS glioma.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans | 1987 |
In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
Topics: Brain Neoplasms; Carboplatin; Carmustine; Cisplatin; Colony-Forming Units Assay; Drug Resistance; Hu | 1988 |
In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
Topics: Brain Neoplasms; Carboplatin; Carmustine; Cisplatin; Colony-Forming Units Assay; Drug Resistance; Hu | 1988 |
Selective delivery of chemotherapeutic agents with a new catheter system.
Topics: Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheters, Indwelling; Cerebral Arteries; Gli | 1988 |
Selective delivery of chemotherapeutic agents with a new catheter system.
Topics: Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheters, Indwelling; Cerebral Arteries; Gli | 1988 |
Visual system toxicity following intra-arterial chemotherapy.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Infusions, Intra-Arterial; Retinal Diseases; | 1988 |
Visual system toxicity following intra-arterial chemotherapy.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Infusions, Intra-Arterial; Retinal Diseases; | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Successful chemotherapy for recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans | 1988 |
Successful chemotherapy for recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Drug Evaluation; Female; Glioma; Hal | 1986 |
Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Drug Evaluation; Female; Glioma; Hal | 1986 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Therapy of malignant brain tumors: comparison of the in vitro activities of vidarabin-monophosphate, BCNU and 5-fluorouracil.
Topics: Brain Neoplasms; Carmustine; Cell Line; Dose-Response Relationship, Drug; Fluorouracil; Humans; Kine | 1987 |
Therapy of malignant brain tumors: comparison of the in vitro activities of vidarabin-monophosphate, BCNU and 5-fluorouracil.
Topics: Brain Neoplasms; Carmustine; Cell Line; Dose-Response Relationship, Drug; Fluorouracil; Humans; Kine | 1987 |
[Neuromeningeal localizations in acute leukemia and non-Hodgkin's lymphoma. Protocol combining BCNU-cytosine arabinoside].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabi | 1987 |
[Neuromeningeal localizations in acute leukemia and non-Hodgkin's lymphoma. Protocol combining BCNU-cytosine arabinoside].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cytarabi | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caffeine; Carmustine; Cisplatin; Cy | 1987 |
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caffeine; Carmustine; Cisplatin; Cy | 1987 |
Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Humans; Infusio | 1987 |
Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Humans; Infusio | 1987 |
[Perioperative cytostatic treatment of malignant supratentorial brain tumors with BCNU with special reference to tumor site].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Humans; Male; Microsurgery; Parietal | 1987 |
[Perioperative cytostatic treatment of malignant supratentorial brain tumors with BCNU with special reference to tumor site].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Humans; Male; Microsurgery; Parietal | 1987 |
Intracranial BCNU.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Intracranial BCNU.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Effect of caffeine on cytotoxicity and sister chromatid exchange induction in sensitive and resistant rat brain tumor cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Caffeine; Carmustine; Cell Line; Cell Survival; DNA Damage; DNA Repair; Dr | 1987 |
Effect of caffeine on cytotoxicity and sister chromatid exchange induction in sensitive and resistant rat brain tumor cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Caffeine; Carmustine; Cell Line; Cell Survival; DNA Damage; DNA Repair; Dr | 1987 |
Infusion of intra-arterial chemotherapy through superselective cerebral catheterization.
Topics: Brain Neoplasms; Carmustine; Catheterization; Humans; Infusions, Intra-Arterial | 1987 |
Infusion of intra-arterial chemotherapy through superselective cerebral catheterization.
Topics: Brain Neoplasms; Carmustine; Catheterization; Humans; Infusions, Intra-Arterial | 1987 |
Intracarotid BCNU for glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Injections, Intr | 1987 |
Intracarotid BCNU for glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Injections, Intr | 1987 |
Response to BCNU of spheroids grown from mixtures of drug-sensitive and drug-resistant cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Count; Cell Separation; Cell Survival; Drug Resistance; R | 1987 |
Response to BCNU of spheroids grown from mixtures of drug-sensitive and drug-resistant cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Count; Cell Separation; Cell Survival; Drug Resistance; R | 1987 |
Pulmonary veno-occlusive disease following therapy for malignant neoplasms.
Topics: Adolescent; Adult; Biopsy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Hodgkin D | 1987 |
Pulmonary veno-occlusive disease following therapy for malignant neoplasms.
Topics: Adolescent; Adult; Biopsy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Hodgkin D | 1987 |
Simultaneous radiotherapy and chemotherapy in the treatment of brain metastases of malignant solid tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1987 |
Simultaneous radiotherapy and chemotherapy in the treatment of brain metastases of malignant solid tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1987 |
Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Child; Child, Preschool; | 1987 |
Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Child; Child, Preschool; | 1987 |
Drug cytotoxicity at elevated temperature. In vitro study on the U-87MG glioma cell line.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; | 1987 |
Drug cytotoxicity at elevated temperature. In vitro study on the U-87MG glioma cell line.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; | 1987 |
Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Energy Metabolism; Femal | 1987 |
Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Energy Metabolism; Femal | 1987 |
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur | 1986 |
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur | 1986 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Ar | 1986 |
Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Ar | 1986 |
Supraophthalmic intracarotid infusion of BCNU for malignant glioma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusions, Intravenous; Male; Middle Age | 1986 |
Supraophthalmic intracarotid infusion of BCNU for malignant glioma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusions, Intravenous; Male; Middle Age | 1986 |
Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1986 |
Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1986 |
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Cisplatin; Glioma; Humans; In | 1986 |
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Cisplatin; Glioma; Humans; In | 1986 |
High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemical a | 1986 |
High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemical a | 1986 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus | 1987 |
Radiologic-pathologic correlation conference: SUNY Upstate Medical Center. Late deterioration after treatment of brain neoplasm.
Topics: Adult; Brain Neoplasms; Carmustine; Combined Modality Therapy; Humans; Male; Radiotherapy; Tomograph | 1985 |
Radiologic-pathologic correlation conference: SUNY Upstate Medical Center. Late deterioration after treatment of brain neoplasm.
Topics: Adult; Brain Neoplasms; Carmustine; Combined Modality Therapy; Humans; Male; Radiotherapy; Tomograph | 1985 |
Effects of dicyclohexylamine sulfate, a spermidine synthase inhibitor, in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Survival; Cyclohexylamines; Eflornithine; Mit | 1985 |
Effects of dicyclohexylamine sulfate, a spermidine synthase inhibitor, in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Survival; Cyclohexylamines; Eflornithine; Mit | 1985 |
Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Dexam | 1986 |
Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Dexam | 1986 |
Drug streaming during intra-arterial chemotherapy.
Topics: Animals; Antineoplastic Agents; Antipyrine; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Carot | 1986 |
Drug streaming during intra-arterial chemotherapy.
Topics: Animals; Antineoplastic Agents; Antipyrine; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Carot | 1986 |
Intracarotid BCNU leukoencephalopathy.
Topics: Astrocytoma; Autopsy; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Humans; Infusion | 1986 |
Intracarotid BCNU leukoencephalopathy.
Topics: Astrocytoma; Autopsy; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Humans; Infusion | 1986 |
Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Rel | 1986 |
Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Rel | 1986 |
Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Dose-Response Relationship, Drug; Glioma; | 1986 |
Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Dose-Response Relationship, Drug; Glioma; | 1986 |
Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Hemiplegia; Humans; Injections, Intra-Arterial; Time Factors; T | 1986 |
Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Hemiplegia; Humans; Injections, Intra-Arterial; Time Factors; T | 1986 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanine.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cross-Linking Reagents; DNA, Neoplas | 1985 |
Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanine.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cross-Linking Reagents; DNA, Neoplas | 1985 |
Intra-arterial BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Diffuse Cerebral Sclerosis of Schilder; Glioma; Humans; Injections, Int | 1985 |
Intra-arterial BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Diffuse Cerebral Sclerosis of Schilder; Glioma; Humans; Injections, Int | 1985 |
Phase I trial of thermochemotherapy for brain malignancy.
Topics: Adult; Body Temperature; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Evaluation; Fe | 1985 |
Phase I trial of thermochemotherapy for brain malignancy.
Topics: Adult; Body Temperature; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Evaluation; Fe | 1985 |
Thymidine kinase in brain-tumor cysts.
Topics: Brain Neoplasms; Carmustine; Cysts; Glioma; Humans; Thymidine Kinase | 1985 |
Thymidine kinase in brain-tumor cysts.
Topics: Brain Neoplasms; Carmustine; Cysts; Glioma; Humans; Thymidine Kinase | 1985 |
Comparative study of the effects of hyperthermia and BCNU on BCNU-sensitive and BCNU-resistant 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Dr | 1985 |
Comparative study of the effects of hyperthermia and BCNU on BCNU-sensitive and BCNU-resistant 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Dr | 1985 |
Effects of hyperthermia on DNA interstrand crosslinking after treatment with BCNU in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug | 1985 |
Effects of hyperthermia on DNA interstrand crosslinking after treatment with BCNU in 9L rat brain tumor cells.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug | 1985 |
Supraophthalmic carotid infusion for brain chemotherapy. Experience with a new single-lumen catheter and maneuverable tip.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; Cispl | 1985 |
Supraophthalmic carotid infusion for brain chemotherapy. Experience with a new single-lumen catheter and maneuverable tip.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; Cispl | 1985 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report.
Topics: Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; Middle | 1985 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report.
Topics: Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; Middle | 1985 |
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Brain Neoplasms; C | 1985 |
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Brain Neoplasms; C | 1985 |
Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Carotid Arteries; Disease Models, Animal; Injections, Intra-Ar | 1985 |
Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Carotid Arteries; Disease Models, Animal; Injections, Intra-Ar | 1985 |
Pharmacokinetics of 11C-BCNU in experimental brain tumor.
Topics: Animals; Brain; Brain Neoplasms; Carbon Isotopes; Carmustine; Female; Isotope Labeling; Kinetics; Ra | 1985 |
Pharmacokinetics of 11C-BCNU in experimental brain tumor.
Topics: Animals; Brain; Brain Neoplasms; Carbon Isotopes; Carmustine; Female; Isotope Labeling; Kinetics; Ra | 1985 |
Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Extracorporeal Circulation; Female; Glioma; Hemoperf | 1985 |
Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Extracorporeal Circulation; Female; Glioma; Hemoperf | 1985 |
Rationale for preirradiation chemotherapy in treatment of malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Premedication | 1985 |
Rationale for preirradiation chemotherapy in treatment of malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Premedication | 1985 |
Topographic electroencephalographic study with power ratio index mapping in patients with malignant brain tumors.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Carmustine; Cerebral Cortex; Electroencephalography; Fema | 1985 |
Topographic electroencephalographic study with power ratio index mapping in patients with malignant brain tumors.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Carmustine; Cerebral Cortex; Electroencephalography; Fema | 1985 |
Transplantation of nervous system tumors in diffusion chambers.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Dose-Response Relationship, Drug; Dose-Response Relati | 1974 |
Transplantation of nervous system tumors in diffusion chambers.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Dose-Response Relationship, Drug; Dose-Response Relati | 1974 |
Extra-axial spread of medulloblastoma.
Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo | 1973 |
Extra-axial spread of medulloblastoma.
Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia.
Topics: Amphotericin B; Animals; Bone Marrow Cells; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; | 1974 |
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia.
Topics: Amphotericin B; Animals; Bone Marrow Cells; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; | 1974 |
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Dexameth | 1974 |
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Dexameth | 1974 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |